WHO Drug Informationapps.who.int/medicinedocs/documents/s20019en/s20019en.pdf · WHO Drug...

337

WHO Drug Information Vol. 26, No. 4, 2012

WHO Drug Information

International Regulatory Harmonization International Conference of Drug Regulatory Authorities 339Quality of medicines in a globalized world: focus on active pharmaceutical ingredients. Pre-ICDRA meeting 352

WHO Programme on International Drug MonitoringGlobal challenges in medicines safety 362

Safety and Efficacy IssuesDalfampridine: risk of seizure 371Sildenafil: not for pulmonary hypertension in children 371Interaction: proton pump inhibitors and methotrexate 371Fingolimod: cardiovascular monitoring 372Pramipexole: risk of heart failure 372Lyme disease test kits: limitations 373Anti-androgens: hepatotoxicity 374Agomelatine: hepatotoxicity and liver failure 375Hypotonic saline in children: fatal hyponatraemia 376Denosumab: fatal hypocalcaemia 376Axitinib: prescriber review 377Velaglucerase alfa: prescriber review 378Cyclizine lactate: prescriber review 378Cardiovascular safety of NSAIDs 380Antibiotics and liver Injury 380Statins: risk of diabetes mellitus? 381Antimalarials: assessing resistance risk 381Simvastatin: increased risk of myopathy/rhabdomyolysis 382

Regulatory Action and NewsNew task force for antibacterial drug development 383NIBSC: new MHRA centre 383New Pakistan drug regulatory authority 384EU clinical trial regulation: public consultation 384Pegloticase approved for chronic tophaceous gout 385Tofacitinib: approved for rheumatoid arthritis 385Rivaroxaban: extended indication approved for blood clotting 385Omacetaxine mepesuccinate: approved for chronic myelogenous leukaemia 386Perampanel: approved for partial onset seizures 386Regorafenib: approved for colorectal cancer 386Teriflunomide: approved for multiple sclerosis 387Ocriplasmin: approved for vitreomacular adhesion 387Florbetapir 18F: approved for neuritic plaque density imaging 387Insulin degludec: approved for diabetes mellitus 388Linaclotide: approved for irritable bowel syndrome 388Meningitis B Vaccine approved for Neisseria meningitidis 389Bromelain-based debriding agent approved for burn wounds 389Drug-eluting stent approved for peripheral arterial disease 389Human insulin products: marketing authorization application withdrawal 390Ridaforolimus: marketing authorization application withdrawal 390

Contents

... (continued)

338


Recent Publications, Information and EventsEvaluation of psychotropic substances 391Pharmacovigilance: towards a safer use of medicines 391Drug-resistant tuberculosis report 392Helminth infection research 392Malaria and dengue control: genetically modified mosquitoes 393Patent opposition database 394Clinical management of dengue 394

WHO Drug Information

Digital library

e-mail table of contents

subscriptions available at:

http://www.who.int/druginformation

Infectious diseases: new peer– reviewed journal freely available online 394

ATC/DDD ClassificationATC/DDD Classification (Temporary) 395ATC/DDD Classification (Final) 398

International Nonproprietary NamesProposed List No. 108 401

Contents (continued)

339


International Regulatory HarmonizationInternational Conference of Drug Regulatory Authorities

The 15th International Conference of Drug Regulatory Authorities (ICDRA) took place in Tallinn, Estonia, 23–26 October 2012. The event was hosted by the Ministry of Social Affairs and the State Agency of Medicines of Estonia in collabo-ration with the World Health Organization. It was attended by over 300 participants from 100 countries. The warm hospitality and excellent logistical support provided by the Agency was greatly appreciated.

The success of the ICDRA was again demonstrated by the increasing number of participants and its ability to respond to the needs and challenges of countries from all parts of the world through development of a relevant, balanced and up-to-date programme. The scope and diversity of topics responded to major trends encounter-ed in the operation of medicines agencies including those issues having an impact on regulatory affairs in a globalized environment. The State Agency of Medicines also organized a one-day visit to their premises in Tartu to offer an overview of activi-ties carried out by a small-country agency. The visit was attended by over 50 people including three from the US Food and Drug Administration.

Regulatory officials contributed to the programme sessions with technical presenta-tions followed by focused discussion. Targeted recommendations were drafted which were considered important in raising awareness of the difficulties faced by agencies or which focused on the continuity and improvement of functionality, networking, col-laboration and cooperation. These recommendations are set out below and on the following pages. Presentations made during the ICDRA are available on the WHO web site at http://www.who.int/medicines/icdra and on the ICDRA web site at http://www.icdra.ee (for a limited time period of six months).

In addition, a pre-ICDRA meeting was convened, 21–22 October 2012, entitled «Quality of medicines in a globalized world: focus on active pharmaceutical ingre-dients». The objective of the meeting was to offer an opportunity for greater interac-tion between regulatory officials and other interested parties, such as industry, civil society, scientific institutions and nongovernmental organizations. A brief summary and recommendations from the sessions is set out on pages 352–361.

15th ICDRA recommendationsPlenary 3. Ensuring the quality of active pharmaceutical ingredientsEnsuring the quality of active pharmaceutical ingredients is currently a hot topic for both regulators and industries. Several countries and regions have recently changed their API regulatory requirements. For example, new legislation in the European Union (EU) has reformed the rules for importing APIs for medicinal products for hu-man use. As of 2013, for imported active substances it has to be demonstrated that they have been manufactured in compliance with standards of good manufacturing

340


practice (GMP) at least equivalent to EU GMP. The first option is that the GMP requi-rements in the exporting country have been assessed by the EU and the country has been put on the list of equivalent countries. Another option is a written confirmation of GMP compliance from the competent regulatory authority of the exporting country. Additionally, the manufacturing units where the active substance was produced should be subject to control and enforcement of GMP at least equivalent to that in the EU. As a third option, and in exceptional cases to avoid drug shortages, the importing country may decide to accept a GMP certificate issued by an EU inspectorate.

The plenary also looked at existing collaborative arrangements between regulators to ensure API quality and discussed the report from the two-day pre-ICDRA meeting which had been focused exclusively on the broader issues linked to ensuring API quality.

ModeratorsAndrzej Rys, European Commission, EU and Xinyu Weng, SFDA, ChinaPresentationsInternational partnerships in response to globalization of manufacturing of APIs: tools, agreements and networks. Janice Soreth, FDA, USA.Report from the pre-ICDRA meeting. Susanne Keitel, EDQM/Council of Europe, EU.

Recommendations

Medicines regulatory authorities should:

• Ensure the quality of active pharmaceutical ingredients (APIs).

• Exporting countries should work closely with the medicines regulatory authorities of importing countries through cooperation, networking and building trust.

Manufacturers should: • Purchase APIs from qualified API manufacturers: price alone should not be the

determinant for selection.

Medicines regulatory authorities and manufacturers should:

• Follow international standards, such as those set out in the WHO Pharmaceutical Starting Material Certification Scheme (SMACS), to facilitate international supply of APIs.

Recommendations reported from the pre-ICDRA meeting «Quality of medicines in a globalized world: focus on active pharmaceutical ingredients (APIs)»

An overview and recommendations from the pre-ICDRA meeting «Quality of medicines in a globalized world: focus on active pharmaceutical ingredients (APIs)» is set out on page 352. A full report will be published and posted on the WHO web site at http://www.who.int/medicines

National authorities should:

• Tighten national and regional regulatory oversight of APIs and excipients by imple-menting control measures throughout the entire legitimate supply chain.

International Regulatory Harmonization

341


National authorities and manufacturers should:

• Carry out and share global intelligence and data on quality APIs.

• Increase enforcement activities to ensure the quality of APIs.

National authorities and WHO should:

• Increase measures to ensure consumers are aware of the dangers when purchasing medicines outside of the legitimate supply chain.

• Develop new tools and technologies to enable quality control laboratories to detect falsified/counterfeit APIs.

Plenary 4. Regulatory collaboration and networkingRegulators in all countries and throughout all regions are facing many common chal-lenges such as growing interdependence, increasing workload and limited resources. Recently, a series of discussions have emerged in different fora aiming to find new innovative ways to improve collaboration. This plenary forms part of the continuum of discussions between high-level regulatory officials from all six WHO Regions.

ModeratorsGuido Rasi, EMA, EU and John Lim, Singapore.PresentationChallenges of the global health system. Dirceu Bras Barbano, Brazil.Panel discussionYoujun Xu, China; B.R. Jagashetty, India; Hajed M. Hashan, Saudi Arabia; Hiiti Sillo, Tanzania; Oleksii Sloviov, Ukraine; Mary Lou Valdez, USA.

Recommendations

• Encourage innovative global movements to enhance international regulatory collab-oration to yield tangible results beyond what has been achieved to date and taking into account the capacity of medicines regulatory authorities.

• Medicines regulatory authorities should step up commitments to disseminate infor-mation that assists regulatory decision-making by other regulatory authorities.

• International collaborative efforts should look at abbreviating processes and estab-lish reasonable and practical targets so that clear progress can be tracked.

Plenary 5. Pharmacovigilance: vision for the futureThe safety of medicines is an increasing concern for all stakeholders, and regulators have an important role in advancing pharmacovigilance systems. This plenary session was organized in response to a recommendation from the 14th ICDRA to include phar-macovigilance as a main topic at the 15th ICDRA.

The call was consistent with growing awareness of the importance of pharmacovigilance as a component of medicines safety and its worldwide implications, and the perceived urgency to build and strengthen global standards and capacity in pharmacovigilance. In several countries and regions new legislative and organizational initiatives are develop-ing to build more robust pharmacovigilance systems able to monitor safety throughout the product life-cycle.


342


During the session, the panel on pharmacovigilance sought to highlight current chal-lenges, opportunities and developments. Discussion also centered on creating pos-sibilities for improved sharing of knowledge, information and resources to support the application of global best practices in pharmacovilance.

ModeratorsEsnarte Mwape, Zambia and Mary Lou Valdez, USA.PresentationsEU new pharmacovigilance legislation and its impact on global medicines safety. Peter Arlett, EMA, EU.Towards better pharmacovigilance. Singapore regulator’s perspective, Christine Ho, Singapore.Developing pharmacovigilance in an emerging economy. Adeline Osakwe, Nigeria.A vision for advancing pharmacovigilance systems. Karen Midthun, USA.

Recommendations

Member States and WHO should:

• Consider broader interpretation of the pharmacovigilance definition as appropriate to the local environment.

• Develop better tools and capacity for effective:

◊ Risk minimization, benefit/risk assessment.◊ Surveillance, research and decision-making.◊ Integration and cohesive systems.

• Promote a product “life-cycle pharmacovigilance” that considers safety data during:

◊ Clinical trial development.◊ Postmarketing surveillance.◊ Embracing the evidence hierarchy.

• Consider and develop:

◊ Additional sources of data.◊ Common nomenclature.◊ Data standards and common reporting.◊ Data sharing.◊ Appropriate use of standards.

Plenary 6. Current topicsThis plenary session gives an opportunity for ICDRA participants to brief the audience on specific country initiatives and developments and addresses topics of common inte-rest which have emerged either since the ICDRA was first planned or during informal discussion during the conference.

ModeratorMurray Lumpkin, USAPresentationsA global legally-binding treaty on mercury: impications for pharmaceuticals. David Wood, WHO, Geneva.


343


Addressing capacity challenges from the perspective of an emerging regulatory agency. The case of Botswana. Sinah Selelo, Botswana.How to modernize ICDRAs? Lembit Rägo, WHO, Geneva.Need for improvement of medicines regulation in Georgia. Tea Jikia, Georgia.Serbia’s legal and regulatory environment in medicines. Tatjana Sipetik, Serbia.

Recommendations

How to modernize ICDRAs?

• WHO should establish a core working group to advise on action and which would:

◊ Seek views from medicines regulatory authorities on any changes they would suggest for future ICDRAs.

◊ Carry out consultations with all interested parties, including e-surveys.◊ Consider mechanisms for more active linkages and work between ICDRAs.

Workshop A. Current trends in regulating blood and cell therapies ModeratorsJay Epstein, USA and Daniel Roberto Coradi de Freitas, Brazil.

PresentationsBlood as a medicine: summary from pre-ICDRA meeting. Ana Padilla, WHO, Geneva.Regional initiative in developing countries: a road map. Retno Tyas Utami, Indonesia.Plans for regulation of blood products in Zimbabwe. Gugu Mahlangu, Zimbabwe.Considerations on regulation of blood cell therapies. Klaus Chichutek, Germany; Naoyuki Yasuda, Japan.

Recommendations

• Member States should take steps to assure the quality, safety and availability of blood for transfusion, including oversight through regulation, consistent with WHA 63.12 (2010).

• Member States are encouraged to establish essential medicines lists and to include whole blood and blood components for transfusion on their lists.

• WHO should take further steps to strengthen national blood regulatory systems through education and technical support of national medicines regulatory authorities. Priority should be given to:

◊ Publication and training support on the WHO Assessment Criteria for National Blood Regulatory Systems.

◊ Training on GMP for Blood Establishments consistent with WHO Guidelines.◊ Integration of training using available tools.

• Member States are encouraged to develop national regulatory programmes for hematopoietic progenitor cell and other advanced blood cell therapies, taking into account similarities and critical differences with respect to regulation of blood com-ponents for transfusion.


344


• WHO should encourage progress towards regulation of advanced blood cell thera-pies through consideration of relevant best practices, including the establishment and strengthening of national blood regulatory systems.

Workshop B. Networking and collaboration for better regulation of herbal medicines

ModeratorsHiiti Sillo, Tanzania and Duc Vu, Canada.PresentationsExperience of regulatory cooperation on herbal medicines: Mercosur. Laura Castanheira, Mercosur/Brazil.Experience of regulatory cooperation on herbal medicines: International Regulatory Cooperation for Herbal Medicines (IRCH). Lucky Slamet, Indonesia.Experience from IRCH Working Group on Vigilance and Standards of Evidence and Forum on Herbal Harmonization. Duc Vu, Canada.

WHO should:

• Continue to promote international regulatory collaboration among WHO Member States and facilitate efforts in developing harmonization and/or regulatory con-vergence of national quality standards, evaluation criteria of evidence on efficacy, pharmacopoeial monographs and pharmacovigilance methodologies for herbal medicines when required, feasible and appropriate.

• Provide technical support to national regulatory capacity building/strengthening for effective and adequate regulation within a comprehensive national policy and legis-lative framework on health care provision and health systems, and enable national authorities to ensure efficacy, safety and quality of herbal medicines.

• Facilitate implementation of WHO technical guidelines according to circumstances and requirements with regard to:

◊ Verification and establishment of analytical methods for quality control and reference standards for herbal medicines.

◊ Development of pharmacopoeial monographs for herbal medicines.◊ Development and increased dissemination/communication of product infor-

mation on herbal medicines to the general public and health care providers including providers of traditional and complementary medicine, to promote patient safety.

Member States are encouraged to:

• Strengthen communication and collaboration in supporting capacity building of regu-lation for herbal medicines in resource-limited countries.

• Join collaborative networks at sub-regional, regional and international level to share information, adopt best practices, and make use of WHO guidance documents.

• Focus on regulatory worksharing to avoid duplication.

Workshop C. Collaboration and capacity building for vaccines Vaccines are a key area for regulatory collaboration between countries and for further capacity building. Although manufactured in only 40–45 countries, a growing propor-


345


tion of vaccines that are used to immunize the world’s population are manufactured in low- or middle-income countries. As biologicals, vaccines require appropriate regulatory oversight and this needs to be strengthened in many countries.

ModeratorsLaura Castanheira, Brazil and Johanna Gouws, South Africa.PresentationsDeveloping a shared vision and strategy to build and sustain collaborative vaccine regulatory capacity. Lucky Slamet, Indonesia.Networking for regulatory evaluation of vaccines. Catherine Parker, Canada.Leveraging the prequalification process for national regulatory decision-making. Adam Mitangu Fimbo, Tanzania.A global regulatory science agenda for vaccines. Karen Midthun, USA.

Recommendations

Member States should:

• Consider inclusion of vaccines within the scope of existing or emerging regional regulatory collaborative networks.

• Leverage, as appropriate, the WHO prequalification process for national decision-making.

• Consider developing international networking in the area of vaccine lot release.

• Support implementation of the Global Regulatory Science Agenda (2012) for vac-cines.

WHO should:

• Assist Member States to build the capacity of networks for regulation of vaccines.

• Promote effective networking activities for vaccines regulation, including global tele-conferences.

• Invite more experts from low- or middle-income countries to participate in the WHO vaccine prequalification process.

• Communicate the priorities and benefits of the Global Regulatory Science Agenda for vaccines to Member States.

Workshop D. Progress and challenges in regulating paediatric medicines ModeratorAgnes Saint-Reymond, EMA, EU.PresentationsUpdate on paeditric initiatives and on the Paediatric Medicines Regulators Network. Agnes Saint-Reymond, EMA, EU.WHO Paediatric Medicines Regulators Network: country experience. Delese Darko, Ghana.Regulating paediatric medicine: a viewpoint from the TGA. Jason Ferla, Australia.


346


WHO should:

• Make the Better Medicines for Children/Make Medicines Child Size initiative sustain-able through continuous support to national regulatory authorities and local industry with appropriate resources.

• Continue supporting and funding the network of regulatory agencies for paediatric medicines (PmRN) and its training activities (regular webinars and annual meeting).

• Continue to work on affordable and appropriate (heat and humidity resistant) paediatric formulations (e.g., guidelines).

• Provide support to market shaping to obtain affordable paediatric formulations and avoid shortages.


• Harmonize regulatory procedures for paediatric medicines to address market fragmentation.

• Share information on pharmacovigilance on paediatric medicines to make it more efficient.

• Join the PmRN network and encourage participation in training initiatives.

• Identify and address barriers to making paediatric medicines available to children.

Workshop G. Assessing and responding to training needs of regulators ModeratorJustina Molzon, USA.PresentationsCoordinating training of regulators: the EMA experience. Emer Cooke, EU.Challenges in addressing training needs for regulators. Lilit Ghazaryan, Armenia.Training needs to support East African Community regulatory harmonization. Fred Moin Siyoi, Kenya.Training, triage and transparency. Justina Molzon, USA.

Recommendations


• Develop a model curriculum to ensure sufficient training to implement medicines regulation effectively.

• Promote competency in evaluation of information submitted for review.

• Initiate academic training programmes on regulatory science.

• Ensure training of the next generation of regulators.

• Leverage expertise of others and tap into existing programmes in order to conserve resources.

• Focus on good review practices to promote consistency and transparency.


347


• Use CTD/eCTD as a common information-sharing platform.

WHO should:

• Encourage Member States to engage in self and external assessments of core regu-latory competencies consistent with available guidelines and international models of best practices.

Workshop H. Responding to globalization of clinical trials ModeratorAlar Irs, Estonia.PresentationsConsideration of mutual recognition of clinical trials: study on ethnic factors in China, Japan and Republic of Korea. Naoyuki Yasuda, Japan.Streamlining the clinical trial approval process: NRA networks, information exchange and cooperation. Laura Castanheira, Brazil.European cooperation in clinical trial approval: why and how. Alar Irs, Estonia.

Recommendations


• Express views and expectations to medicines developers regarding the applicability of results of multinational trials in their settings and be encouraged to harmonize requirements with other national regulators on a regional basis to foster local clinical development of new medicines from all regions and their timely access to patients.

• Foster mechanisms to engage in dialogue with commercial and non-commercial sponsors of clinical trials to advise on the expectations of regulators regarding plan-ning and conduct of trials.

• Establish cooperation schemes in assessing clinical trial applications and sharing assessment results to reduce duplication of work and improve coherence of regula-tory decisions.


• Provide adequate resources for regulatory capacity building and collaboration in the field of clinical trial application assessments to increase patient safety and facilitate clinical development of new medicines.

WHO should:

• Define the minimum dataset to be presented and assessed together with the clinical trial application to facilitate worksharing.

• Advise governments on setting up efficient regulatory frameworks for clinical trial approval and surveillance.

• Develop a minimum set of data that a regulatory authority would be recommended to make available to other regulators regarding the assessment results of clinical trials.


348


Workshop I. Regulatory harmonization

ModeratorEmer Cooke, EMA, EU.PresentationsAPEC experience in developing regulatory convergence. Mike Ward, Canada.Consideration of regulatory harmonization: comparison of medicines, medical devices and cosmetics. Nobumasa Nakashima, Japan.Progress and challenges for East African Community medicines registration harmonization project. Hiiti Sillo, Tanzania.

Recommendations

WHO should:

• Make efforts to support greater accessibility of information to facilitate harmonization and convergence activities.

WHO and medicines regulatory authorities should:

• Seek opportunities for prospective harmonization in areas such as advanced therapies.

Workshop J. Patient and healthcare professional involvement in medicine/medical device regulation

ModeratorsMurray Lumpkin, USA and Gordon Sematiko Katende, Uganda.PresentationsInvolving the healthcare professional and patient view in the EU. Tomas Salmonson, SwedenChallenges, opportunites and learning points from stakeholder engagement in medical device regulation. Raymond Chua, Singapore.Update on TGA Blueprint reforms. Mark McDonald, Australia.Patient and healthcare professional involvement in medicines regulation. Cordula Landgraaf, Switzerland.

Recommendations

WHO should:

• Encourage medicines regulatory authorities to engage external stakeholders (healthcare professionals and patients) in communication and active participation in the regulation of medicines and medical devices. The choice of communication channels and methods should be dependent on local conditions.

• Encourage and provide support to medicines regulatory authorities to adjust their processes and procedures to improve quality of services by applying user friendly policies allowing stakeholder involvement in the regulation of health technologies aiming to follow and implement good review and good governance practices.


• Improve strategies for targeted communication to patients, healthcare professionals and industry to increase overall transparency of regulatory processes and decisions.


349


Workshop K. New tools for effective collaboration in combating SSFFC medicines Substandard/spurious/falsified/counterfeit medicines — SSFFCs — affect many nations across all WHO Regions. During recent years, high-level political discussions have led to establishment of the Member State Mechanism on SSFFC Medicines by the World Health Assembly in 2012. At the same time, regions and countries are continuing their own efforts to tackle the problems. The session presented an overview of some of the developments.

ModeratorPaul Orhi, Nigeria.PresentationsChina’s new measures for combating counterfeit drugs. Lei Chen, China.West African experience in combating SSFFC medicines. Wiltshire Johnson, Sierra Leone.The UK strategy for combating falsified medicines. Gerald Heddell, UK.

Recommendations


• Focus on the public health implications of SSFFC medical products.

• Actively support the establishment of the new Member States Mechanism within the framework of WHO to enable international collaboration to combat SSFFC medical products, through collaboration with ICDRA, regional anti-counterfeit initiatives and expert advice from other stakeholders.

• The New Member States Mechanism should enable information exchange to help in the prevention and identification of national and regional actions in cases of suspect incidents of SSFFC medical products.

Member States and regions, with WHO and other partner assistance, should: • Strengthen their capacity and develop tools to detect, prevent and control the circu-

lation of SSFFC medical products.

• Strengthen through capacity building and international collaboration their regulatory systems.

• Create a global monitoring system enabling exchange for information on SSFFC medical products.

Workshop L. Should regulators do everything? Best practices for prioritization and worksharing All regulators at national and regional level have limited resources and are finding it difficult to cope with increasing workloads. It is clear that more efficient use of existing resources is needed using various tools such as prioritization, collaboration and work-sharing.


350


ModeratorMike Ward, Canada.PresentationsElements for a risk-based approach in marketing authorization. Petra Dörr, Switzerland.Regulatory prioritization and worksharing: a Singapore perspective. Christina Lim, Singapore.Collaborative inspections involving East African Community authorities. Dennis Mwesigwa, Uganda.International Generic Drug Regulators Pilot Initiative. Mike Ward, Canada.

Member States are encouraged to:

• Consider the application of a risk-based approach to the allocation of resources and infrastructure within national regulatory authorities that considers:

◊ The continuum of risk associated with medicinal products and facilities.◊ Their national context.◊ The effective use of information and expertise from other regulatory

authorities.

WHO should:

• Develop an analytical tool and methodology that would assist national regulatory authorities in introducing a more risk-based alignment of resources, processes and operational structure. Such a tool would complement existing national regulatory authority assessment tools.

• Engage Member States and relevant international initiatives, such as the Interna-tional Generic Drug Regulators Pilot Initiative, in the design and implementation of a future model for the Programme for Prequalification of Medicines.


• Consider strategies and mechanisms to promote the exchange of staff and other joint activities as a means of building capacity, promoting regulatory convergence and establishing trust.

Workshop M. How should medical device products be regulated?In many countries, the regulation of medical devices is less harmonized and has not reached the same point as medicines regulation. The challenge of regulating medical devices is further compounded by the huge complexity and variety of products and diversity of regulatroy systems. However, during recent years many low- and middle-income countries have started to implement medical device regulation. In many countries, the regulatory authorities in charge of medical device regulation are often the same as those for medicines. Due to increasing interest in this area, this was the first time that an ICDRA session was devoted to the topic and updates were presented from several countries and regions followed by general discussion.

ModeratorJosée Hansen, The Netherlands.PresentationsMedical devices regulatory system in China. Chenguang Cao, China.


351


Regulation of medical devices: Tanzanian experience. Adam Mitangu Fimbo, Tanzania.Challenges in regulating medical devices: the European perspective. Josée Hansen, The Netherlands.

Recommendations

• Medical devices should be regulated to protect public health and promote their proper use.

• Nomenclature systems for medical devices should be harmonized for better understanding by regulators and to better protect public health.

• WHO should encourage collaboration between medicines regulatory authorities with well established regulatory systems for medical devices and countries with less developed systems.

Workshop N. Role of regulators in addressing availability Together with other governmental institutions, regulators also have a responsibility to facilitate availability of needed medicines. Unfortunately, many needed medicines are not available to the patient for a variety of reasons. The role and practices of regulators in addressing availabiliy varies considerably from country to country and under different circumstances. Consequently, there is a lot to learn from each other. Promoting best practices and better collaboration among regulators in addressing the problem of avai-lability can certainly offer solutions.

ModeratorsKristin Raudsepp, Estonia and Sonam Dorji, Bhutan.PresentationsChallenges with drug shortages in a small island state: Barbados experience. Maryam Karga-Hinds, Barbados.Addressing drug shortages: Australian experience. Jason Ferla, Australia.Challenges of ensuring availability of quality essential medicines. Sonam Dorji, Bhutan.


• Consider developing an on-line list of shortages of medicines and actively communi-cate this information to healthcare professionals.

• Utilize the provisions in their available legislation to avoid shortage and availability problems as far as possible.


• Provide a legal framework to foresee crisis situations and develop emergency plans to ensure that the population is protected from severe shortage and unforeseen sud-den unavailability of medicines.

• Define the role and obligations of manufacturers to prevent challenges regarding the availability and shortage of medicines so that patients do not lack the necessary treatment.


352


WHO should:

• Expand the safety alert system to enable exchange of information among MRAs when challenges regarding the availability and shortage of medicines arise which may have repercussions on other countries and internationally.

• Encourage and facilitate information sharing and networking on biosimilar evaluation status to benefit small- and middle-resourced medicines regulatory authorities.

Pre-ICDRA meeting. Quality of medicines in a globalized world: focus on active pharmaceutical ingredients

This two-day meeting covered in-depth issues related to the quality of active pharma-ceutical ingredients (APIs). Many highly technical presentations were made during the three plenaries and ten workshops dedicated to topics such as how quality can be assessed, what measures need to be taken to ensure manufacture in compliance with good manufacturing practices (GMP), or how to procure safely whilst making best use of worksharing opportunities between regulatory authorities. Other topics ranged from new regional legislative initiatives to ensure API quality; need for assessment of API quality as part of marketing authorization; use of established worksharing sche-mes to reduce duplication, and ways of securing API supply chain security. In addition, innovative issues were discussed and included: considering blood as an API for blood products, specific challenges related to starting materials of herbal medicines, and har-monization of pharmacopoeias.

Plenary 1. The importance of starting materials for quality medicinesEnsuring starting material quality for medicines is high on the agenda for both regulators and industry. In an era of globalization and diminishing resources, collaboration among regulatory authorities is fundamental to safeguarding public health. Agreement on com-mon standards and exchange of information are important measures to be taken, while open dialogue between stakeholders must be promoted in combination with effective collaboration and networking among regulatory authorities.

Moderators: Susanne Keitel, EDQM/European Council, EU and Xinyu Weng, SFDA, China.PresentationsThe challenges of globalization for the quality of medicines. Susanne Keitel, EDQM/European Council.Viewpoints from industry associations. George France, IFPMA; Julie Maréchal-Jamil, EGA-IGPA; Barbara Steinhoff, WSMI.API manufacturer’s viewpoint. Prashant Deshpande, CIPLA, India.

Recommendations

To achieve consistent and effective regulation of active pharmaceutical ingredients (APIs) it is recommended that:

1. All organizations involved in the API supply chain collaborate in communication and cooperative activities designed to achieve a common understanding of:


353


• Applicable standards.

• Responsibilities in relation to the quality of APIs. 2. The regulation of APIs should:

• Be science- and knowledge-based.

• Be appropriate and proportional.

• Be based on harmonized API standards.

• Avoid unnecessary duplication of regulatory activities.

Plenary 2. Challenges of ensuring the quality of APIsAlthough the supply of APIs has become increasingly global, their sourcing is concen-trated in few regions and countries. Regulators from both well-resourced and resource-limited settings are facing equal challenges in ensuring the quality of APIs. The solution requires a holistic approach to ensuring API quality, including increased information exchange, collaboration and convergence of regulatory approaches.

Moderators: Johanna Gouws, MCC, South Africa and Deusdedit Mubangizi, WHO, Geneva.PresentationsAPI regulation in China: progress and challenges. Xinyu Weng, SFDA, China.The new EU rules for APIs: how to get prepared. Stefan Fuehring, European Commission, EU.Challenges of assuring API quality in resource limited settings. Deusdedit Mubangizi, WHO, Geneva.Indonesian experience in controlling API quality. Antoia Retno Tyas Utami, NADFC, Indonesia.

Recommendations

1. Dialogue and multilateral initiatives should be established between regulators to increase cooperation, convergence, harmonization, transparency and to build trust.

2. Capacity building activities in resource-limited settings should collaborate with, and leverage, relevant organizational expert assessment (for example WHO, EDQM, PIC/S and stringent regulatory authorities) to build API regulation capacity and ensure access to quality-assured APIs. In particular, capacity building initiatives should focus on building practical experience and knowledge during training.

Workshop 1. Blood as an APIThe regulation of blood products is complex and currently lags behind other areas of medicines regulation, particularly in terms of equal distribution of regulatory capacity. Discussion focused on the need for strengthening national blood regulatory systems as a key component of making safe, quality blood products available, together with the potential for treating blood and blood products as essential medicines.

ModeratorsJay Epstein, CBER/FDA, USA and Paul Strengers, IPFA, The Netherlands.


354


PresentationsBlood and blood components as essential medicines. Jay Epstein, CBER/FDA, USAThe WHO Model List of Essential Medicines. Ana Padilla, WHO, Geneva.Regulatory frameworks for blood and blood components. Catherine Parker, Health Canada; Petra Dörr, Swissmedic, Switzerland; Naoyuki Yasuda, MHWL, Japan.

Recommendations

1. Workshop participants endorsed the concept of whole blood and blood components as essential medicines.

2. Interested parties are encouraged to participate in applications for listing of whole blood and blood components (e.g., red blood-cell concentrates) on the WHO Model List of Essential Medicines through timely communication to WHO.

3. WHO is encouraged to make known any applications for listing of whole blood and blood components as Essential Medicines through the WHO Regional Offices.

4. In considering listing of whole blood and red blood-cell concentrates as essential medicines, WHO should note the need to:

• Establish and strengthen national blood regulatory systems through education and technical support to regulators of medicines.

• Promote establishment of adequate blood system infrastructures.

• Assist Member States to avoid potential unintended consequences to existing blood systems.

Workshop 2. Strategies to prevent counterfeit/falsified APIsDuring the session it was emphasized that it can be very difficult to detect if an API included in a finished dosage form, is falsified/counterfeit. Moreover, APIs can reach a large number of patients as they are usually included in more than one single dose unit. APIs, including those being falsified/counterfeited, can spread easily to several continents in the various stages of production, i.e., as batches of starting materials, intermediates and as a finished dosage form.

Counterfeit/falsified APIs will penetrate more easily into markets that have less strin-gent regulatory measures and less surveillance capacity in place. Communication and information sharing is therefore very important as, increasingly, strict measures in some countries may lead to redirection of falsified/counterfeit APIs and excipients to other less secure destinations. Among the existing tools that may help in preventing and detecting falsified/counterfeit APIs are the following: new screening technologies (such as NIR and Raman spectroscopy), certification schemes, reporting systems and pharmaco-vigilance reports.

ModeratorGerald Heddell, MHRA, United KingdomPresentationsStrategies for fighting falsified/counterfeit starting materials for medicinal products: a regulator’s perspective. Lisa Bernstein, FDA, USA.Preventing counterfeit/ falsified APIs – the European API manufacturer’s view. Marieke van Dalen, MSD/APIC, The Netherlands.


355


Preventing counterfeit/ falsified APIs: a viewpoint from the Netherlands. Marcel Moester, Healthcare Inspectorate, The Netherlands.

Recommendations

Regulatory authorities should:

1. Tighten national and regional oversight of APIs and excipients through control measures throughout the legitimate supply chain.

National authorities and manufacturers should:

2. Strengthen communication and information sharing. Action should take the form of:

• Global intelligence and data gathering

• Capacity building through collaborative training programmes.

• Global cooperation by convergence of standards towards worksharing oppor-tunities.

3. Increase enforcement action.

National authorities and WHO should:

4. Strengthen activities to increase consumer awareness of the dangers posed when purchasing medicines outside of the legitimate supply chain.

5. Develop new tools and technologies to enable quality control laboratories to detect falsified/counterfeit APIs and through:

• Harmonization of technologies.

• Certification.

• Reporting systems.

• Pharmacovigilance.

Workshop 3. The importance of assessing API quality as part of marketing authorizationThe API supply chain is complex and effective regulation is needed at both national and international levels. The importance of assessing API quality as part of the marketing authorization was emphasized during the workshop. However, many regulators may lack the specific technical capacity required and remain heavily dependent on work car-ried out by regulators in other agencies. Harmonizing assessment capacity will require a high level of networking and information sharing among regulators.

ModeratorMaryam Mehmandoust, ANSM, FrancePresentationsAPI assessment from Japanese experience. Naoyuki Yasuda, MHLW, Japan.News on regulatory requirements regarding API quality to be documented in CTD module 3. Jutta Reidl, Swissmedic, Switzerland.Challenges in assessing APIs as part of marketing authorization. Antonia Retno, Tyas Utami, NADFC, Indonesia


356


Recommendations

1. Regulators should collaborate on the identification of available API information and explore how to share the information effectively, including recognition of outcomes of inspections conducted by stringent regulatory authorities.

2. Regulators should establish appropriate procedures to obtain critical technical information relating to APIs that is required for the assessment of dossiers.

3. Existing capacity of medicines regulatory authorities, including technical expertise required for API quality assessment, should be benchmarked to allow the develop-ment of appropriate capacity building programmes.

4. The feasibility of developing API regulatory networks should be assessed. The activities of such networks could include information sharing and training in the conduct of assessments and inspections.

Workshop 4. Collaboration in GMP inspection of API manufacturersAt the present time, it is becoming increasingly evident that cooperative and collabo-rative arrangements between regulators is the key to effective regulation of APIs. An essential element of monitoring ongoing compliance with quality standards is the conduct of GMP inspections, which may be complicated by the geographical distribution of API and FPP manufacturers.

ModeratorsDavid Cockburn, EMA, EU, and Marcel Moester, Healthcare Inspectorate, The Netherlands.PresentationsRegulation of APIs in the Brazilian market. Jacqueline Condack Barcelos, ANVISA, Brazil.GMP inspection collaboration: past, present and future. David Cockburn, EMA, EU.Optimization of inspections process – industry perspective. Stefan Rönninger, Hoffmann-La Roche/IFPMA, Switzerland.

Recommendations

1. Regulators should continue to explore mechanisms for enhancing access to regula-tory information by national authorities in resource-limited settings. This should include outcomes of inspections by stringent regulatory authorities, for instance EudraGMP.

2. Regulators should harmonize inspection processes, such as:

• Applying a risk-based approach to the design of GMP inspection programmes.

• Use of common inspection report formats.

• Avoiding duplication by relying on stringent regulatory authority GMP certificates.

3. WHO, in collaboration with other concerned parties, should explore methods to leverage existing capacity building and training initiatives, such as those of PIC/S.

4. Although ICH Q7 is a key resource, a convergence of interpretation of this guidance by different regulators is needed. Reference to resources should be made, such as WHO’s respective explanatory notes.


357


Workshop 5. Collaboration in assessing API documentation In the current global medicines market, API manufacturers often supply to several fi-nished pharmaceutical product (FPP) manufacturers. This provides opportunities for collaboration between regulators both regionally and internationally.

ModeratorHelen Bruguera, EDQM/Council of EuropePresentationsCollaboration in assessing API documentation: the certification procedure. Helen Bruguera, EDQM/Council of Europe.Collaboration in assessing API documentation: a European regulator perspective. Maryam Mehmandoust, ANSM, France.Opportunitites for generic medicines industry in more collaborative approaches to assessing API documentation. Jan Moors, TEVA.

Recommendations

1. Regulators should create greater transparency, harmonization and access to exist-ing API assessment information to avoid duplication of regulatory efforts.

2. National authorities in resource-limited settings are encouraged to take advantage of the existing EDQM certificate of suitability (CEP) procedure and the WHO prequa-lification of APIs scheme to reduce workload and that of industry whilst ensuring high quality APIs.

3. All stakeholders involved in API manufacture and the supply chain are encouraged to continue collaboration towards achieving consistent and effective regulation of APIs. This requires dialogue between regulators, between industry and between regulators and industry.

Workshop 6. Building capacity and ensuring supply of APIs A complex API supply chain requires effective regulation at national, regional and inter-national levels. For this to be achieved, a high level of networking and information shar-ing is needed between regulators as well as communication and cooperation within industry, and between industry and regulators. API quality assurance is a global issue that requires regulatory authorities of highly-resourced countries to contribute to capa-city building aimed at addressing regulatory gaps.

ModeratorsLouise Dery, Health Canada and Harry Rothenfluh, WHO.PresentationsAssuring quality of APIs in Ukraine. Denys Gurak, Ukraine.Capacity building in API supply: Japanese experience. Hiroshi Kato, Pharmaceuticals and Medical Devices Agency, Japan.

Recommendations

1. Regulators should continue to harmonize standards and regulatory processes, such as GMP inspections, and pursue opportunities for cooperation, building of mutual trust and worksharing.

2. National authorities in resource limited settings should be encouraged to take advantage of existing training and capacity building programmes such as those of


358


PIC/S, the WHO Prequalification of Medicines Programme and those offered by other stringent regulatory authorities. 3. Capacity building activities by WHO and stringent regulatory authorities should:

• Focus on addressing regulatory gaps in quality assessment, toxicological evalua-tion, GMP compliance, laboratory testing, etc.

• Be designed to provide hands-on experience.

• Be competency based and meet the needs of those being trained. 4. Regulators should develop a consistent approach for sharing regulatory information and making information about regulatory outcomes publicly available.

Workshop 7. Specific challenges for herbal medicinesChallenges for herbal medicines in ensuring the quality and safety of starting materials centre on a lack of harmonized regulatory approaches, standards and testing methodo-logies. Discussion focused on opportunties for achieving better regulatory convergence.

ModeratorHubertus Cranz, AESGP PresentationsIRCH working progress on quality of herbal medicines. Yixin Chen, SFDA, China.GMP in the production of herbal medicinal products: a pragmatic approach. Barbara Steinhoff, AESGP.The challenges faced when developing herbal monographs. Samantha Atkinson, MHRA, United Kingdom.Challenges when introducing new analytical assay methods to established monographs. Michael Wierer, EDQM/Council of Europe.

1. WHO should strengthen and coordinate international regulatory collaboration among member countries to support and develop, when possible, harmonization or regulatory convergence of quality standards, evidence on efficacy and safety surveil-lance methodologies for herbal medicines.

2. WHO should support regulatory capacity building in countries to develop adequate regulations, in combination with national policy on health care practices and health systems to ensure the safety and quality of herbal medicines.

3. WHO should facilitate the development of testing methodologies for reference stan-dards, herbal monographs, and to enhance patient safety by increasing communica-tion of product information to the public and healthcare providers including alternative and traditional medicine providers.

Workshop 8. Supply chain integrity of APIs Ensuring supply chain integrity is important for both finished products and APIs. The API supply chain has its own specificity which needs to be considered when planning and applying control measures. Exchange of best practices and information are crucial to the building and maintenance of secure supply chain integrity.


359


ModeratorsKim Dayman-Rutkus, Health Canada and Stefan Fuehring, European Commission, EU.PresentationsThe threat of medicines supply from global sourcing of APIs. Gerald Heddell, MHRA, United Kingdom.APEC roadmap on global supply chain integrity. Lisa Bernstein, FDA, USAIndustry challenges to secure supply chain integrity in the global environment. George France, Novartis/IFPMAChallenges of maintaining supply chain integrity of APIs: a generic industry perspective. Igor Lifshitz, TEVA, Israel.

Recommendations

1. Regulators should:

• Collaborate to achieve convergence of standards and engage with manufacturers to ensure a common understanding of requirements.

• Cooperate in regulatory practice, including applying a risk-based approach, in order to avoid duplication of effort.

2. Manufacturers and regulators should be aware of risks to API supply chains and work towards minimization of these risks. More intensive communication and synergy should be established within existing initiatives.

3. Effective quality auditing by finished product manufacturers is crucial to assure com-pliance of the API supply chain with required standards and can contribute to preven-tion of supply crises.

4. Regulatory initiatives and collaboration to assure quality of APIs should be strate-gic, practical and designed to avoid duplication. Any increase of regulation should be balanced by training and capacity building. Existing multinational and international initiatives should continue to play a key role.

5. When assessing risks to the API supply chain, regulators should consider the complexity of the environment, including frequent site and ownership transfers, cross-contamination, change control, design of production lines, reporting culture, investiga-tion skills and environmental issues.

6. The API industry needs to adopt an innovative approach and benchmark against other industries. Industry may consider strengthening information-sharing of audit findings which may be relevant for other actors.

Workshop 9. Collaboration and harmonization of pharmacopoeias Pharmacopoeias are embedded in their respective national or regional regulatory environment. Retrospective harmonization has proven difficult to achieve. Prospec-tive harmonization may be easier but presents certain challenges after the initial work has been done, as the maintenance process over time and the establishment of the related reference standards and logistics need to be viewed within a long-term perspec-tive. Complete pharmacopoeial harmonization is only possible once regulatory systems


360


have also been harmonized. Developments in science and medical practice, global-ization and the presence of adulterated products require pharmacopoeias to constantly adjust. Convergence and reinforced collaboration among pharmacopoeial committees and regulators, supported by adequate interaction with industry, will assist in facing new challenges and resource constraints.

Quality control laboratories may increasingly encounter medical products with unexpected impurities or added substances. Close collaboration with regulators and manufacturers will be essential in such crisis situations.

ModeratorsSusanne Keitel, EDQM/Council of Europe and Gugu Mahlangu, Zimbabwe.PresentationsInternational cooperation among world pharmacopoeais: focus on recent events. Sabine Kopp, WHO, Geneva.Towards good pharmacopoeial practices: an industry view on harmonization. J. Mark Wiggins, MSD-Merck/IFPMA, Switzerland.Harmonization lf pharmacopoeias: a generic industry perspective. Manish Gangrade, Cipla, India.

Recommendations

1. The pharmacopoeias should use opportunities for collaboration and worksharing globally, regionally, and interregionally.

2. WHO should provide a neutral platform for discussion among pharmacopoeias and the development of good pharmacopoeial practice as a basis for further collabora-tion, worksharing, convergence and ultimately prospective harmonization. Ideally, this undertaking would be further facilitated by harmonization of regulatory requirements.

Workshop 10. Prequalification of APIs The WHO Prequalification of Medicines Programme (PQP) facilitates access to qua-lity medicines through assessment of products and inspection of manufacturing sites. Since good quality APIs are vital to the production of good quality medicines also need-ed for disease treatment programmes, PQP has implemented a scheme to prequalify APIs. A list of prequalified APIs provides UN agencies, medicines regulatory authoriites and other interested parties with information on APIs that have been found to meet WHO-recommended quality standards.

Moderators: Hiiti Sillio, Tanzania and Valerie Faillat-Proux, Sanofi/IFPMA, Switzerland.PresentationsWHO API prequalification: success and challenges. Antony Fake, WHO, Geneva.WHO API prequalification and site inspections. Deusdedit Mubangizi, WHO, Geneva.Assessor experience with WHO API prequalification. Maryam Mehmandoust, ANSM, France.Prequalification of APIs: viewpoint from a manufacturer. Navneet Anand, IPCA, India.The API PQP: a new tool for drug quality, industrial feedback, experience and perspective as participant and user. Valerie Faillat-Proux, Sanofi/IFPMA, Switzerland.


361


Recommendations

1. WHO, national regulators and industry should continue to support the WHO API prequalification scheme to:

• Ensure availability of APIs of known quality and GMP of manufacturers of essential medicines.

• Assist national regulatory decision-making processes in resource-limited settings.

• Build capacity in resource-limited settings by involvement in the WHO API prequalification scheme.

2. WHO and medicines regulators should collaborate further to avoid duplication of effort, increase harmonization and encourage industry participation in the WHO API prequalification. 3. A collaborative approach to inspection and assessment of APIs used during WHO API prequalification is recommended to medicines regulatory authorities to facilitate:

• Tapping into international skills.

• Ensuring transparency.

• Facilitating ownership of outcomes.

• Contributing to capacity building.

• Sharing the workload and avoiding duplicative inspections.

4. Existing tools of information sharing should be developed further and promoted to facilitate collaboration.

Plenary 3. Best practices and collaboration in regulation of APIs

ModeratorsSusanne Keitel, EDQM/Council of Europe, EU and Harry Rothenfluh, WHO.PresentationsRegulators and industry: tentative identification of joint priorities to address API quality challenges. Georges France, Novartis/IFPMA, Switzerland and Isabelle Clamou, EFPIAPanel discussion

----------------------------

General discussionPre-ICDRA recommendations for presentation at Plenary 3, 15th ICDRA.

* * * * *


362


WHO Programme for International Drug Monitoring

Global challenges in medicines safetyNorms and standards Systems are in place to develop and promote the use of global norms and standards. While harmonized definitions and terminologies for pharmacovigilance exist, additional work is needed to define a broader framework for gathering data on the safety, efficacy and rational use of medicines. Equally, data management

systems that facilitate data-sharing and usage by all stakeholders in pharmaco-vigilance are essential.

Regulatory and policy aspectsOnce a safety issue has been identified and validated it must be communicated to medicines regulatory authorities (MRAs) for appropriate action. In developed countries, data collected in pharmaco-vigilance systems are most commonly used for medicines regulatory activities

A 2008 WHO-led assessment of pharmacovigilance activities in 55 low- and middle-income countries (1) confirmed that countries in resource-limited settings face a number of challenges in pharmacovigilance related to:

• Limited experience with newer medicines.

• Overburdened healthcare systems.

• Poor medicines regulation.

• The presence of informal medicines markets.

• Inadequate adverse events databases.

• Inadequate or limited access to information.

• Significant resource constraints.

The United Nations Millennium Development Goals represent a historic commitment to a time-frame for addressing some of the world’s greatest development challenges. Millennium Development Goal number eight specifically relates to providing access to affordable essential medicines as a fundamental human right (2). However, efforts to improve access to medicines have not met with a proportionate attention to de-velopment of pharmacovigilance systems. This is a concern because access to new medicines is being increased in those very settings that currently have little or no capacity for pharmacovigilance.

For the most part, efforts in advancing pharmacovigilance in the developed and de-veloping parts of the world have progressed in parallel fashion with little overlap. The role of WHO in consolidating these efforts is of primary importance.

Strategy for promoting best pharmacovigilance practices in resource-limited settings

363


such as updating product information or suspending or withdrawing a product from the market. But this is not the case in many developing countries — presu-mably because the information is consi-dered inadequate to trigger or support regulatory decisions. However, a majority of these countries share pharmacovigil-ance information with public health programmes, drug information centres and health professionals or drugs and therapeutics committees. Pharmacovigi-lance information is less commonly used when elaborating essential medicines lists, therapeutic guidelines or in providing information to the public.

Methodological issuesNational pharmacovigilance systems rely heavily on spontaneous reporting of adverse reactions by health professionals and manufacturers and, in some set-tings, by patients. Spontaneous reporting systems are the easiest to establish and the cheapest to run and have proven their value in the early identification of products that need to be recalled and in capturing risks that were not identified during clinical trials. However, because of low and irregular reporting, it is difficult to determine the actual number of indivi-duals experiencing an adverse reaction to the medicine. Additional methods are needed to establish quantitative aspects of medicines safety, identify specific risk factors and high-risk groups and provide valid clinical characteristics of problems associated with specific medicines.

Risk management Recent market withdrawals of medicines with high market penetration (3, 4), uncer-tainty about the safety of antidepressants in children and adolescents (5) — and the confusion over reports of cardiac events associated with rosiglitazone (6) — have intensified questioning about safety issues. The pharmaceutical industry is required by stringent regulatory agencies to provide full details of risk management plans prior to product approval with clear

pharmacovigilance plans that identify, characterize and/or quantify risks and delineate risk minimization activities (7). However, very little has been done to adapt these measures for patient safety in the developing world.

Missing stakeholdersIn most countries, only healthcare profes-sionals are currently encouraged to report adverse drug reactions. Yet it has been repeatedly demonstrated that healthcare professionals only forward a small num-ber of reports they receive (8). World-wide, efforts are being made to include consumer organizations in the national pharmacovigilance network. Early results of these efforts indicate that new dimen-sions of medicine-related problems can be identified and described sooner by patients themselves (9). However, if consumer reporting is to be optimized, methodology and best practice must be internationally agreed and promoted.

Worldwide, the use of traditional medi-cines has grown. However, few countries include practitioners of traditional medi-cines in their pharmacovigilance network (1), thus missing out on valuable informa-tion from this group of health professio-nals.

Preventable harms and irrational use of medicinesOngoing morbidity and mortality from adverse drug reactions remains high and represents a significant yet preventable burden on national health systems (10). Dear doctor letters sent by manufactu-rers to provide information on potential adverse drug reactions (ADRs) to a spe-cific product and how to avoid them, and safety advisories issued by MRAs and manufacturers to health professionals regarding specific products, have limited impact on prescribing practices. We need to understand why preventable ADRs continue to occur and to develop other methods to mitigate or avoid them.


364


Patient care and case managementIn order to prevent, diagnose and man-age relatively rare ADRs, health profes-sionals need information that is up-to-date, well-collated, analysed, validated, and presented in a system that is easy to navigate and process. While databases such as the Cochrane Collaboration and the National Institute for Health and Clinical Excellence (NICE) are good resources, they are not comprehensive or readily accessible to a busy health professional.

Dependence, adverse events due to poor quality medicinesAbuse liability assessment is complex and requires specific, relevant data. Calls have already been made for better use of pharmacovigilance data in this area (11). The data could also contribute to the identification of poor quality and substan-dard medicines.

Communications in pharmacovigilanceThe controversies surrounding the withdrawal of rofecoxib (12) and reports of psychosis with SSRIs (13) highlight the current need for effective, timely and transparent sharing of medicines safety information. Communicating risk-benefit assessment is a huge challenge that involves presenting understandable, coherent information in a responsible and timely fashion, both within professional circles and to the general public.

Pharmacovigilance training and capacity building The lack of staff trained in pharmaco-vigilance seems to be the most serious limiting factor for the development of pharmacovigilance in low- and middle-income countries (1). Competencies in cross-cutting scientific areas are normally required in carrying out pharmacovigil-ance functions. While very few acade-mic institutions offer formal education in pharmacovigilance, several international agencies are stepping in with various

training programmes and activities to support pharmacovigilance in countries. These efforts need to be harmonized to ensure global standards and best prac-tices in pharmacovigilance.

Under-reporting, poor quality reports and signal detectionThe primary function of pharmacovigil-ance is to provide early warning signals of hitherto unknown ADRs. The Bayesian Confidence Propagation Neural Network (BCPNN) and other statistical methods have a high early predictive value and can greatly enhance traditional signal detection procedures. However, the usefulness of these methods relies on the amount and quality of the data available (14, 15). Since pharmacovigilance has not been part of the basic training of prac-tising health workers, considerable efforts are needed to promote the importance of pharmacovigilance and to instil a report-ing culture in this group. Under-reporting can seriously compromise the usefulness of pharmacovigilance data.

High burden diseases and global health initiatives In the developing world, malaria, HIV/AIDS and tuberculosis treatment pro-grammes and immunization programmes have received a lot of attention as com-ponents of the Millennium Development Goals. Initiatives such as the Global Fund for HIV, TB and Malaria have dramatically improved access to good quality medi-cines and reduced the cost of treatment for these diseases. However, efforts have fallen short in not including any phar-macovigilance component or measures for strengthening regulatory systems (16). Between 2003 and 2008, access to antiretroviral medicines in low- and middle-income countries rose ten-fold (17). Yet very little information is available on ADRs in these settings. It is vital to gather data on adverse drug reactions in resource-limited settings, since different populations with different co-morbidities are being treated, compared to treated


365


populations in resource-rich countries. These data are essential for the develop-ment of policy and country or regional treatment guidelines and to provide better information for patient management.

WHO Pharmacovigilance Strategy The WHO Programme for International Drug Monitoring (the Programme) aims to address these challenges through a comprehensive and global WHO Phar-macovigilance Strategy that leverages available pharmacovigilance expertise in the developed world to respond to the pharmacovigilance needs of low- and middle-income countries. The specific objective is to build systems that promote the best use of medicines by identifying, minimizing and managing the risks with these products. The long term objective is to advance best practices in pharma-covigilance as a global, cross-cutting theme in both developed and developing settings.

Strategic Partners The Programme came into existence in 1968 following two resolutions of the World Health Assembly (WHA 17.39 and WHA 19.35) that requested WHO to develop methods for monitoring adverse reactions to medicines. In 1978, an agreement was reached with the Swedish Government to transfer opera-

tional activities of the Programme to a Collaborating Centre in Uppsala while retaining responsibility for policy aspects, coordination, and dissemination of infor-mation at WHO, Geneva.

The Programme brings together all re-levant stakeholders to develop and enact a pharmacovigilance strategy for the safety and safe use of medicines world-wide. These stakeholders include:

• Member countries participating in the Programme.

• The WHO Medicines Safety Team at Headquarters, and the six WHO regions and country offices.

• The WHO Collaborating Centre for International Drug Monitoring/Uppsala Monitoring Centre (UMC), Sweden.

• The WHO Collaborating Centre for Training and Advocacy in Pharmaco-vigilance, in Accra, Ghana.

• The WHO Collaborating Centre for Pharmacovigilance and Patient Safety in Rabat, Morocco.

• The WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway.

In addition, the Pharmacovigilance Strate-gy benefits from direct input from various other programmes within WHO: Medi-

The WHO Pharmacovigilance Strategy

• Develops measures that build on the established experience and strength of the Programme and its international network.

• Exploits the current global interest, awareness and favourable atmosphere for pharmacovigilance in general.

• Aggressively addresses the weaknesses in current practices for more effective delivery of Programme goals.

• Strikes new partnerships and alliances to mitigate the many threats and chal-lenges facing the development of pharmacovigilance, particularly in resource-limited settings.


366


cines Regulatory Support, the Medicines Prequalification Programme, various public health programmes dealing with HIV, TB, malaria, vaccines, neglected tropical diseases, and the WHO Family of Classifications (FIC), the WHO Patient Safety Programme, etc.

Different technical agencies are invited to assist in the implementation of the phar-macovigilance strategy at national and regional levels. These include Manage-ment Sciences for Health (MSH), Sys-tems for Improved Access to Pharma-ceuticals and Services (SIAPS)/USAID and professional organizations such as ISoP, FIP, ISPE, etc., as well as acadae-mia, nongovernmental organizations and national information centres.

Industry input is channeled through ins-titutions such as the Council for Interna-tional Organizations of Medical Sciences (CIOMS), the International Conference on Harmonization (ICH) and the Inter-national Federation of Pharmaceutical Manufacturers Associations (IFPMA).

The Programme also benefits from the expertise of stringent regulatory autho-rities, individual consultants and other expert networks. Overall guidance and expert advice are provided by the WHO Advisory Committee on Safety of Medici-nal Products (ACSoMP).

Strategic choices: prioritizing the challenges Given the breadth of challenges and available resources, the approach for advancing the Pharmacovigilance Stra-tegy will continue to be priority-driven, implementing activities in a phased, step-wise manner. Establishing norms and standards for pharmacovigilance will have the highest priority for high burden diseases in selected countries. A strategic approach will be to ensure that at least minimum pharmacovigilance systems, structures and processes are in place in countries before planning for advanced activities such as medication

errors, monitoring events due to poor quality medicines, or drug resistance.

Strategic activitiesNorms, standards and guidelinesOver the years, partners within the Pro-gramme have been working together to develop and promote norms and stan-dards for best practice and innovation in the collection, storage, analysis and communication of pharmacovigilance data. These collaborative efforts will continue with a focus on, but not limited to, priority diseases (HIV, TB and mala-ria), special populations (children, women and the elderly), consumers, and new medicines. The resulting publications, handbooks and guidelines will be made available to Member States and those in-terested in medicines and patient safety.

Classifications, terminologies and definitionsThe WHO Collaborating Centre for Drug Statistics Methodology is responsible for the Anatomical Therapeutic and Chemical (ATC) classification and Defined Daily Dosage (DDD) system. An international working group oversees the work which provides important tools to allow the classification of medicines and measure-ment of drug utilization across and within countries.

The activities of CIOMS cover a broad range of drug safety topics via working groups. Senior scientists from regulatory authorities, the pharmaceutical industry and acadaemia form part of working groups that have developed tools such as the international reporting forms for adverse drug reactions (CIOMS I repor-ting form), terminologies and definitions of adverse drug reactions. These efforts will be continued, particularly in the context of the expanding scope of pharmacovigi-lance towards harmonized standards and comparable data. The Programme will collaborate with the FIC and the Depart-ment of Traditional and Complementary Medicines (TRM) to produce an interna-


367


tional standard terminology and classifi-cation system for uniform data collection, monitoring, and evaluation of traditional medicines.

Exchange of information From WHO HQ, the Programme has established a network of designated national medicines information officers to manage the regular exchange of infor-mation between Member States on the safety and efficacy of pharmaceutical products. This practice will continue with information disseminated through publica-tion of the WHO Pharmaceuticals News-letter (18) and by distribution of one-page Alerts (19) on an ad hoc basis.

Relevant restrictive regulatory decisions will be published in the United Nations Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. WHO will also continue to publish updates to this list in Pharmaceuticals: Restrictions in use and availability. WHO Regional mechanisms for exchanging and analysing information, including bulletins, journals, etc., will be exploited further to make information available more quickly, widely, and in an open and transparent manner. Specific methods of communica-tion or cooperation of proven usefulness, such as e-mail groups, communities of practice, regional observatories and web platforms will be encouraged and pur-sued.

Training and capacity buildingWHO, together with its collaborating centres and other technical partners, will continue to organize courses and training programmes to build and strengthen pharmacovigilance capacity in various countries.

The following additional activities will be advocated to improve efficiency:

• Integrating pharmacovigilance into the curriculum.

• Developing a comprehensive training module that countries can adapt and use.

• Working with countries to apply phar-macovigilance within a regulatory framework.

• Increasing support to countries by developing and maintaining a database of pharmacovigilance experts.

• Developing specifc modules and train-ing activities for pharmacovigilance for inclusion in public health programmes.

• Developing online courses for e-learn-ing and self-training in pharmacovigi-lance.

• Establishing centres of excellence to provide training in key pharmaco-vigilance methodologies and research areas.

• Advancing twinning arrangements and exchange programmes in pharmaco-vigilance between countries.

• Organizing quality translations of key documents and guidelines into all UN official languages.

Minimizing preventable harms from medicinal productsCapturing comprehensive data as a source of learning is the basis for iden-tifying areas of change and promoting recommendations for minimizing pre-ventable adverse drug reactions. The Programme will work with partners such as the World Alliance for Patient Safety to promote an extended role for pharmaco-vigilance centres, unveil medication errors reported as adverse drug reac-tions, understand systemic failures res-ponsible for adverse drug reactions, and propose corrective solutions to minimize adverse events due to medicines.

Regulatory aspectsThe Programme will propose measures to ensure that pharmacovigilance will con-


368


Additional methods and data sources to complement spontaneous reportingThe Programme will develop methods of scientific rigour that can complement spontaneous reporting. Cohort event monitoring (CEM) and targeted spon-taneous reporting (TSR) are two such methods that have been developed and will be promoted. Other sources of data — registries, population databases, electronic health-care records, etc., — will also be exploited as useful sources of pharmacovigilance information to support signal detection and global information exchange.

Broader use of existing pharmacovigilance dataExisting WHO Adverse Drug Reaction Terms (WHO-ART) such as drug abuse, drug dependence, or withdrawal syn-drome, provide a good starting point for detecting dependence liability in thera-peutic use. Ascertaining whether the reaction terms ‘treatment ineffective’ and ‘therapeutic effect decreased’ could serve as surrogate markers for identifying medicines of poor quality will be explored. The UMC is also engaged in identifying indicators of dependence liability and therapeutic inefficacy in the WHO ADR database. Such investigations will be supported further to inform the work of various expert committees in WHO (for example, the Expert Committee on Drug Dependence, Expert Committee on the Selection and Use of Essential Medi-cines) and other programmes such as the WHO Quality Assurance of Medicines Programme.

Public health programmes The Programme will continue working with various disease treatment pro-grammes to introduce the principles of pharmacovigilance to the treatment of priority diseases (HIV, TB and malaria), as well as neglected diseases (leish-maniasis, lymphatic filariasis, schisto-

tribute to regulatory decision-making and in turn will be strengthened by asso-ciation. Partners will organize training programmes to build pharmacovigilance capacity in regulatory agencies. In particular, the training programmes will strengthen regulatory capacity to assess pharmacovigilance systems and risk management plans and will create an enabling environment within countries for industries to fulfil their pharmacovi-gilance obligations. Many small-sized countries receive less than 100 individual case safety reports per year — a number too small to assist in signal detection or inform local regulatory decisions. The Programme will address this issue by bringing together smaller countries with similar demographics, genetic back-ground, nutritional status and co-morbidi-ties to consolidate their data for common regulatory decision-making.

Access to data and responsible communicationThe WHO Collaborating Centre for Inter-national Drug Monitoring at the Uppsala Monitoring Centre (UMC) manages the WHO global database of individual case safety reports (20). Every effort is made to ensure that the database is populated with the best quality data from countries, whilst adhering to applicable country laws and regulations, so that the Programme can fulfil its mandate of detecting signals and providing global information on drug safety. As regards initiatives such as EudraVigilance (the European Union Pharmacovigilance database), WHO will continue to work with the European Medicines Agency (EMA) for the optimal transmission of reports to the WHO global database.

The Programme will share the results of signal assessments with national autho-rities. Assessments will also be made public through WHO bulletins, newsletters and scientific journals for broader dis-semination and knowledge sharing.


369


somiasis and Chagas). The use of CEM and TSR will be promoted for safety data within these programmes, and to identify issues concerning operative procedures and actual implementation of the guide-lines (21).

Global health initiatives and minimum pharmacovigilance requirements WHO will work with various stakeholders (including the Global Fund and UNITAID) to ensure that treatment programmes supported by these initiatives will include at least the minimum pharmacovigilance components (22). A pharmacovigilance tool kit (23) has also been developed to facilitate the technical implementa-tion of pharmacovigilance within these programmes. The WHO Collaborating Centre for Advocacy and Training in Phar-macovigilance, Accra, Ghana, will have a leading role in both maintaining the tool kit and in assisting countries in the imple-mentation of minimum pharmacovigilance requirements. Additional technical agen-cies such as SIAPS and regional partners will also be brought in to facilitate global implementation.

Electronic transfer and data management systemsAccording to ICH standards, individual case safety reports have to be ‘E2b com-patible’ where E2b defines the format for the electronic transfer of individual case safety reports (ICSRs). In view of this, and in support of countries that do not have a data management system of their own, the UMC has developed a data ma-nagement tool (VigiFlow™) which allows a seamless online submission of ICSRs that include all E2b fields. VigiFlow™ also allows national centres to manage their data locally, thereby eliminating the need for additional software for national database management. WHO will work with the UMC to promote use of this data management tool as a cost effective way of setting up national databases

in resource limited settings. The tool is available free of cost to any country that will use it solely for submitting reports to the WHO database. A nominal fee will be charged if the tool is also used to set up and manage a national database. The proceeds will then be used to develop the tool further and for creating newer versions and upgrades that will then be provided free of charge to subscribing countries.

Many countries have self-designed data-bases for managing their data. WHO will work with these countries to determine additional solutions to support E2b stand-ards of reporting. Additional tools will be developed as needed to support newer methods such as CEM, reporting in a pandemic, consumer reporting, or off-line reporting solutions for countries with little or no internet connectivity. For example, in 2009, amidst concerns of a predicted influenza pandemic and in preparation for a possible surge of adverse events following immunization (AEFI) reports, the UMC developed PaniFlow®, a tool for reporting adverse events related to pan-demic influenza vaccines. The tool has been offered to all WHO Member States.

References

1. Olsson S et al. An analysis of pharmacovi-gilance activities in 55 low and middle income countries. Drug Safety, 2010;33(8):689–703.

2. World Health Organization. Health and the Millennium Development Goals. 2005 at http://whqlibdoc.who.int/publica-tions/2005/9241562986.pdf

3. World Health Organization. Alert No. 102: Voluntary withdrawal of cerivastatin – reports of rhabodomyolysis. 2001. http://www.who.Int/medicines

4. World Health Organization. Drugs of current interest. WHO Pharmaceuticals Newsletter, 2004;5:7. http://www.who.Int/medicines

5. World Health Organization. WHO Pharma-ceuticals Newsletter 2004;4:1. http://www.who.Int/medicines


370


6. World Health Organization. WHO Phar-maceuticals Newsletter 2008;1:3. http://www.who.Int/medicines

7. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) at http://www.ich.org

8. Patricia Wilkie. Patient reporting of adverse drug reactions. DIA Today, 2006;6:21–23.

9. Medawar C, Herxheimer A. A comparison of adverse drug reactions from professionals and users relating to risk of dependence and suicidal behaviour with paroxetine. Interna-tional Journal of Risk and Safety in Medicine 2003;15:5–19.

10. Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ, 2004;329(7456):15–9.

11. World Health Organization. Thirty-fourth Expert Committee on Drug Dependance. Technical Report Series, No. 942, 2006 at http://www.who.Int/medicines

12. Harlan M, Krumholz, Joseph S Ross et al. What have we learnt from Vioxx? BMJ 2007;334:120–123.

13. M Kauffman. Selective serotonin reup-take inhibitor (SSRI) drugs: more risks than benefits? Journal of American Physicians and Surgeons 2009;14(1):7–12.

14. Lindquist M et al. A retrospective evalua-tion of a data mining approach to aid finding new adverse reaction signals in the WHO International Database. Drug Safety 2000, 23(6):533–542.

15. Bate et al. A data mining approach for signal detection and analysis. Drug Safety 2002;25(6):393–397.

16. Pal S et al. Pharmacovigilance and Safety of medicines. In: The World Medicines Situa-tion, WHO/EMP/MIE/2011.2.9. 2011. http://www.who.Int/medicines

17. World Health Organization, United Nations Children’s Fund, UNAIDS. Towards universal access: scaling up priority HIV/AIDS interven-tions in the health sector. 2009. http://www.who.Int/medicines

18. World Health Organization. WHO Phar-maceuticals Newsletter at http://www.who.int/medicines

19. World Health Organization. Drug Alerts at http://www.who.int/medicines

20. World Health Organization Collaborating Centre for International Drug Monitoring/ Uppsala Monitoring Centre at http://www.who-umc.org

21. World Health Organization. A practical handbook on the pharmacovigilance of medi-cines used in the treatment of tuberculosis: enhancing the safety of the TB patient. 2012. http://www.who.int/medicines/publications

22. World Health Organization/Global Fund to Fight AIDS, Tuberculosis and Malaria. Mini-mum requirements for a functional pharma-covigilance system. 2010. http://www.who.int/medicines

23. World Health Organization. A pharmacovi-gilance tool kit at http://www.pvtoolkit.org


371


Safety and Efficacy IssuesDalfampridine: risk of seizure United States of America — The Food and Drug Administration (FDA) is report-ing a risk of seizures in patients with multiple sclerosis (MS) who are starting dalfampridine (Ampyra®). The majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.

Although the mechanism of action in MS patients is not fully understood, studies in animals show increased neuronal activity in response to the drug. In addi-tion, the drug label has been updated to clarify recommendations that kidney function should be checked in patients before starting dalfampridine. Additionally, patients who miss a dose should not take extra doses—an extra dose can increase seizure risk.

Reference: FDA Drug Safety Communication, 23 July 2012 at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfo-rHumanMedicalProducts/ucm313055.htm

Sildenafil: not for pulmonary hypertension in childrenUnited States of America — The Food and Drug Administration (FDA) is recom-mending that sildenafil (Revatio®) not be prescribed to children aged 1–17 years of age for pulmonary arterial hypertension (PAH). This recommendation is based on a recent long-term clinical paediatric trial showing that: (i) children taking a high dose of sildenafil had a higher risk of death than children taking a low dose and (ii) the low doses of sildenafil are not effective in improving exercise ability (1).Most deaths were caused by pulmonary hypertension and heart failure.

Sildenafil is a phosphodiesterase-5 inhibitor used to treat pulmonary arterial hypertension. It is also marketed in the prescription product Viagra®, for adult male erectile dysfunction.

Sildenafil is not approved for the treat-ment of PAH in children, and in light of this new clinical trial information, off-label use of the drug in paediatric patients is not recommended. Sildenafil is approv-ed to improve exercise ability and delay clinical worsening of PAH in adult patients. The current Revatio® label recommends avoiding doses higher than 20 mg three times a day. The effect of Revatio® on the risk of death with long-term use in adults is unknown (2).

References

1. Barst RJ, Ivy DD, Gaitan G, et al. A rando-mized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treat-ment-naïve children with pulmonary arterial hypertension. Circulation 2012;125:324–334.

2. FDA Drug Safety Communication, 30 August 2012 at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm317743.htm

Interaction: proton pump inhibitors and methotrexateCanada — The labelling for metho-trexate and proton pump inhibitors (PPIs) is being updated to include information on a potential interaction between these products.

Methotrexate is used in the treatment of cancer and autoimmune diseases and proton pump inhibitors are acid reducers used in the treatment of heartburn or acid indigestion.

372


The use of these two products at the same time by patients may increase the amount of methotrexate in the blood leading to side effects. The possible risks include kidney failure, low red blood cell count, inflammation of the digestive tract, irregular heartbeat, muscle pain, infections, and diarrhoea. While a defi-nite association between PPI use and an increase in methotrexate has not been confirmed, there have been a number of studies suggesting a possible interaction.

PPIs, in general, should be prescribed at the lowest dose and for the shortest duration of therapy appropriate to the condition being treated.

The following PPIs are available in Canada:

Dexlansoprazole; esomeprazole; ome-prazole; losec; lansoprazole; pantopra-zole; pantoprazole/magnesium, and rabeprazole. PPIs are also available in combination with other drugs.

Reference: Information Update, 2012–157, 19 October 2012 at http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/ 2012_157-eng.php

Fingolimod: cardiovascular monitoringCanada — Healthcare professionals have been advised of stronger recom-mendations regarding first-dose cardio-vascular monitoring and use in patients with pre-existing cardiovascular con-ditions of fingolimod (Gilenya®), a drug indicated for the treatment of relapsing-remitting multiple sclerosis.

Isolated delayed-onset cardiovascular events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose of fingolimod. Health Canada has completed its review, which included a number of international reports of deaths, several of which were considered possibly associated with fin-

golimod. No deaths have been reported in Canada.

Fifty-four Canadian case reports of serious cardiovascular adverse events, possibly associated with fingolimod, have been reported between March 2011 and January 2012. The majority of these cases have occurred within 6 hours of the first dose and consisted of bradycardia, hypertension, hypotension and dizziness/malaise/palpitations.

Initiation of fingolimod treatment results in reversible heart rate decrease and has also been associated with atrio-ventricu-lar conduction delays and isolated cases of serious cardiovascular events and unexplained death.

An electrocardiogram (ECG) should be performed and blood pressure measured prior to and 6 hours after the first dose. All patients should be monitored for signs and symptoms of bradyarrhythmia, with hourly pulse and blood pressure measu-rement for at least 6 hours after the first dose. Reference: Communication from Novartis Pharmaceuticals Canada Inc. dated 21 August 2012 at http://www.hc-sc.gc.ca/dhp-mps/me-deff/advisories-avis/prof/_2012/gilenya_hpc-cps-eng.php

Pramipexole: risk of heart failureUnited States of America — The Food and Drug Administration (FDA) is repor-ting a possible increased risk of heart failure with pramipexole (Mirapex®), a drug used to treat Parkinson disease and restless legs syndrome. Results of recent studies suggest a potential risk of heart failure that needs further review of available data.

Pramipexole is a dopamine agonist used to treat the signs and symptoms of Parkinson disease and moderate to severe symptoms of primary restless legs syndrome. It works by acting in place of

Safety and Efficacy Issues

373


and treatment are imperative to facilitate recovery and prevent long-term sequelae.

Lyme disease test kits are class II in vitro diagnostic devices intended for the detec-tion of antibodies to Borrelia burgdorferi in human serum, plasma or cerebrospinal fluid.

The first tier consists of an enzyme immunoassay, such as an enzyme-linked immunosorbent assay (ELISA), or an indirect immunofluorescent assay. If the result of first-tier testing is negative, the sample is reported to be negative for antibodies to B. burgdorferi and is not tested further. If the result is positive or indeterminate, second-tier testing with a standardized Western blot is then performed. Even when the conventional two-tiered testing approach is used, the sensitivity and specificity of the combined test results can be less than optimal.

The currently available Lyme disease test kits have been found to have limitations of sensitivity and specificity, particularly when used on patients with acute infec-tion, which is usually easily treated with antibiotics.

In a comprehensive study of 280 serum samples from well-characterized Lyme disease patients, the sensitivity of the two-tiered approach was as low as 38% for the sera of patients who had erythema migrans during the acute phase and 67% during their convalescence after antimi-crobial treatment. In late Lyme disease, the sensitivity increased to 87% for the sera of patients with early neuroborre-liosis and to 97% for the sera of patients with Lyme arthritis.

Serologic test results are supplemental to the clinical diagnosis of Lyme disease and should not be the primary basis for making diagnostic or treatment decisions.

Extracted from Canadian Adverse Reaction Newsletter, Volume 22, Number 4, October 2012.

dopamine, produced by specific areas of the brain that control movement.

The FDA has evaluated a pooled analysis of randomized clinical trials and found that heart failure was more frequent with Mirapex® than with placebo; however, these results were not statistically signifi-cant. FDA also evaluated two epidemio-logic studies that suggested an increased risk of new onset of heart failure with Mi-rapex use (1, 2). Study limitations make it difficult to determine whether excess heart failure was related to Mirapex® use or other influencing factors.

Because of the study limitations, the FDA is not able to determine whether Mira-pex® increases the risk of heart failure and will update the public when more information is available.

References

1. Renoux C, Dell’Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21:34-41. 2. Mokhles MM, Trifirò G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65:358-64. 3. MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US). Drug & Supplements Monograph: Pramipexole. Avai-lable at http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697029.html.

4. FDA Drug Safety Communication, 19 September 2012 at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfo-rHumanMedicalProducts/ucm320054.htm

Lyme disease test kits: limitationsCanada — As of June 2012, Health Canada has received one incident report of false-negative serologic test results for 24 patients that may have delayed treat-ment. Timely recognition of Lyme disease


374


References

1. Establishing the performance characte-ristics of in vitro diagnostic devices for the detection of antibodies to Borrelia burgdorferi. Silver Spring (MD): Office of In Vitro Diagnos-tic Device Evaluation and Safety, Center for Devices and Radiological Health, US Food and Drug Administration; 2011.

2. Steere AC. Lyme disease. N Engl J Med 1989;321(9):586–96.

3. Johnson BJB. Laboratory diagnostic testing for Borrelia burgdorferi infection. In: Halperin JJ (editor). Lyme disease: an evidence-based approach. Cambridge (MA): CAB Internatio-nal; 2011. p. 73-88.

4. Canadian Public Health Laboratory Network. The laboratory diagnosis of Lyme borreliosis: guidelines from the Canadian Public Health Laboratory Network. Can J Infect Dis Med Microbiol 2007;18(2):145–8.

5. US Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44(31):590–1.

6. US Centers for Disease Control and Pre-vention (CDC). Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997;46(RR-10):1-55.

7. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43(9):1089–134.

8. Hovius JWR, van Dam AP, Fikrig E. Late manifestations of Lyme borreliosis. In: Fra-tamico PM, Smith JL, Brogden KA (editors). Sequelae and long-term consequences of infectious diseases. Washington (DC): ASM Press; 2009. p. 9–25.

9. Aguero-Rosenfeld ME, Wang G, Schwartz I, et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18(3):484–509.

10. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003;187(8):1187–99.

11. Brown SL, Hansen SL, Langone JJ, et al. Lyme disease test kits: potential for misdia-gnosis. US Food and Drug Administration Medical Bulletin; 1999 (summer).

12. FDA public health advisory. Assays for antibodies to Borrelia burgdorferi: limitations, use, and interpretation for supporting a clinical diagnosis of Lyme disease. Washington (DC): US Food and Drug Administration; 1997. Publication no. 1997-520-050.

13. Ang CW, Notermans DW, Hommes M, et al. Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. Eur J Clin Microbiol Infect Dis 2011;30(8):1027–32.

14. Müller I, Freitag MH, Poggensee G, et al. Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immu-nol 2012:595427

15. Public Health Agency of Canada. Lyme disease fact sheet. Ottawa (ON): The Agency.

Anti-androgens: hepatotoxicityCanada — Anti-androgens are a class of drugs used in androgen deprivation therapy for the treatment of advanced or metastatic prostate cancer. They are classified into two groups: nonsteroidal anti-androgens (flutamide, bicalutamide and nilutamide) and steroidal anti-androgens (cyproterone acetate).

Both groups work by competing with circulating androgens for receptor sites within the prostate cell, thus promoting apoptosis and inhibiting prostate cancer growth. Steroidal anti-androgens have the added ability of suppressing the produc-tion of testosterone. Depending on the


375


4. Lin AD, Chen KK, Lin AT, et al. Antian-drogen-associated hepatotoxicity in the mana-gement of advanced prostate cancer. J Chin Med Assoc 2003;66(12):735–40.

Agomelatine: hepatotoxicity and liver failure

United Kingdom — There have been several serious cases of hepatotoxicity reported with agomelatine (Valdoxan®, Thymanax®). These include six reports worldwide of hepatic failure. The existing recommendations to perform liver func-tion tests in all patients receiving agome-latine at treatment initiation and during treatment have been extended to include testing when the dose is increased.

Agomelatine should be immediately discontinued if patients present with symptoms or signs of potential liver injury, or if an increase in serum transaminases in liver function tests exceeds three times the upper limit of normal. Patients should be informed of the symptoms of potential liver injury and advised to stop taking agomelatine immediately and seek urgent medical advice if these symptoms appear.

Agomelatine is an antidepressant indicat-ed for the treatment of major depressive episodes in adults. Agomelatine is a melatonin MT1 and MT2 receptor agonist, and antagonist at the serotonin 5-HT2C receptor, thereby increasing levels of dopamine and noradrenaline in areas of the brain involved in mood control.

Following several reports of liver injury, including hepatic failure, all available data on elevated transaminases and hepato-toxicity with agomelatine use have been reviewed.

Prescribers are advised to monitor liver function frequently and are warned about the risk of hepatitis and elevated transa-minase levels. Agomelatine is contra-indicated in patients with hepatic impair-ment (cirrhosis or active liver disease).

drug, anti-androgens are indicated for use in monotherapy, or in combination with radiotherapy, luteinizing hormone-releasing hormone analogues or orchi-ectomy for complete androgen blockade.

Although the risk of hepatotoxicity and hepatic failure is currently labelled in the Canadian product monographs for fluta-mide, a recent safety review conducted by Health Canada suggested that hepa-totoxicity remains an important safety concern.

As of 31 March 2012, Health Canada has received 25 case reports of hepatotoxicity in men aged 60–98 years old that were suspected of being associated with anti-androgens, 24 of which were serious. The most common adverse reactions included jaundice, increased liver enzyme levels, nausea, hepatic necrosis, ascites and hepatitis.

The risk of hepatotoxicity with the use of anti-androgens has also been described in the clinical literature. Although both steroidal and nonsteroidal anti-androgens have been associated with hepatotoxicity, the frequency of these adverse reactions, and their clinical features, appear to differ from one drug to another.

Extracted from Canadian Adverse Reaction Newsletter, Volume 22, Number 4, October 2012.

References

1. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: Are they all the same? J Cancer Res Clin Oncol 2006;132(Suppl 1):S17–26.

2. Manso G, et al. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006;4:253–9.

3. Thole Z. Hepatotoxicity induced by anti-androgens: a review of the literature. Urol Int 2004;73(4):289–95.


376


paediatric specialist settings, such as renal, cardiac, liver, high dependency, and intensive care units.

References

1. Playfor et al. Hypotonic intravenous solutions in children. Expert Opin. Drug Saf 2004;3(1);67–73

2. Yung et al. Randomized controlled trial of intravenous maintenance fluids. J Paediatr Child Health 2009;49:9–14

3. Kannan et al. Intravenous fluid regimen and hyponatraemia among children: a ran-domized controlled trial. Paediatr Nephrol 2010;25:2303–2309

4. Drysdale et al. The impact of the National Patient Safety Agency intravenous fluid alert on iatrogenic hyponatraemia in children. Eur J Paediatr 2010;169 (7):813–817

5. Drug Safety Update, Volume 6, Issue 3, October 2012 at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/

Denosumab: fatal hypocalcaemia

United Kingdom — Cases of severe symptomatic hypocalcaemia have occur-red in patients receiving denosumab 120 mg (Xgeva®) or 60 mg (Prolia®). Some of these cases were fatal in those receiv-ing the 120 mg dose.

Pre-existing hypocalcaemia must be corrected prior to initiating denosumab, and supplementation of calcium and vitamin D is required in all patients receiv-ing the 120 mg dose unless hyper-calcaemia is present. Although hypo-calcaemia most commonly occurs within the first six months of treatment, it may occur at any time.

Denosumab 120 mg solution for injection (Xgeva®) is given once every four weeks for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.

Reference: Drug Safety Update, Volume 6, Issue 3, October 2012 at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199558

Hypotonic saline in children: fatal hyponatraemia

United Kingdom — Four children have died of cerebral oedema caused by very low levels of serum sodium after receiving intravenous hypotonic saline (0.18% sa-line/4% glucose solution) in hospital. This solution is now contraindicated in children except under expert medical supervision in paediatric specialist settings – such as renal, cardiac, liver, high dependency and intensive care units.

Intravenous hypotonic saline (0.18% saline/4% glucose infusion solution) is given to maintain normal fluid and electro-lyte requirements or to replenish substan-tial deficits or continuing losses.

Following the restart of a public inquiry, primarily into the deaths of three children in the UK who died of cerebral oedema secondary to hyponatraemia after ad-ministration of intravenous hypotonic saline, the Commission on Human Medicines (CHM) has recently reviewed all data on the benefits and risks of this solution when used in children.

There have been over 50 reported per-manent neurological injuries or deaths in children worldwide as a result of iatro-genic hyponatraemia associated with the use of hypotonic intravenous fluids, often in previously healthy children undergoing routine elective surgery. In addition, seve-ral published studies and reviews have demonstrated hyponatraemia after ad-ministration of hypotonic intravenous fluids such as 0.18% saline/4% glucose (1–4). On the basis of the evidence from the review, the CHM concluded that the use of 0.18% saline/4% glucose should be contraindicated in all but a limited group of children treated by experts in


377


Denosumab 60 mg solution for injection (Prolia®) is given once every six months for the treatment of osteoporosis in post-menopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk.

Signs and symptoms of hypocalcaemia include altered mental status, tetany, seizures and QTc prolongation. Hypo-calcaemia with denosumab most com-monly occurs within the first six months of dosing, but it can occur at any time during treatment

Reference: Drug Safety Update, Volume 6, Issue 3, October 2012 at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199560

Axitinib: prescriber reviewAustralia — Recently marketed, axitinib (Inlyta®) is another addition to the group of tyrosine kinase inhibitors — sorafenib, sunitinib and pazopanib — for renal cell carcinoma. Its anti-angiogenic effects stem from its inhibition of the vascular endothelial growth factor receptors (1–3).

Early trials of axitinib in patients with refractory metastatic disease were promising (1,2). In a more recent open-label randomized phase III trial of 723 patients, axitinib (5 mg twice daily) was compared with sorafenib (400 mg twice daily). At enrolment, patients had progres-sive disease despite previous treatment with sunitinib, bevacizumab plus interfe-ron alfa, temsirolimus or cytokines.

The safety of axitinib seems to be com-parable to sorafenib. Adverse reactions were very common, with over half of the patients in the trial having their axitinib dose reduced or interrupted because of an event. Diarrhoea, hypertension, fatigue, decreased appetite, nausea, dysphonia and hand-foot syndrome were

the most common. Thrombocytopenia, lymphopenia, creatinine elevation, hypo-calcaemia and lipase elevation were also common. Axitinib can affect thy-roid and liver function so these should be measured at baseline and regularly during treatment.

High blood pressure is a problem with axitinib and should be controlled with antihypertensives. In persistent cases, the axitinib dose may need to be reduced, or interrupted then restarted at a lower dose when blood pressure has norma-lised. Proteinuria occurs with axitinib and should be monitored before and during treatment.

Axitinib is metabolized mainly by cyto-chrome P450 (CYP) 3A4, but also by CYP1A2, CYP2C19 and UGT1A1 so there is a potential for drug interactions. Concomitant use of strong CYP3A4 inhibitors or inducers may affect axitinib concentrations.

The prognosis for patients with advanced renal cell carcinoma is poor. Axitinib provides another option for those who have relapsed despite previous treat-ment. Although it may temporarily reduce disease progression, it does not seem to prolong overall survival any more than sorafenib. It is not known how axitinib will compare to other treatments for this disease.

Extracted from the Australian Prescriber, Volume 35, Number 5, 2012 at http://www.australianprescriber.com

References

1. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975–84.

2. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462–8.


378


3. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378: 1931–9.

Velaglucerase alfa: prescriber reviewAustralia — Gaucher disease is one of the lysosomal storage diseases. A genetic disorder results in a lack of glucocerebro-sidase. This enzyme deficiency leads to accumulation of glucocerebroside in macrophages, with enlargement of the liver and spleen. There can be bone involvement, anaemia and thrombo-cytopenia.

Enzyme replacement therapy has been available since the 1990s, first with alglucerase and later with the genetically engineered imiglucerase. While imi-glucerase was produced from Chinese hamster ovary cells, velaglucerase alfa is produced from human fibroblast cell lines. It has the same amino acid sequence as natural glucocerebrosidase.

As Gaucher disease is relatively rare (only about 400 patients in Australia), the clinical trials of velaglucerase have been small. In a trial of adults with no recent use of imiglucerase, 12 symptomatic pa-tients were given intravenous infusions of velaglucerase every other week for up to nine months. There were improvements in their haemoglobin and platelet counts. Liver and spleen volumes reduced. These improvements were sustained in nine patients who entered an extension study for an additional 39 months (1).

A phase III study randomized 34 patients to be treated with velaglucerase 60 units/kg or imiglucerase for nine months. Patient haemoglobin concentration was the primary outcome. Mean haemo-globin increased and there was also an increase in mean platelet counts and decreases in liver and spleen volumes.

These results showed that the efficacy of velaglucerase is not inferior to that of imiglucerase.

A shortage of imiglucerase in 2009 led to patient treatments being reduced. Some of the effects of reduced treatment were reversed in a group of 32 patients who were switched to velaglucerase. However, imaging in ten of these patients detected an increase in liver volume in five patients after six months of velaglu-cerase (2).

The safety data for velaglucerase came from 94 adults and children. Reactions to the infusion were the most common problem. These included headache, fever, nausea, dizziness and altered blood pressure. Adverse events which were more frequent than with imigluce-rase included headache, fever, diarrhoea, hypertension and arthralgia. Patients may also complain of bone pain or back pain. No data are available concerning the use of velaglucerase in pregnancy or lactation.


References

1. Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651–6.

2. van Dussen L, Cox TM, Hendriks EJ, Morris E, Akkerman EM, Maas M, et al. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Hae-matologica 2012 Jul 6. doi:10.3324/haema-tol.2011.059071.

Cyclizine lactate: prescriber review Australia — Cyclizine, an antihistamine, is already being used (tablets and injec-table solution) as an antiemetic after


379


occasionally occurred in patients with underlying neuromuscular disorders.

Because of its anticholinergic effects, cyclizine may precipitate urinary retention and incipient glaucoma. Monitoring is recommended in patients with glaucoma, obstructive disease of the intestine, liver disease, epilepsy and prostatic hyper-trophy. As cyclizine may cause thickening of bronchial secretions, it should be used with caution in patients with asthma or chronic obstructive pulmonary disease. This drug may increase the adverse effects of other anticholinergic drugs.

Cyclizine is contraindicated in patients with severe heart failure. It is a category B3 drug and its use in pregnancy and lactation is not recommended.

This drug is effective for preventing post-operative nausea and vomiting, and is comparable to other antiemetics such as ondansetron, granisetron and droperidol. Cyclizine is not recommended for children and there have been no studies in older people.


References

1. Carlisle J, Stevenson CA. Drugs for pre-venting postoperative nausea and vomiting. Cochrane Database Syst Rev 2008, issue 4.

2. O’Brien CM, Titley G, Whitehurst P. A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in children. Anaesthesia 2003;58:707–11.

3. Laffey JG, Boylan JF. Cyclizine and droperi-dol have comparable efficacy and side effects during patient-controlled analgesia. Ir J Med Sci 2002;171:141–4.

4. Johns RA, Hanousek J, Montgomery JE. A comparison of cyclizine and granisetron alone and in combination for the prevention of pos-toperative nausea and vomiting. Anaesthesia 2006;61:1053–7.

surgery in Australia. However, the solution for injection (Valoid ®) has only recently been approved by the Therapeu-tic Goods Administration.

A Cochrane review of antiemetics ana-lysed 10 studies of parenteral cyclizine (1). The trials were mainly in women having surgery (caesarean, laparoscopy), except for one study in boys. An analy-sis of these studies found that cyclizine decreased the risk of nausea by 65% and vomiting by 55%, compared to placebo. Overall, cyclizine’s antiemetic effect was comparable to ondansetron. However in the study of boys having surgery for hypospadias, cyclizine was no better than placebo (2).

In a trial not included in the review, cyclizine was compared to droperi-dol in patients administering their own analgesia after surgery. Thirty women were randomized to receive cyclizine or droperidol during surgery and then after, intravenously, with patient-controlled mor-phine. Nausea scores were comparable between treatments, with three patients in each group needing extra antiemetics (3).

Cyclizine has also been used in com-bination with other antiemetics. Before anaesthesia, 960 women undergoing day surgery were given intravenous cyclizine 50 mg, intravenous granisetron 1 mg, or both. Postoperative nausea and vomi-ting were less common with combination treatment than with cyclizine or granise-tron alone (4).

Drowsiness is common with cyclizine and it may have additive effects with alcohol and other drugs that cause nervous system depression such as hypnotics, sedatives and anaesthetics. Other adverse effects include dizziness, dry mouth, constipation, blurred vision, headache, somnolence, dyskinesia, tremor, convulsions, transient speech disorders and injection-site reactions. Disorientation, restlessness, agitation, insomnia and hallucinations have also been reported. Temporary paralysis has


380


Drug-induced liver injury (DILI) can be classified as hepatocellular, cholestatic or mixed depending on the specific liver function test abnormalities that occur. As with other liver diseases, DILI can present with jaundice, malaise, abdominal pain, unexplained nausea and anorexia.

Antibiotics are a common cause of DILI, probably because of the high rate of exposure in the community. Most cases are idiosyncratic and are therefore rare, unpredictable (from the pharmacology of the antibiotic) and largely dose-independent (1, 2).

Genetic variability is considered to be the most important risk factor, although specific genetic markers have not yet been elucidated for most antibiotics (1). Other potential risk factors include: previous hepatotoxic reaction to a specific antibiotic; female sex; increasing age, and co-morbid illnesses.

An important exception are tetracyclines, where high doses seem to be a predictor of liver injury (2).

Treatment consists primarily of withdrawal of the causative antibiotic and supportive care if required. Most cases are mild and self-limiting (1). However, rare cases of acute liver failure and death have been reported (1). Chronic liver disease is a very rare complication but is more likely to develop if the antibiotic is continued despite evidence of liver injury.

The Centre for Adverse Reactions Moni-toring (CARM) has received a total of 360 reports of liver injury associated with the use of non-tuberculosis antibiotics since January 2000. Seven reports (2%) involved a fatality. The majority of CARM reports of liver injury were associated with β-lactam penicillins. Amoxicillin/clavula-nic acid, flucloxacillin and erythromycin were the antibiotics most often implicated in the development of liver injury in New Zealand.

Cardiovascular safety of NSAIDsEuropean Union —The European Medicines Agency (EMA) has finalized a review of recently published information on the cardiovascular safety of nonsteroi-dal anti-inflammatory drugs (NSAIDs).

The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that evidence from newly available published data sources, inclu-ding meta-analysis of clinical trials and observational studies, and the results of an EU-funded independent research project, the ‘Safety of nonsteroidal anti-inflammatory drugs’ (SOS) project, on the cardiovascular safety of this class of medicines confirm findings from previous reviews, conducted in 2005 and 2006.

Most of the data related to the three most widely used NSAIDs – diclofenac, ibuprofen and naproxen. In relation to naproxen and ibuprofen, the CHMP was of the opinion that the current treatment advice adequately reflects the knowledge regarding the safety and efficacy of these medicines.

For diclofenac, the latest evidence appears to show a consistent but small increase in the risk of cardiovascular side effects compared with other NSAIDs, similar to the risks of COX-2 inhibitors, another class of painkillers.

Reference: European Medicines Agency Press Release, EMA/CHMP/667707/2012.19 October 2012 at http://www.ema.europa.eu

Antibiotics and liver Injury New Zealand — Prescribers are advised of the risk of liver injury associated with antibiotic treatment. Early recognition is essential as withdrawal of the causative antibiotic is the most effective treatment (1). Specialist advice should be sought in all cases of severe liver injury and in patients who fail to improve despite with-drawal of the antibiotic.


381


Healthcare professionals should be aware of the association of new-onset T2DM with the use of statins and are advised to monitor at risk patients accord-ing to best practice guidelines.

Extracted from Prescriber Update, Vol. 33, No. 3, September 2012 at http://www.medsafe.govt.nz/profs/PUArticles References

1. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–42.

2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Archives of Internal Medicine 2012;172:144–52.

Antimalarials: assessing resistance riskThe Medicines for Malaria Venture has developed a framework to evaluate the risk of resistance for the antimalarial compounds in its portfolio. A paper based on this work A framework for assessing the risk of resistance for antimalarials in development has been published in the Malaria Journal at http://www.malariajour-nal.com/

A cross-resistance test using a panel of multidrug-resistant strains of the para-site will check for pre-existing resistance liability. This will ensure that none of MMV’s compounds are cross-resistant with other drugs.

The framework also includes selection experiments in the laboratory that mea-sure how easy it is for the parasite to develop resistance, in other words, the likelihood of the occurrence of mutations that confer resistance. This is achieved by measuring the minimal inoculum for resistance — the minimum number of parasites from which a resistant one is

Extracted from Prescriber Update, Vol. 33, No. 3, September 2012 at http://www.medsafe.govt.nz/profs/PUArticles

References

1. Polson JE. Hepatotoxicity due to antibiotics. Clinics in Liver Disease 2007;11:549–61, vi.

2. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. Journal of An-timicrobial Chemotherapy 2011;66:1431–46.

3. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opinion on Drug Safety 2007;6:673–84.

Statins: risk of diabetes mellitus?New Zealand — Statins (HMG-CoA reductase inhibitors) are one of the most widely prescribed classes of medicinal products in New Zealand. PHARMAC estimates that over 1.7 million statin pres-criptions were written for over 400,000 patients during 2011.

Recent publications have suggested that there may be an association of new-onset type 2 diabetes mellitus (T2DM) with the use of statins (1, 2). The Medicines Ad-verse Reactions Committee (MARC) has reviewed relevant studies and concluded that there is a small, but statistically signi-ficant association, particularly in patients already at risk of T2DM. Nevertheless, the MARC considered that the benefits of statin treatment clearly outweigh any risk of developing new-onset T2DM.

A total of six meta-analyses were re-viewed by the MARC. The studies all had limitations and suggest that other indivi-dual risk factors may also contribute to the association. The risk factors included: raised fasting glucose level; body mass index greater than 30kg/m2; raised trigly-cerides, and history of hypertension.

There was insufficient data to exclude an effect with any individual statin or to sup-port a dose-dependent relationship.


382


An increased risk of myopathy/rhabdo-myolysis within the recommended dose range for simvastatin can also be seen with concomitant administration of certain medications. Simvastatin is indicated in patients at high risk of coronary events.

Concomitant use of the recommended dosage of simvastatin with certain drugs and grapefruit juice increases the risk of myopathy/rhabdomyolysis. Patients currently tolerating the 80 mg dose of simvastatin who need an interacting drug that is either contraindicated, such as potent inhibitors of CYP3A4, cyclospo-rine, danazol, and gemfibrozil, or asso-ciated with an increase of plasma level of simvastatin should be switched to an alternative statin with less potential for a drug-drug interaction.

Reference: Communication from Merck Canada Inc. dated 7 November 2012 athttp://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/zocor_hpc-cps-eng.php

likely to be selected by drug pressure. Although this is already being done, the framework offers a standard, systematic method.

This new framework could also be used by other malaria researchers to test their compounds for potential resistance, measure the genetic ability of parasites to develop resistance and the intensity of the resistance.

Reference: MMV Press Release, 22 August 2012 at http://www.mmv.org

Simvastatin: increased risk of myopathy/rhabdomyolysisCanada — Healthcare professionals have been informed of new safety recommendations on dosage related to the increased risk of myopathy/rhabdo-myolysis, particularly with the 80 mg dose of simvastatin (Zocor®, and generics).

Spontaneous monitoring systems are useful in detecting signals of relatively rare, serious or unexpected adverse drug reactions. A signal is defined as “reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented pre-viously. Usually, more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information”. All signals must be vaidated before any regulatory decision can be made.


383


Regulatory Action and NewsNew task force for antibacterial drug developmentUnited States of America — The Food and Drug Administration has announced the formation of an internal task force to support development of new antibacterial drugs, a critical public health goal and priority for the agency.

As part of its work, the Antibacterial Drug Development Task Force will assist in developing and revising guidance rela-ted to antibacterial drug development, as required by the Generating Antibiotic Incentives Now (GAIN) Title of the Food and Drug Administration Safety and In-novation Act (FDASIA).

Research and development for new antibacterial drugs has been in decline in recent decades and the number of new FDA-approved antibacterial drugs has been falling steadily since the 1980s. During this time, the persistent and some-times indiscriminate use of existing anti-bacterial drugs worldwide has resulted in antibacterial drug resistance or antibiotic resistance.

More than 70% of the bacteria that cause hospital-associated infections are resis-tant to at least one type of commonly used antibacterial drug.

The task force plans to:

• Explore novel scientific approaches to facilitate antibacterial drug develop-ment, including broader use of clinical pharmacology data, statistical meth-ods, innovative clinical trial designs, additional available data sources, and advancement of alternative measures to evaluate clinical effectiveness of potential new therapies.

• Identify issues related to unmet medical needs for antibacterial drugs, reasons for the lack of a robust pipeline for antibacterial drug development, and new approaches for weighing the risks, benefits, and uncertainties of potential new antibacterial drugs.

• Evaluate existing FDA guidance related to antibacterial drug development, determine if revision or elaboration is needed, and identify areas where future guidance would be helpful, as set out in the GAIN Title of FDASIA.

• Use existing collaborative agreements to work with think tanks and other thought leaders to explore various ap-proaches that could enable antibacterial drug development, including innovative study designs and statistical analytical methods.

Reference: FDA News Release, 12 Septem-ber 2012 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm

NIBSC: new MHRA centre United Kingdom — On 1 April 2013 the National Institute for Biological Standards and Control (NIBSC), currently part of the Health Protection Agency (HPA), will officially become a new centre of the Medicines and Healthcare products Regulatory Agency (MHRA) alongside the Clinical Practice Research Datalink (CPRD).

The MHRA and NIBSC already work closely together and have common interests in managing risks associated with biological medicines, facilitating development of new medicines safely and effectively, and maintaining UK expertise

384

WHO Drug Information Vol. 26, No. 4, 2012Regulatory Action and News

Under the Drug Act 1976, Pakistan was the first country in Asia to implement good manufacturing practices. Currently, there is a shortage of trained human resources across public and private sectors for pharmaceutical procurement, manage-ment and dispensation. Irrational use of medicines continues to increase health care costs. With enactment of the DRAP, the role of pharmacists is officially reco-gnized.

It is hoped that the new DRAP Act 2012 can serve as a tool to fill the gaps and also allow the huge Pakistani pharma-ceutical sector to play a role in improving access to safe medicine of good quality, at affordable cost. A copy of the DRAP Act is available at http://ppapak.org.pk/drap2012[1].pdf

Reference: Pakistan Pharmacists Association (PPA), 17 November 2012 at http://ppapak.org.pk

EU clinical trial regulation: public consultation United Kingdom — The European Commission proposes to simplify the rules for the conduct of clinical trials and harmonize the way trials are conducted in the European Union. The proposed Regulation will replace the Clinical Trials Directive 2001/20/EC which has been the subject of significant concern amongst commercial and academic researchers since its introduction in 2004.

It is widely acknowledged that the Direc-tive has reduced the attractiveness of the EU for conducting clinical trials on medicines. The Directive brought in unnecessary administrative and regu-latory burdens, lacked clarity in some aspects and some Member States have introduced additional requirements when implementing the Directive which limit harmonization, create delays and increase costs for researchers.

The number of clinical trials conducted in the European Union fell by 25% between

and ability to contribute to assuring the quality and safety of medicines in Europe and beyond.

These developments will create a new organization that is a world leader in supporting science and research and the regulation of medicines and medical devices, and will strengthen support provided to the UK’s medicine’s industry.

Reference: Medicines and Healthcare pro-ducts Regulatory Agency at http://www.mhra.gov.uk/NewsCentre/CON203876

New Pakistan drug regulatory authority Pakistan — The Drug Regulatory Autho-rity of Pakistan (DRAP) bill was enacted by the Government of Pakistan on 12 November 2012. The bill had earlier been approved by the National Assembly and Senate after being moved by the Minister for National Regulation and Services. DRAP is envisaged as regulating the manufacturing, import, export, storage, distribution and sale of therapeutic goods in line with the Drugs Act 1976.

The World Health Organization has provided support to Pakistan. Many missions were commissioned to review various aspects of the pharmaceutical regulations. The mission formulated and recommended the detailed framework that endeavors to strengthen the national medicines regulatory system. Pharma-ceutical manufacturers have been ad-vised of the technical guidance provided by WHO and the WHO Prequalification of Medicines Programme.

There was long awaited need to establish a national medicines regulatory authority to implement internationally recognized standards in the regulation of pharma-ceuticals. The tragic incidence in Lahore, where more than 160 cardiac patients died due to contaminated medicines, put more emphasis on the establishment of a regulatory authority in Pakistan.

385

WHO Drug Information Vol. 26, No. 4, 2012 Regulatory Action and News

2007 and 2011. In the UK, the number of commercial trials fell by 22% over the same period. Although this decline cannot be attributed solely to the Directive, it did have an effect on the cost and feasibility of conducting clinical trials.

The Medicines and Healthcare products Agency (MHRA) is consulting on the European Commission’s proposal for a Clinical Trial Regulation and are keen to hear the views of interested parties. Responses can be be sent by e-mail to [email protected].

Reference: Medicines and Healthcare pro-ducts Agency, 5 November 2012, at http://www.mhra.gov.uk/Publications/Consul-tations/Medicinesconsultations/MLXs/CON202300

Pegloticase approved for chronic tophaceous goutEuropean Union — On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for pegloticase (Krystexxa®), 8 mg/ml, concentrate for solution for infusion indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine-oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

The active substance of Krystexxa® is pegloticase, an ‘other antigout prepara-tion’ (M04AK02) and is a polyethylene-glycol-modified recombinant mammalian uricase of the therapeutic class ‘bio-urico-lytic agents that reduce serum uric acid’.

The benefits with Krystexxa® are its ability to reduce serum uric acid to an undetectable level in patients who have failed to respond to conventional urate-lowering therapy (xanthine-oxidase

inhibitors or uricosuric agents). The most common side-effects are infusion reac-tions/anaphylactic reactions and serious cardiac events, and gout flares have been identified.

Reference: European Medicines Agency at http://www.ema.europa.eu/ema/ index.jsp

Tofacitinib: approved for rheumatoid arthritisUnited States of America — The Food and Drug Administration has approved tofacitinib (Xeljanz®) to treat adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate.

The use of Xeljanz® was associated with an increased risk of serious infections, including opportunistic infections, tuber-culosis, cancers and lymphoma. Treat-ment is also associated with increases in cholesterol and liver enzyme tests and decreases in blood counts.

The FDA has approved Xeljanz® with a Risk Evaluation and Mitigation Strategy (REMS). The most common adverse reactions in clinical trials were upper respiratory tract infections, headache, diarrhoea, and inflammation of the nasal passage and the upper part of the pha-rynx.

Reference: FDA News Release, 6 Novem-ber 2012 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm?source=govdelivery

Rivaroxaban: extended indication approved for blood clottingUnited States of America — The Food and Drug Administration has ex-panded the approved use of rivaroxaban (Xarelto®) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

386


The most common adverse reactions reported by patients receiving Fycompa® in clinical trials include: dizziness, drow-siness, fatigue, irritability, falls, upper res-piratory tract infection, weight increase, vertigo, ataxia, gait disturbance, balance disorder, anxiety, blurred vision, dysarth-ria, asthenia, aggression, and hyper-somnia.

The Fycompa® label has a boxed warning on the risk of serious neuro-psychiatric events, including irritability, aggression, anger, anxiety, paranoia, euphoric mood, agitation, and mental sta-tus changes. Some of these events were reported as serious and life-threatening. Violent thoughts or threatening behavior were also observed in a few patients.

Fycompa® will be dispensed with a patient Medication Guide that provides important instructions on its use and drug safety information.

Reference: FDA News Release, 22 October 2012 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325038.htm

Regorafenib: approved for colorectal cancerUnited States of America — The Food and Drug Administration has approved regorafenib (Stivarga®) to treat patients with metastatic colorectal cancer.

Stivarga® is a multikinase inhibitor that blocks several enzymes that promote cancer growth. The drug was reviewed under the FDA’s priority review pro-gramme that provides an expedited six-month review for drugs that offer major advances in treatment or that provide treatment when no adequate therapy exists.

Colorectal cancer is the third most com-mon cancer in men and in women and the third leading cause of cancer death in men and in women in the United States.

Xarelto® is already FDA-approved to reduce the risk of DVTs and PEs from occurring after knee or hip replacement surgery, and to reduce the risk of stroke in non-valvular atrial fibrillation.

The major side effect observed is bleed-ing, similar to other anti-clotting drugs.

Reference: FDA News Release, 2 Novem-ber 2012 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/

Omacetaxine mepesuccinate: approved for chronic myelogenous leukaemiaUnited States of America — The Food and Drug Administration has approved omacetaxine mepesuccinate (Synribo®) to treat adults with chronic myelogenous leukemia (CML), a blood and bone mar-row disease.

On 4 September 2012, the FDA approved bosutinib (Bosulif®) to treat patients with chronic, accelerated or blast phase Phi-ladelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies.

The most common side effects reported during clinical studies include throm-bocytopenia, anaemia, neutropenia, febrile neutropenia, diarrhoea, nausea, weakness and fatigue, injection site reac-tion, and lymphopenia.


Perampanel: approved for partial onset seizuresUnited States of America — The Food and Drug Administration has approved perampanel (Fycompa®) to treat partial onset seizures in patients with epilepsy aged 12 years and older.

387


Stivarga® is being approved with a boxed warning indicating that severe and fatal liver toxicity occurred during clinical studies. The most common side effects reported include weakness or fatigue, loss of appetite, palmar-plantar erythro-dysesthaesia, diarrhoea, mucositis, weight loss, infection, high blood pres-sure, and dysphonia.


Teriflunomide: approved for multiple sclerosis United States of America — The Food and Drug Administration has approved teriflunomide (Aubagio®), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

For most people with MS, relapse is initially followed by remissions. However, over time, recovery periods may be in-complete, leading to progressive decline.

The most common side effects of Auba-gio® in clinical trials include diarrhoea, abnormal liver tests, nausea, and hair loss.

The Aubagio® label contains a boxed warning to alert prescribers and patients to the risk of liver problems, including death, and a risk of birth defects. Phy-sicians should carry out blood tests to check liver function before initiation and periodically during treatment. Aubagio® is labelled as pregnancy category X, which means women of childbearing age must have a negative pregnancy test before starting the drug and use effective birth control during treatment.

Aubagio® will be dispensed with a patient Medication Guide that provides important instructions on its use and drug safety information.


Ocriplasmin: approved for vitreomacular adhesionUnited States of America — The Food and Drug Administration has approved ocriplasmin (Jetrea®), the first drug to treat symptomatic vitreo-macular adhesion.

The most common side effects reported in patients treated with Jetrea® include eye floaters, bleeding of the conjunc-tiva, eye pain, photopsia, blurred vision, unclear vision, vision loss, retinal edema, and macular edema.


Florbetapir 18F: approved for neuritic plaque density imagingEuropean Union — The European Medi-cines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for florbetapir 18F (Amyvid®) as a diagnostic agent in patients who are being evalua-ted for Alzheimer Disease (AD) or other causes of cognitive decline.

Amyvid® is a radiopharmaceutical agent used in positron emission tomography (PET) imaging which can highlight amy-loid protein plaques in the brain.

Alzheimer disease is the most com-mon cause of dementia in the elderly, affecting up to 5.1 million people in the European Union. Accurate diagnosis of AD has been hampered to date by the lack of diagnostic tests. The current gold standard for confirming a clinical diagnosis of AD is post-mortem autopsy.

388


A negative Amyvid® PET scan can rule out the presence of AD, and is expected to reduce the frequency of false positive diagnosis. However, a positive Amyvid® scan is consistent with, but does not independently establish, the diagnosis of AD since β-amyloid neuritic plaque deposition may also be present in the brain of asymptomatic elderly and some neurodegenerative dementias, including Parkinson disease dementia and Lewy body dementia.

Common adverse reactions include head-ache and taste alterations.


Insulin degludec: approved for diabetes mellitusEuropean Union —The European Medi-cines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for insulin degludec, a new basal ana-logue insulin for the treatment of diabetes mellitus in adults. It is introduced in a pre-filled pen in two formulations — 100 units/ml and 200 units/ml.

This is the first insulin approved in Europe at a higher strength than the EU-wide standard of 100 units/ml, for many years the only strength of insulin available across the EU. It will be marketed under the trade name Tresiba®. The approval of a 200 units/ml insulin, allowing doses up to 160 units in a single injection, is expected to respond to the growing need for higher-dose insulin.

To reduce the risk of medication errors, the 200 units/ml strength is only pres-ented in a pre-filled pen, both strengths are dialled-in units, the pack design of the two strengths has been clearly differenti-ated and an educational programme has been agreed.


Linaclotide: approved for irritable bowel syndrome

European Union — The European Medi-cines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended authorization of linaclotide (Constella®) for adults with moderate to severe irritable bowel syndrome with constipation, a common subtype of the disease. Linaclotide is a new, synthetic 14-amino-acid peptide, which works by increasing the secretion of fluid in the intestine and accelerating the movement of material through the gut. It is taken by mouth once a day at least 30 minutes before a meal.

The CHMP based its recommendation on the results of two main clinical studies showing superiority of linaclotide over placebo in terms of improving symptoms after 12 weeks. These effects were sustained for at least six months. How-ever, it noted that around half of the patients in the main studies did not respond to linaclotide sufficiently, leading to the recommendation that prescribers should assess patients regularly and reconsider treatment if there is no improvement in symptoms after four weeks.

The most common side effect in clinical trials was diarrhoea, which was repor-ted in a fifth of the patients taking the medicine. The Agency is recommending that patients with severe or prolonged diarrhoea should be monitored closely when taking linaclotide and that it should be used with caution in patients prone to water or electrolyte-balance disturbances.

Reference: European Medicines Agency Press Release, EMA/CHMP/611096/2012.21 September 2012 at http://www.ema.europa.eu

389


process and prevent further complications such as infections in burn victims.

Data from clinical studies have shown that, compared to standard of care, NexoBrid® reduces the time to successful eschar removal and the need for excisio-nal surgery in patients with severe burn wounds. The studies have also shown that wounds not treated optimally after debridement with NexoBrid® can be associated with longer time to complete wound closure.

Reference: European Medicines Agency Press Release, EMA/CHMP/406865/2012.21 September 2012 at http://www.ema.europa.eu

Drug-eluting stent approved for peripheral arterial disease

United States of America — The Food and Drug Administration has approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a femoropopliteal artery narrowed or blocked as a result of peripheral artery disease (PAD). The Zilver PTX Stent includes a self-ex-panding metal stent that keeps an artery open coated on its outer surface with paclitaxel. In clinical studies, the most common major adverse event was reste-nosis requiring additional treatment to re-establish adequate flow in the artery. The device is contraindicated in patients with stenoses that cannot be dilated to permit passage of the catheter or proper placement of the stent, patients who can-not receive recommended drug therapy due to bleeding disorders, or women who are pregnant, breastfeeding, or plan to become pregnant in the next five years.

Reference: FDA News Release, 15 Novem-ber 2012 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327068.htm

Meningitis B Vaccine approved for Neisseria meningitidis

European Union —The European Medi-cines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorization for Bexsero®, a new vac-cine intended for the immunization of indi-viduals over two months of age against invasive meningococcal disease caused by Neisseria meningitidis group B.

There is currently no authorized vac-cine available in the European Union for bacterial meningitis caused by Neisseria meningitidis group B. Each year, approximately 1.2 million cases of invasive meningococcal disease are recorded worldwide, of which 7000 occur in Europe. Over 90% of cases of menin-gococcal meningitis and septicaemia are caused by five of the 13 meningococcal serogroups, specifically groups A, B, C, W135 and Y. In Europe, group B is the most prevalent meningococcal serogroup.Whereas there are authorized vaccines to protect against meningococcal disease caused by groups A, C, W135 and Y, there is currently none available that provides broad coverage against group B meningococcal disease.

Reference: European Medicines Agency Press Release, EMA/CHMP/728052/2012.16 November 2012 at http://www.ema.europa.eu

Bromelain-based debriding agent approved for burn woundsEuropean Union — The European Medi-cines Agency (EMA) has recommended approval of a concentrate of proteolytic enzymes enriched in bromelain (Nexo-Brid®), an orphan-designated medicine, for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burn. Eschar is the dried-out, thick, leathery, black necrotic tissue that covers severe burn wounds. Its removal is essential to initiate the wound healing

390


Human insulin products: mark-eting authorization application withdrawalEuropean Union — The European Medi-cines Agency (EMA) has been notified by the manufacturer of its decision to withdraw its application for a centralized marketing authorizations for the human insulin medicines Solumarv®, Isomarv® and Combimarv® (human insulin), all as 100 international units (IU)/ml solution for injection. They were intended to be used for the treatment of patients with diabetes mellitus who require insulin for the main-tenance of glucose homeostasis.

The company stated that it has decided to withdraw the application to have sufficient time to repeat and submit bioequivalence T1D [type-1 diabetes] pharmacokinetic/pharmacodynamic data on each clamp study in order to comply with the planned new insulin guideline.

Reference: European Medicines Agen-cy Press Release. 27 November 2012 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001665.jsp&mid=WC0b01ac058004d5c1

Ridaforolimus: marketing authori-zation application withdrawalEuropean Union — The European Medi-cines Agency (EMA) has been notified by the manufacturer of its decision to withdraw its application for a centralized marketing authorization for the medicine ridaforolimus (Jenzyl®), 10-mg tablets. Ridaforolimus was intended to be used for the treatment of patients with metasta-tic soft-tissue sarcoma or bone sarcoma as a maintenance therapy.

The company stated that it has decided to withdraw the application since the CHMP considers that the data provided do not allow the Committee to conclude on a positive benefit-risk balance.

Reference: European Medicines Agen-cy Press Release. 30 November 2012 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001667.jsp&mid=WC0b01ac058004d5c1

391


Evaluation of psychotropic substances The Thirty-fifth WHO Expert Committee on Drug Dependence met in Hammamet, Tunisia, 4–8 June 2012. This was the first meeting where the Guidance on the WHO review of psychoactive substances for international control, adopted by the WHO Executive Board in January 2010, was applied.

The report of this meeting contains a summary of the Committee’s evalua-tions. Eleven substances were evalua-ted, two of which were critical reviews: γ-hydroxybutyric acid (GHB) and keta-mine. GHB was recommended to be rescheduled from Schedule IV to Sche-dule II of the Convention on Psychotropic Substances.

The report also discusses the nine sub-stances that were pre-reviewed: dextro-methorphan, tapentadol, N-benzylpipera-zine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphe-nyl)piperazine (MeOPP), 1-(3,4-methy-lenedioxybenzyl)piperazine (MDBP), γ-butyrolactone (GBL), and 1,4-butane-diol (1,4-BD). Of these, tapentadol, BZP, GBL and 1,4-BD were recommended for critical review.

Issues identified for consideration at future Expert Committee meetings are listed in the report. Also discussed were: the use of terms, use of pharmacovigi-lance data for the assessment of abuse and dependency potential, balancing medical availability and prevention of abuse of medicines manufactured from controlled substances, and improving the process for substance evaluation.

The printed version of the report is avai-lable from the WHO Bookshop in English and French (http://apps.who.int/bookor-ders) and is currently available online at http://www.who.int/medicines

Reference: World Health Organization. WHO Access and Control Newsletter, Number 14, November 2012. http://www.who.int/medicines

Pharmacovigilance: towards a safer use of medicinesPractical topics in pharmacovigilance is a handbook addressed to practitioners with the aim of highlighting the importance of early adverse drug reaction identification in clinical practice. The book describes practical challenges facing physicians and how to deal with them.

Information and reviews address various subjects: clinically-significant drug-drug interactions — including those involving herbals and food — and interactions that can cause hospitalization due to bleed-ing, falls, electrolyte disturbances and cardiovascular symptoms. The handbook also contains practical information on the role of pharmacogenetics, hyper-sensitivity reactions and drug-induced Q-T interval prolongation.

A description of activities within the Argentinian Food and Drug Administration (ANMAT) and the structure and functions of the national pharmacovigilance system are also provided. Finally, it gives com-plete and practical guidance on better communication of pharmacovigilance issues. All chapters are fully referenced and the book includes easy-to-read tables.

Reference: Practical topics in pharmacovigi-lance. Eds. Raquel Herrero Comoglio and Luis

Recent Publications, Information and Events

392


by soil, and affect the poorest and most deprived communities. More than 1.5 billion people, or 24% of the world’s population are infected, with the greatest numbers occurring in sub-Saharan Africa, the Americas, China and east Asia.

The current strategy to control infections is through periodic deworming of at-risk people living in endemic areas. The research priorities identified are focused on improving this control through five major core themes:

• Intervention.

• Epidemiology and surveillance.

• Environmental and social ecology.

• Data and modelling.

• Fundamental biology.

The report also outlines the need for appropriate health research policies and building research capacity in disease-endemic countries where the infections occur.

The Disease Reference Group on Hel-minth Infections is part of an independent think tank of international experts, established by TDR to identify key research priorities. The mandate was to evaluate information on research and challenges in helminthiases of public health importance, including onchocer-ciasis, lymphatic filariasis, soil-transmitted helminthiases, schistosomiasis, food-borne trematodiases and taeniasis/cysticercosis.

This is one of ten disease and thematic reference group reports that have come out of the TDR think tank contributing to the development of the Global Report for Research on Infectious Diseases of Poverty.

Reference: Helminth infections research prio-rities identified. TDR news item. 16 October 2012 at http://www.who.int/tdr/news/2012/hel-minth_infections2/en/index.html

Alesso in collaboration with ANMAT and the Uppsala Monitoring Centre. ISSBN 978-987-28104-1-2. Sociedad Argentina de Farmacovi-gilancia at http:www.safv.org.ar

Drug-resistant tuberculosis reportMedecins Sans Frontières and the Inter-national Union Against Tuberculosis and Lung Disease have released the second edition of DR-TB Drugs Under the Micros-cope, a report examining prices, sources and issues surrounding medicines used for treatment of drug-resistant TB (DR-TB). With new, faster tools diagnosing more people than ever before, DR-TB is a growing epidemic requiring an immediate treatment response.

The report also looks at recent progress on drugs in the pipeline, with two com-pletely new compounds (bedaquiline and delamanid) due for approval soon. How these drugs will be used in treatment regimens will be critical in managing DR-TB treatment in the future — whether they are added to existing regimes or new ones are devised. The report also looks at the issues surrounding access to DR-TB drugs, with a focus on linezolid and clofazimine.

Reference: Medecins Sans Frontières – Access Campaign. Press Release. DR-TB Drugs Under the Microscope (second edition) at http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition

Helminth infection research Research gaps and challenges have been identified in a new report on hel-minth infections, Helminth infections research priorities identified, published by the Disease Reference Group on Helminth Infections of the Special Pro-gramme for Research and Training in Tropical Diseases (TDR) .

Helminths are a broad range of organ-isms that include intestinal parasitic worms. They are the most common infections worldwide when transmitted


393


Malaria and dengue control: genetically modified mosquitoes A public online consultation is now being held concerning the draft guidance framework to provide quality standards for assessing the safety and efficacy of genetically modified (GM) mosquitoes for malaria and dengue control.

So far, trials of GM mosquitoes have been conducted in enclosed spaces, such as large cages, or under controlled field conditions. Once published, the guidance document is intended to help those plan-ning and conducting all phases of testing.

The main method currently under discus-sion seeks to suppress the number of wild mosquitoes by changing the males genetically so that their offspring do not survive to adulthood after release in the field.

Another method, which is still under deve-lopment, is to genetically change mos-quitoes so that they no longer transmit malaria parasites and dengue pathogens.

The guidance framework development process has been led by two organi-zations: TDR, the Special Programme for Research and Training in Tropical Diseases and the Foundation for the National Institutes of Health (FNIH) in the United States. Drafting and review were undertaken through collaboration with more than 40 experts worldwide. It has gone through a series of reviews by health experts in developing and deve-loped countries, as well as experts from other fields including molecular biology, ecology, regulatory requirements, and ethical, social and cultural issues. This is its first public consultation.

TDR has been working for several years to develop a pool of scientists well trained in the assessment and management of biosafety for human health and the environment in relation to the potential use of GM mosquitoes for the control of

vector-borne diseases. Courses in bio-safety have been held in regional training centres in Africa, Asia and Latin America for 148 participants from 51 countries between 2008 and 2010.

Reference: Special Programme for Research and Training in Tropical Diseases. Guidance Framework for testing genetically modified mosquitoes.TDR news item. 29 October 2012. http://www.who.int/tdr/news/2012/guidance_framework/en/index.html

Patent opposition databaseA new online resource for civil society and patient groups in developing countries to challenge unwarranted medicines patents has been launched by Médecins Sans Frontières (MSF). The Patent Opposition Database comes as many developing countries face dramatically high medi-cines prices because patents block the production of lower-cost generic versions.MSF relies on affordable medicines for its medical work in more than 60 countries; in the case of HIV treatment, over 80 per cent of medicines used in developing countries are generics.

A ‘patent opposition’— a legal challenge to prevent or overturn the granting of an unwarranted patent — is allowed under international trade rules as a way to keep checks and balances on pharmaceutical patenting. In countries where they are allowed, like Brazil, India or Thailand, patent oppositions have successfully prevented undeserved patent monopolies from being granted and allowed generic competition to bring the price of medi-cines down.

Successful examples include the opposi-tion by Indian groups to a patent applica-tion in India on the HIV fixed-dose-com-bination zidovudine/lamivudine, on the grounds that it was not a ‘new invention’, but simply the combination of two existing drugs. This combination is now widely used in HIV treatment in developing countries.


394


A pre-grant opposition filed by the Cancer Patient Aid Association was also the spur for the rejection of a patent application on the salt form of imatinib, on the basis that the medicine was merely a new form of an old medicine.

The Patent Opposition Database aims to guide civil society groups through the process of challenging an unjustified patent. It will allow organizations to forge new alliances and share vital specialist knowledge, as a patent application can often be challenged in different countries on the same basis. It contains a search-able listing of 45 patent oppositions rela-ting to key medicines and over 200 other supporting documents that will aid in the building of future patent oppositions.

Reference: Médecins Sans Frontières (MSF) Press Release, 2 October 2012 at http://www.patentoppositions.org

Clinical management of dengueThe Handbook for clinical management of dengue has been produced to help heal-thcare practitioners at all levels manage dengue. Aspects of managing severe cases of dengue are also described for practitioners at higher levels of health care. Additional and more specific guid-ance on the various areas related to cli-nical management of dengue (from other sources in WHO and elsewhere) are cited in the reference sections. This handbook is not intended to replace national treat-ment training materials and guidelines, but it aims to assist in the development of such materials produced at a local, national or regional level.

This publication complements the 2009 edition of Dengue: Guidelines for diagno-sis, treatment, prevention and control.

Reference: Special Programme for Research and Training in Tropical Diseases. The Hand-book for clinical management of dengue. 2012. http://www.who.int/medicines/areas/quality_safety/35thecddmeet/en/index.html

Infectious diseases: new peer–reviewed journal freely available onlineInfectious Diseases of Poverty is an open access, peer–reviewed journal publishing topics and methods that address essen-tial public health questions. These include various aspects of the biology of pathogens and vectors, diagnosis and detection, treatment and case manage-ment, epidemiology and modeling, zoonotic hosts and animal reservoirs, control strategies and implementation, new technologies and application. Trans-disciplinary or multisectoral effects on health systems, ecohealth, environmental management, and innovative technology are also considered.

The inaugural issue is themed Health Systems Research for Infectious Di-seases of Poverty. Twelve articles have been selected to discuss treatment stra-tegies, disease surveillance and interven-tions, as well as innovative programmes which provide a link between policy level and academic research.

Research submitted to Infectious Di-seases of Poverty will follow an efficient online submission process, a rapid, high quality peer-review service, and imme-diate publication upon acceptance. There are no colour charges or limits on the number of figures or embedded movies.

The published version of articles will be immediately placed in PubMed Cen-tral and other freely accessible full text repositories. Publication costs are cur-rently supported by the National Institute of Parasitic Diseases and the Chinese Centre for Disease Control and Preven-tion, so authors do not need to pay an article-processing charge.

Reference: Infectious Diseases of Poverty at http://www.idpjournal.com/about/


395


The following anatomical therapeutic chemical (ATC) codes, defined daily doses (DDDs) and alterations were agreed by the WHO International Working Group for Drug Statistics Methodology in October 2012. Comments or objections to the de-cisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology at [email protected]. The new ATC codes and DDDs will be considered final and be included in the January 2014 issue of the ATC Index. The inclusion of a substance in the lists does not imply any recommendation for use in medicine or pharmacy.

New ATC 5th level codes: aflibercept L01XX44 amlodipine and diuretics C08GA02 bedaquiline J04AK05 canagliflozin A10BX11 candesartan and amlodipine C09DB07 cineole R05CA13 cridanimod L03AX18 dabrafenib L01XE23 dimethyl fumarate N07XX09 dolutegravir J05AX12 ethacizine C01BC09 gemigliptin A10BH06 indacaterol and glycopyrronium bromide R03AL04 ipidacrine N06DA05 laquinimod N07XX10 levofloxacin, combinations with other antibacterials J01RA05 lixisenatide A10BX10 lorcaserin A08AA11 mebicar N06BX21 meldonium C01EB22 mercaptamine S01XA21 metformin and repaglinide A10BD14 olodaterol R03AC19 perindopril, amlodipine and indapamide C09BX01 phenibut N06BX19 ponatinib L01XE24 radium (223Ra) dichloride V10XX03

ATC/DDD Classification

ATC/DDD Classification (Temporary)

ATC level INN Common name ATC code

396


rosuvastatin and acetyl- salicylic acid C10BX05 rosuvastatin and ezetimibe C10BA06 sequifenadine R06AX32 technetium (99mTc) etarfolatide V09IA08 teriflunomide L04AA31 trametinib L01XE25 trastuzumab emtansine L01XC14 ulipristal G03XB02 vilanterol and fluticasone furoate R03AK10 vilanterol and umeclidinium bromide R03AL03 vintafolide L01CA06

New ATC level codes (other than 5th levels):ACE inhibitors, other combinations C09BXAdrenergics in combination with anticholinergics R03AL 1

Change of ATC codes:

ferric oxide dextran complexes B03AC06 B03AC 2

ferric oxide polymaltose complexes B03AC01 B03AC 2

ferric sodium gluconate complex B03AC07 B03AC 2

ferric sorbitol gluconic acid complex B03AC05 B03AC 2

fibrinogen, human B02BC10 B02BC30 3

iron-sorbitol-citric acid complex B03AC03 B03AC 2

saccharated iron oxide B03AC02 B03AC 2

Change of ATC code and/or ATC level name:

R03AK03 fenoterol and other drugs R03AL01 fenoterol and ipatroprium bromide for obstructive airway diseasesR03AK04 4 salbutamol and other drugs R03AK04 salbutamol and sodium for obstructive airway diseases cromoglicate R03AL02 salbutamol and ipatroprium bromideR03AK07 4 formoterol and other drugs R03AK07 formoterol and budesonide for obstructive airway diseases R03AK08 formoterol and beclometasone R03AK09 formoterol and mometasone

Change of ATC level names:

Adrenergics and other drugs for Adrenergics in combination R03AK obstructive airway diseases with corticosteroids or other drugs, excl. anticholinergics


INN Common name Previous ATC New ATC

Previous New

Previous New ATC code


397


Change of ATC level names (continued):

Iron trivalent, parenteral preparations Iron, parenteral preparations B03ACsalmeterol and other drugs for salmeterol and fluticasone R03AK06 obstructive airway diseasesthyrotropin thyrotropin alfa H01AB01

1 Split of ATC 4th level R03AK, separate 4th level for combinations with anticholinergics 2 ATC 5th levels deleted, all products classified on the 4th level only (B03AC Iron, parenteral

preparations)3 Combinations previously classified in B02BC10 should be altered to B02BC30 combinations

(existing code)4 Separate ATC 5th levels for the various combinations (split of code). New ATC 4th level

(R03AL) for combinations with anticholinergics

New DDDs:

DDD unit Adm.R ATC code

colecalciferol 20 mcg O A11CC05gemigliptin 50 mg O A10BH06ivacaftor 0.3g O R 07AX02pasireotide 1.2 mg P H01CB05thyrotropin alfa 0.9 mg P H01AB01



398


The following anatomical therapeutic chemical (ATC) classifications, defined daily doses (DDDs) and alterations were agreed by the WHO International Working Group for Drug Statistics Methodology in October 2012. They have been included in the January 2013 version of the ATC Index. The inclusion of a substance in the lists does not imply any recommendation for use in medicine or pharmacy. The WHO Colla-borating Centre for Drug Statistics Methodology can be contacted at [email protected].

New ATC 5th level codes:

eberconazole D01AC17 fluticasone, combinations R01AD58 glycerol phenylbutyrate A16AX09 limbal stems cells, autologous S01XA19 linaclotide A06AX04 lipegfilgrastim L03AA14 lurasidone N05AE05 masitinib L01XE22 metformin and alogliptin A10BD13 peginesatide B03XA04 pertuzumab L01XC13 poliomyelitis oral, bivalent, live attenuated J07BF04 quifenadine R06AX31 regorafenib L01XE21 tamsulosin and solifenacin G04CA53 tofacitinib L04AA29 trenonacog alfa B02BD12 vismodegib L01XX43Change of ATC codes:

prucalopride A03AE04 A06AX05tegaserod A03AE02 A06AX06 Change of ATC level names:

Drugs for functional bowel disorders Drugs for functional gastro- A03A intestinal disorders Drugs acting on serotonin receptors Serotonin receptor antagonists A03AE


ATC/DDD Classification (Final)


INN Common name Previous ATC New ATC


399


Other drugs for functional bowel Other drugs for functional gastro- A03AX disorders intestinal disordersLaxatives Drugs for constipation A06Laxatives Drugs for constipation A06ABulk producers Bulk-forming laxatives A06ACOther laxatives Other drugs for constipation A06AXtetrachlorodecaoxide sodium chlorite D03AX11etynodiol and estrogen etynodiol and ethinylestradiol G03AA01quingestanol and estrogen quingestanol and ethinyl- G03AA02 estradiol lynestrenol and estrogen lynestrenol and ethinylestradiol G03AA03megestrol and estrogen megestrol and ethinylestradiol G03AA04norethisterone and estrogen norethisterone and ethinyl- G03AA05 estradiolnorgestrel and estrogen norgestrel and ethinylestradiol G03AA06levonorgestrel and estrogen levonorgestrel and ethinyl- G03AA07 estradiolmedroxyprogesterone and estrogen medroxyprogesterone and G03AA08 ethinylestradioldesogestrel and estrogen desogestrel and ethinylestradiol G03AA09gestodene and estrogen gestodene and ethinylestradiol G03AA10norgestimate and estrogen norgestimate and ethinyl- G03AA11 estradioldrospirenone and estrogen drospirenone and ethinyl- G03AA12 estradiolnorelgestromin and estrogen norelgestromin and ethinyl- G03AA13 estradiolnomegestrol and estrogen nomegestrol and estradiol G03AA14chlormadinone and estrogen chlormadinone and ethinylestradiol G03AA15megestrol and estrogen megestrol and ethinylestradiol G03AB01lynestrenol and estrogen lynestrenol and ethinylestradiol G03AB02levonorgestrel and estrogen levonorgestrel and ethinyl- G03AB03 estradiolnorethisterone and estrogen norethisterone and ethinyl- G03AB04 estradiol desogestrel and estrogen desogestrel and ethinylestradiol G03AB05gestodene and estrogen gestodene and ethinylestradiol G03AB06chlormadinone and estrogen chlormadinone and ethinylestradiol G03AB07dienogest and estrogen dienogest and estradiol G03AB08reproterol and other drugs for reproterol and sodium R03AK05 obstructive airway diseases cromoglicate Other urologicals, incl. antispasmodics Urologicals G04B Urinary antispasmodics Drugs for urinary frequency G04BD and incontinenceTests for renal function Tests for renal function and V04CH ureteral injuries

Change of ATC level names (continued):



400


New DDDs:

DDD unit Adm.R ATC code

dexmedetomidine 1 mg P N05CM18droperidol 2.5 mg P N05AD08leuprorelin 60 mcg Depot implant L02AE02linagliptin 5 mg O A10BH05pirfenidone 2.4 g O L04AX05rilpivirine 25 mg O J05AG05

Herbal medicinal products*

New ATC 5th level codes:

Hederae helicis folium R05CA12

* Assessed and approved by regulatory authorities based on dossiers including efficacy, safety, and quality data (e.g. the well-established use procedure in EU).

ATC level Common name ATC code


WHO Drug Information, Vol. 26, No. 4, 2012 Proposed INN: List 108

401

International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List No. 14, 2011 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement). Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM). Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

Proposed INN: List 108 WHO Drug Information, Vol. 26, No. 4, 2012

402

Proposed International Nonproprietary Names: List 108 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 108 Proposed INN not later than 9 May 2013 Publication date: 10 January 2013

Dénominations communes internationales proposées: Liste 108 Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste 108 de DCI Proposées le 9 mai 2013 au plus tard. Date de publication: 10 janvier 2013

Denominaciones Comunes Internacionales Propuestas: Lista 108 Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en WHO Drug Information, es decir, para la Lista 108 de DCI Propuestas el 9 de mayo de 2013 a más tardar. Fecha de publicación: 10 de enero de 2013

Proposed INN (Latin, English, French, Spanish) DCI Proposée DCI Propuesta

Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée Nombre químico o descripción: Acción y uso: Fórmula molecular Número de registro del CAS: Fórmula desarrollada

abiciparum pegolum # abicipar pegol pegylated composite protein for clinical applications (CPCA), with

alternative scaffold domain to antigen receptors based on ankyrin repeats, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)]; glycyl-seryl-ankyrin repeats (3-35, 36-68, 69-101, 102-123)-lysyl-dialanyl-bis(triglycyl-seryl) linker (127-134)-cysteinyl (1-135), conjugated via a maleimide group linker (thioether bond to C135) to a single linear methoxy polyethylene glycol 20 (mPEG20) angiogenesis inhibitor

abicipar pégol protéine composite pour applications cliniques (CPCA) pégylée, avec une charpente de domaine alternative aux récepteurs d'antigènes basée sur des répétitions ankyrine, anti-[Homo sapiens VEGFA (facteur A de croissance de l’endothélium vasculaire, VEGF-A, VEGF)]; glycyl-séryl-domaine à répétitions ankyrine (3-35, 36-68, 69-101, 102-123)-lysyl-dialanyl-linker bis(triglycyl-séryl) (127-134)-cystéinyl (1-135), conjugué via un linker du groupe maléimide (liaison thioéther à C135) à une molécule linéaire unique de méthoxy polyéthylène glycol 20 (mPEG20) inhibiteur de l'angiogénèse

WHO Drug Information, Vol. 26 , No. 4, 2012 Proposed INN: List 108

403

abicipar pegol proteína compuesta para aplicaciones clínicas (CPCA) pegilada, con

una estructura de dominio alternativa a los receptores de antígenos basada en repeticiones de la ankirina, anti-[Homo sapiens VEGFA (factor A de crecimiento endotelial vascular, VEGF-A, VEGF)]; glicil-seril-dominio de repeticiones de ankirina (3-35, 36-68, 69-101, 102-123)-lisil-dialanil-conector bis(triglicil-seril) (127-134)-cisteinil (1-135), conjugado mediante un conector maleimida (enlace tioéter en C135) en una molécula lineal única de metoxi polietilenglicol 20 (mPEG20) inhibidor de la angiogenesis

C617H969N173O199S2 (protein component)

1327278-94-3

GSDLDKKLLE AARAGQDDEV RILMANGADV NARDSTGWTP LHLAAPWGHP 50 EIVEVLLKNG ADVNAADFQG WTPLHLAAAV GHLEIVEVLL KYGADVNAQD 100KFGKTAFDIS IDNGNEDLAE ILQKAAGGGS GGGSC 135

adelatinibum adelatinib (2R)-2-methyl-2-{[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-

4-yl]amino}-N-(2,2,2-trifluoroethyl)butanamide tyrosine kinase inhibitor, antineoplastic

adélatinib (2R)-2-méthyl-2-{[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin- 4-yl]amino}-N-(2,2,2-trifluoroéthyl)butanamide inhibiteur de la tyrosine kinase, antinéoplasique

adelatinib (2R)-2-metil-2-{[2-(1H-pirrolo[2,3-b]piridin-3-il)pirimidin-4-il]amino}- N-(2,2,2-trifluoroetil)butanamida inhibidor de la tirosina kinasa, antineoplásico

C18H19F3N6O

944842-54-0

N

NHN

NH

CF3

CH3

CH3

HN

N

O

afoxolanerum afoxolaner 4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-

4,5-dihydro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}naphthalene-1-carboxamide insecticide (veterinary drug)

afoxolaner 4-{5-[3-chloro-5-(trifluorométhyl)phényl]-5-(trifluorométhyl)- 4,5-dihydro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl}naphtalène-1-carboxamide insecticide (usage vétérinaire)

afoxolaner 4-{5-[3-cloro-5-(trifluorometil)fenil]-5-(trifluorometil)-4,5-dihidro- 1,2-oxazol-3-il}-N-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}naftaleno- 1-carboxamida insecticida (uso veterinario)


404

C26H17ClF9N3O3

1093861-60-9

HN

NH

CF3

O

O

NOF3C

Cl

F3Cand enantiomeret énantiomèrey enantiómero

afuresertibum afuresertib N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-

1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide antineoplastic

afurésertib N-[(2S)-1-amino-3-(3-fluorophényl)propan-2-yl]-5-chloro-4-(4-chloro-1-méthyl-1H-pyrazol-5-yl)thiophène-2-carboxamide antinéoplasique

afuresertib N-[(2S)-1-amino-3-(3-fluorofenil)propan-2-il]-5-cloro-4-(4-cloro- 1-metil-1H-pirazol-5-il)tiofeno-2-carboxamida antineoplásico

C18H17Cl2FN4OS

1047644-62-1

O

HN

H

F

NH2

S

Cl

N N

CH3

Cl

albutrepenonacogum alfa # albutrepenonacog alfa human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma

thromboplastin component) 148-threonine variant fusion protein with prolyl(human coagulation factor IX 148-threonine variant-(137-153)-peptide fusion protein with human serum albumin, produced in CHO cells (alfa glycoform) blood coagulation factor

albutrépénonacog alfa variant 148-thréonine du facteur IX humain de la coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophilique B) protéine de fusion avec le prolyl(variant 148-thréonine du facteur IX humain de la coagulation-(137-153)-peptide, protéine de fusion avec l’albumine sérique humaine, produit par culture de cellules CHO (glycoforme alfa) facteur de coagulation sanguine

albutrepenonacog alfa variante 148-treonina del factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofílico B) proteína de fusión con prolil(variante 148-treonina del factor IX humano de la coagulación-(137-153)-péptido, proteína de fusión con albumina sérica humana, producida por cultivo de células CHO (glicoforma alfa) factor de coagulación sanguínea


405

C5077H7846N1367O1588PS67 (peptide)

1357448-54-4

HO2C CO2H

NH2HHO2C

CO2H

NH2HO

SHO

O O

HO2CCO2H

NH2H

OH

OCO2H

NH2H

PO

HO OH

E7-8-15-17-20-21-26

27-30-33-36-404-carboxyGlu

Y155

O-sulfoTyr

D64

3-hydroxyAsp

S158

O-phosphonoSer

Sequence / Séquence / SecuenciaYNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAETVF 150PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400VSRYVNWIKE KTKLTPVSQT SKLTRAETVF PDVDAHKSEV AHRFKDLGEE 450NFKALVLIAF AQYLQQCPFE DHVKLVNEVT EFAKTCVADE SAENCDKSLH 500TLFGDKLCTV ATLRETYGEM ADCCAKQEPE RNECFLQHKD DNPNLPRLVR 550PEVDVMCTAF HDNEETFLKK YLYEIARRHP YFYAPELLFF AKRYKAAFTE 600CCQAADKAAC LLPKLDELRD EGKASSAKQR LKCASLQKFG ERAFKAWAVA 650RLSQRFPKAE FAEVSKLVTD LTKVHTECCH GDLLECADDR ADLAKYICEN 700QDSISSKLKE CCEKPLLEKS HCIAEVENDE MPADLPSLAA DFVESKDVCK 750NYAEAKDVFL GMFLYEYARR HPDYSVVLLL RLAKTYETTL EKCCAAADPH 800ECYAKVFDEF KPLVEEPQNL IKQNCELFEQ LGEYKFQNAL LVRYTKKVPQ 850VSTPTLVEVS RNLGKVGSKC CKHPEAKRMP CAEDYLSVVL NQLCVLHEKT 900PVSDRVTKCC TESLVNRRPC FSALEVDETY VPKEFNAETF TFHADICTLS 950EKERQIKKQT ALVELVKHKP KATKEQLKAV MDDFAAFVEK CCKADDKETC 1000FAEEGKKLVA ASQAALGL 1018

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro18-23 51-62 56-71 73-82 88-99 95-109 111-124132-289 206-222 336-350 361-389 486-495 508-524 523-534557-602 601-610 633-679 678-686 698-712 711-722 749-794793-802 825-871 870-881 894-910 909-920 947-992 991-1000

Modified residues / Résidus modifiés / Restos modificados

Glycosylation sites (N,S,T) / Sites de glycosylation (N,S,T) / Posiciones de glicosilación (N,S,T)Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179** potential sites / sites potentiels / posiciones posibles

aldoxorubicinum aldoxorubicin N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-

hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]- 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide topoisomerase inhibitor, antineoplastic

aldoxorubicine N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-tridéoxy-α-L-lyxo-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotétracén-2-yl}-2-hydroxyéthylidène]- 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide inhibiteur de la topoisomérase, antinéoplasique

aldoxorubicina N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-tridesoxi-α-L-lyxo-hexopiranosil)oxi]-2,5,12-trihidroxi-7-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracen-2-il}-2-hidroxietilideno]-6-(2,5-dioxo-2,5-dihidro-1H-pirrol-1-il)hexanohidrazida inhibidor de la topoisomerasa, antineoplásico


406

C37H42N4O13

1361644-26-9

OHO

O OH

OH

N

H O

O

OH

NH2

CH3

OCH3

OH

NH

ON

O

O

alectinibum alectinib 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-

6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile tyrosine kinase inhibitor, antineoplastic

alectinib 9-éthyl-6,6-diméthyl-8-[4-(morpholin-4-yl)pipéridin-1-yl]-11-oxo- 6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile inhibiteur de la tyrosine kinase, antinéoplasique

alectinib 9-etil-6,6-dimetil-8-[4-(morfolin-4-il)piperidin-1-il]-11-oxo-6,11-dihidro-5H-benzo[b]carbazol-3-carbonitrilo inhibidor de la tirosina kinasa, antineoplásico

C30H34N4O2 1256580-46-7

NH

CN

N

N

O

O

H3C

H3C CH3

apitolisibum apitolisib (2S)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-methyl-4-(morpholin-

4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}piperazin-1-yl)- 2-hydroxypropan-1-one antineoplastic

apitolisib (2S)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-méthyl-4-(morpholin- 4-yl)thiéno[3,2-d]pyrimidin-6-yl]méthyl}pipérazin-1-yl)- 2-hydroxypropan-1-one antinéoplasique

apitolisib (2S)-1-(4-{[2-(2-aminopirimidin-5-il)-7-metil-4-(morfolin-4-il)tieno[3,2-d]pirimidin-6-il]metil}piperazin-1-il)-2-hidroxipropan-1-ona antineoplásico


407

C23H30N8O3S 1032754-93-0

N

NCH3

O

S

N

N

H3C

N

O

N

N

H2N

H OH

belnacasanum belnacasan 1-[(2S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl]-

N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-L-prolinamide caspase inhibitor

belnacasan 1-[(2S)-2-(4-amino-3-chlorobenzamido)-3,3-diméthylbutanoyl]- N-[(2R,3S)-2-éthoxy-5-oxooxolan-3-yl]-L-prolinamide inhibiteur de la caspase

belcanasán 1-[(2S)-2-(4-amino-3-clorobenzamido)-3,3-dimetilbutanoil]- N-[(2R,3S)-2-etoxi-5-oxooxolan-3-il]-L-prolinamida inhibidor de la caspasa

C24H33ClN4O6

273404-37-8

O

H

NH

OH

N

HN

H O

OO

CH3

H3C

H3C

O

H2N

ClH

CH3

bimagrumabum # bimagrumab immunoglobulin G1-lambda2, anti-[Homo sapiens ACVR2B (activin

A receptor type IIB, ActR-IIB)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), hinge (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfide with lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (224-224'':227-227'')-bisdisulfide myostatin inhibitor

bimagrumab immunoglobuline G1-lambda2, anti-[Homo sapiens ACVR2B (récepteur type IIB de l'activine A, ActR-IIB)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), charnière (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfure avec la chaîne légère lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (224-224'':227-227'')-bisdisulfure inhibiteur de la myostatine


408

bimagrumab inmunoglobulina G1-lambda2, anti-[Homo sapiens ACVR2B

(receptor tipo IIB de la activina A, ActR-IIB)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), bisagra (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfuro con la cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (224-224'':227-227'')-bisdisulfuro inhibidor de la miostatina

1356922-05-8

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGASVKV SCKASGYTFT SSYINWVRQA PGQGLEWMGT 50INPVSGSTSY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARGG 100WFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200NHKPSNTKVD KRVEPKSCDK THTCPPCPAP EAAGGPSVFL FPPKPKDTLM 250ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 445

Light chain / Chaîne légère / Cadena ligeraQSALTQPASV SGSPGQSITI SCTGTSSDVG SYNYVNWYQQ HPGKAPKLMI 50YGVSKRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC GTFAGGSYYG 100VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 142-198 259-319 365-423 22''-96'' 142''-198'' 259''-319'' 365''-423''Intra-L 22'-90' 139'-198' 22'''-90''' 139'''-198''' Inter-H-L 218-216' 218''-216''' Inter-H-H 224-224'' 227-227''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:295, 295''

brilacidinum brilacidin N4,N6-bis[3-{[5-(carbamimidamido)pentanoyl]amino}-

2-{[(3R)-pyrrolidin-3-yl]oxy}-5-(trifluoromethyl)phenyl]pyrimidine- 4,6-dicarboxamide antibiotic

brilacidine N4,N6-bis[3-{[5-(carbamimidamido)pentanoyl]amino}- 2-{[(3R)-pyrrolidin-3-yl]oxy}-5-(trifluorométhyl)phényl]pyrimidine- 4,6-dicarboxamide antibiotique

brilacidina N4,N6-bis[3-{[5-(carbamimidamido)pentanoil]amino}- 2-{[(3R)-pirrolidin-3-il]oxi}-5-(trifluorometil)fenil]pirimidina- 4,6-dicarboxamida antibiótico


409

C40H50F6N14O6

1224095-98-0

N NHN

HN

O O

OO

F3CCF3

HN O

HNO

NHHN

NH

NH2

NH

H2N

H

NH

H

HN

concizumabum # concizumab immunoglobulin G4-kappa, anti-[Homo sapiens TFPI (tissue factor

pathway inhibitor, lipoprotein-associated coagulation inhibitor)], humanized monoclonal antibody; gamma4 heavy chain (1-448) [humanized VH (Homo sapiens IGHV3-21*01 (85.70%) -(IGHD)-IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -Homo sapiens IGHG4*01 (CH1 (122-219), hinge S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (227-227":230-230")-bisdisulfide hemostatic agent

concizumab immunoglobuline G4-kappa, anti-[Homo sapiens TFPI (inhibiteur de la voie du facteur tissulaire, inhibiteur de la coagulation associé aux lipoprotéines)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-448) [VH humanisé (Homo sapiens IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -Homo sapiens IGHG4*01 (CH1 (122-219), charnière S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (227-227":230-230")-bisdisulfure hémostatique

concizumab inmunoglobulina G4-kappa, anti-[Homo sapiens TFPI (inhibidor de la vía del factor tisular, inhibidor de la coagulación asociado a lipoproteínas)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-448) [VH humanizado (Homo sapiens IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -Homo sapiens IGHG4*01 (CH1 (122-219), bisagra S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (227-227":230-230")-bisdisulfuro hemostático


410

1312299-39-0 Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQT PEKRLEWVAT 50ISRSGSYSYF PDSVQGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARLG 100GYDEGDAMDS WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK 448

Light chain / Chaîne légère / Cadena ligeraDIVMTQTPLS LSVTPGQPAS ISCKSSQSLL ESDGKTYLNW YLQKPGQSPQ 50LLIYLVSILD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQATHFP 100QTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219



copanlisibum copanlisib 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-

2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide antineoplastic

copanlisib 2-amino-N-{7-méthoxy-8-[3-(morpholin-4-yl)propoxy]- 2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide antinéoplasique

copanlisib 2-amino-N-{7-metoxi-8-[3-(morfolin-4-il)propoxi]- 2,3-dihidroimidazo[1,2-c]quinazolin-5-il}pirimidina-5-carboxamida antineoplásico

C23H28N8O4 1032568-63-0

N

N

N

OCH3

ON NH

O

N

N

ONH2

deferitazolum deferitazole (4S)-2-(2-hydroxy-3-{[(methoxyethoxy)ethoxy]ethoxy}phenyl)-

4-methyl-4,5-dihydro-1,3-thiazol-4-carboxylic acid iron chelator

déféritazole acide (4S)-2-{2-hydroxy-3-{[(méthoxyéthoxy)éthoxy]éthoxy}phenyl)-4-méthyl-4,5-dihydro-1,3-thiazole-4-carboxylique chélateur du fer

deferitazol ácido (4S)-2-(2-hidroxi-4-metil -3-{[(metoxietoxi)etoxi]etoxi}fenil)- 4,5-dihidro-1,3-tiazol-4-carboxílico quelante del hierro


411

C18H25NO7S 945635-15-4

OH

OO

OO

H3C

S

N

CH3

CO2H

deleobuvirum deleobuvir (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-

1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol- 6-yl)prop-2-enoic acid antiviral

déléobuvir acide (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-méthyl-1H-indole-6-carboxamido]cyclobutyl}-1-méthyl-1H-benzimidazol- 6-yl)prop-2-énoïque antiviral

deleobuvir ácido (2E)-3-(2-{1-[2-(5-bromopirimidin-2-il)-3-ciclopentil-1-metil- 1H-indol-6-carboxamido]ciclobutil}-1-metil-1H-benzimidazol- 6-il)prop-2-enoico antiviral

C34H33BrN6O3 863884-77-9

O

HN

N

N

CH3

CO2HN

H3C

N

N

Br

delparantagum delparantag N2-{5-[(5-{5-{L-lysylamino}-2-methoxybenzoyl-L-lysylamino}-

2-methoxybenzoyl-L-lysyl)amino]-2-methoxybenzoyl}- N-(3-carbamoyl-4-methoxyphenyl)-L-lysinamide heparins antidote

delparantag N2-{5-[(5-{5-{L-lysylamino}-2-méthoxybenzoyl-L-lysylamino}- 2-méthoxybenzoyl-L-lysyl)amino]-2-méthoxybenzoyl}- N-(3-carbamoyl-4-méthoxyphényl)-L-lysinamide antidote des héparines

delparantag N2-{5-[(5-{5-{L-lisilamino}-2-metoxibenzoil-L-lisilamino}- 2-metoxibenzoil-L-lisil)amino]-2-metoxibenzoil}-N-(3-carbamoil- 4-metoxfenil)-L-lisinamida antídoto de heparinas

C56H79N13O12

872454-31-4

H2NO

HN

OCH3

NH

HH O

NH2

4


412

dupilumabum # dupilumab immunoglobulin G4-kappa, anti-[Homo sapiens IL4R (interleukin 4

receptor, IL4RA, IL-4RA, CD124)], Homo sapiens monoclonal antibody; gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfide with kappa light chain (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimer (231-231'':234-234'')-bisdisulfide immunomodulator

dupilumab immunoglobuline G4-kappa, anti-[Homo sapiens IL4R (récepteur de l'interleukine 4, IL4RA, IL-4RA, CD124)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfure avec la chaîne légère kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (231-231'':234-234'')-bisdisulfure immunomodulateur

dupilumab inmunoglobulina G4-kappa, anti-[Homo sapiens IL4R (receptor de la interleukina 4, IL4RA, IL-4RA, CD124)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223),bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfuro con la cadena ligera kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (231-231'':234-234'')-bisdisulfuro inmunomodulador


EVQLVESGGG LEQPGGSLRL SCAGSGFTFR DYAMTWVRQA PGKGLEWVSS 50ISGSGGNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR 100LSITIRPRYY GLDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450G 451

Light chain / Chaîne légère / Cadena ligeraDIVMTQSPLS LPVTPGEPAS ISCRSSQSLL YSIGYNYLDW YLQKSGQSPQ 50LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGF YYCMQALQTP 100YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219




413

dusigitumabum # dusigitumab immunoglobulin G2-lambda2, anti-[Homo sapiens IGF1 (insulin-like

growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], Homo sapiens monoclonal antibody; gamma2 heavy chain (1-446) [Homo sapiens VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfide with lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (222-222'':223-223'':226-226'':229-229'')-tetrakisdisulfide immunomodulator, antineoplastic

dusigitumab immunoglobuline G2-lambda2, anti-[Homo sapiens IGF1 (facteur de croissance 1 analogue à l'insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l'insuline, somatomédine A)], Homo sapiens anticorps monoclonal; chaîne lourde gamma2 (1-446) [Homo sapiens VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), charnière (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfure avec la chaîne légère lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimère (222-222'':223-223'':226-226'':229-229'')-tétrakisdisulfure immunomodulateur, antinéoplasique

dusigitumab inmunoglobulina G2-lambda2, anti-[Homo sapiens IGF1 (factor de crecimiento análogo a la insulina tipo 1, somatomedina C) y IGF2 (factor de crecimiento análogo a la insulina tipo 2, somatomedina A)], anticuerpo monoclonal de Homo sapiens ; cadena pesada gamma2 (1-446) [Homo sapiens VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfuro con la cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (222-222'':223-223'':226-226'':229-229'')-tetrakisdisulfuro inmunomodulador, antineoplásico


QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYDINWVRQA TGQGLEWMGW 50MNPNSGNTGY AQKFQGRVTM TRNTSISTAY MELSSLRSED TAVYYCARDP 100YYYYYGMDVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligeraQSVLTQPPSV SAAPGQKVTI SCSGSSSNIE NNHVSWYQQL PGTAPKLLIY 50DNNKRPSGIP DRFSGSKSGT SATLGITGLQ TGDEADYYCE TWDTSLSAGR 100VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 147-203 260-320 366-424 22''-96'' 147''-203'' 260''-320'' 366''-424''Intra-L 22'-89' 139'-198' 22'''-89''' 139'''-198''' Inter-H-L 134-216' 134''-216''' Inter-H-H 222-222'' 223-223'' 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH VH N81:73, 73'' H CH2 N84.4:296, 296''


414

elosulfasum alfa # elosulfase alfa human N-acetylgalactosamine-6-sulfatase (chondroitinsulfatase,

galactose-6-sulfate sulfatase, EC=3.1.6.4) dimer (139-139')-disulfide glycosylated (produced by CHO cells) enzyme

élosulfase alfa N-acétylgalactosamine-6-sulfatase humaine (chondroïtinesulfatase, 6-sulfate de galactose sulfatase, EC=3.1.6.4) (139-139')-disulfure du dimère glycosylée (produite par des cellules CHO) enzyme

elosulfasa alfa N-acetilgalactosamina-6-sulfatasa humana (condroitinsulfatasa, 6-sulfato de galactosa sulfatasa, EC=3.1.6.4) (139-139')-disulfuro del dímero glicosilado (producido por células CHO) enzima

C5020H7574N1364O1418S34

9025-60-9

OCO2H

NH2H

Monomer / Monomère / MonómeroAPQPPNILLL LMDDMGWGDL GVYGEPSRET PNLDRMAAEG LLFPNFYSAN 50PLCSPSRAAL LTGRLPIRNG FYTTNAHARN AYTPQEIVGG IPDSEQLLPE 100LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF DEWFGSPNCH FGPYDNKARP 150NIPVYRDWEM VGRYYEEFPI NLKTGEANLT QIYLQEALDF IKRQARHHPF 200FLYWAVDATH APVYASKPFL GTSQRGRYGD AVREIDDSIG KILELLQDLH 250VADNTFVFFT SDNGAALISA PEQGGSNGPF LCGKQTTFEG GMREPALAWW 300PGHVTAGQVS HQLGSIMDLF TTSLALAGLT PPSDRAIDGL NLLPTLLQGR 350LMDRPIFYYR GDTLMAATLG QHKAHFWTWT NSWENFRQGI DFCPGQNVSG 400VTTHNLEDHT KLPLIFHLGR DPGERFPLSF ASAEYQEALS RITSVVQQHQ 450EALVPAQPQL NVCNWAVMNW APPGCEKLGK CLTPPESIPK KCLWSH 496

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro139-139' 282-393 282'-393' 463-492 463'-492' 475-481 475'-481'


C53 , 53'

3-oxoAla

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)Asn-178 Asn-178' Asn-397 Asn-397'

emapticapum pegolum emapticap pegol β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-

β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-adenylyl-(3′→5′) -β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-adenylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-guanosine 6-{2-(N-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5’-phosphate immunomodulator


415

émapticap pégol β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-adénylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)- β-L-guanosine 5’-hydrogénophosphate de 6-{2-(N-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan- 1,2-diyl)]oxy}acétamido)acétamido}hexyle immunomodulateur

emapticap pegol β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-adenilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)- β-L-guanosina 5’-hidrógenofosfato de 6-{2-(N-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan- 1,2-diil)]oxi}acetamido)acitamido}hexilo inmunomodulador

C393H501N153O286P40[C2H4O]2n

1390630-22-4

R- =

HN

O

NCH2

O

O

O

OH3C

OH3C

n

n

-L-ribo-[(3'-5')-R-pG-C-A-C-G-U-C-C-C-U-C-A- C-C-G-G-U-G-C-A-A-G-U-G-A-A-G-C-C-G-U- G-G-C-U-C-U-G-C-G]

emixustatum emixustat (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol

retinol isomerase inhibitor

émixustat (1R)-3-amino-1-[3-(cyclohexylméthoxy)phényl]propan-1-ol inhibiteur de l'isomérase du rétinol

emixustat (1R)-3-amino-1-[3-(ciclohexilmetoxi)fenil]propan-1-ol inhibidor de la retinol isomerasa


416

C16H25NO2 1141777-14-1

ONH2

H OH

entolimodum # entolimod L-methionyl-L-arginylglycyl-L-seryl-hexa(L-histidyl)glycyl-

(Enterobacteria phage T7 major capsid protein 10A-(1-11)-peptidyl)-L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tetra(L-aspartyl)-L-lysyl- L-aspartyl-L-prolyl-(Salmonella dublin flagellin-(1-176)-peptidyl)- L-seryl-L-prolylglycyl-L-isoleucyl-L-seryl-pentaglycyl-L-isoleucyl- L-leucyl-L-aspartyl-L-seryl-L-methionylglycyl-(Salmonella dublin flagellin-(402-505)-peptide) immunomodulator

entolimod L-méthionyl-L-arginylglycyl-L-séryl-hexa(L-histidyl)glycyl-(principale protéine (10A) de la capside de l'Enterobacteria phage T7 -(1-11)-peptidyl)-L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tétra(L-aspartyl)- L-lysyl-L-aspartyl-L-prolyl-(flagelline de Salmonella dublin -(1-176)-peptidyl)-L-séryl-L-prolylglycyl-L-isoleucyl-L-séryl-pentaglycyl- L-isoleucyl-L-leucyl-L-aspartyl-L-séryl-L-méthionylglycyl-(flagelline de Salmonella dublin-(402-505)-peptide) immunomodulateur

entolimod L-metionil-L-arginilglicil-L-seril-hexa(L-histidil)glicil-(proteína principal (10A) de la cápsida del Enterobacteria fago T7 -(1-11)-peptidil)- L-arginil-L-aspartil-L-leucil-L-tirosil-tetra(L-aspartil)-L-lisil-L-aspartil- L-prolil-(flagelina de Salmonella dublin -(1-176)-peptidil)-L-seril- L-prolilglicil-L-isoleucil-L-seril-pentaglicil-L-isoleucil-L-leucil-L-aspartil-L-seril-L-metionilglicil-(flagelina de Salmonella dublin-(402-505)-péptido) inmunomodulador

C1464H2419N457O519S8

951628-22-1

MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDPMAQVINT NSLSLLTQNN 50LNKSQSSLSS AIERLSSGLR INSAKDDAAG QAIANRFTSN IKGLTQASRN 100ANDGISIAQT TEGALNEINN NLQRVRELSV QATNGTNSDS DLKSIQDEIQ 150QRLEEIDRVS NQTQFNGVKV LSQDNQMKIQ VGANDGETIT IDLQKIDVKS 200LGLDGFNVNS PGISGGGGGI LDSMGTLINE DAAAAKKSTA NPLASIDSAL 250SKVDAVRSSL GAIQNRFDSA ITNLGNTVTN LNSARSRIED ADYATEVSNM 300SKAQILQQAG TSVLAQANQV PQNVLSLLR 329

eravacyclinum eravacycline (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-

tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide tetracycline antibiotic, bacteriostatic

éravacycline (4S,4aS,5aR,12aS)-4-(diméthylamino)-7-fluoro-3,10,12,12a-tétrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acétamido]-1,4,4a,5,5a,6,11,12a-octahydrotétracème-2-carboxamide antibiotique du groupe des tétracyclines, bactériostatique


417

eravaciclina (4S,4aS,5aR,12aS)-4-(dimetilamino)-7-fluoro-3,10,12,12a-

tetrahidroxi-1,11-dioxo-9-[2-(pirrolidin-1-il)acetamido]-1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida antibiótico del grupo de las tetraciclinas, bacteriostático

C27H31FN4O8

1207283-85-9

OOH OH

NH2

H N

H3C

CH3

OOH

HH

O

OH

F

HN

N

O

evodenosonum evodenoson methyl 4-{3-[6-amino-9-(N-cyclopropyl-β-D-ribofuranosyluronamide)-

9H-purin-2-yl]prop-2-yn-1-yl}piperidine-1-carboxylate adenosine receptor agonist

évodénoson 4-{3-[6-amino-9-(N-cyclopropyl-β-D-ribofuranosyluronamide)- 9H-purin-2-yl]prop-2-yn-1-yl}pipéridine-1-carboxylate de méthyle agoniste du récepteur de l'adénosine

evodenosón 4-{3-[6-amino-9-(N-ciclopropil-β-D-ribofuranosiluronamida)-9H-purin-2-il]prop-2-in-1-il}piperidina-1-carboxilato de metilo agonista del receptor de la adenosina

C23H29N7O6 844873-47-8

N

N

NH2

N

N

NO

O

H3C

O

ONH

OH

OH

evolocumabum # evolocumab immunoglobulin G2-lambda, anti-[Homo sapiens PCSK9 (proprotein

convertase subtilisin/kexin type 9)], Homo sapiens monoclonal antibody; gamma2 heavy chain (1-441) [Homo sapiens VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01)) [8.8.8] (1-115) -IGHG2*01 (CH1 (116-213), hinge (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfide with lambda light chain (1'-215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfide hypocholesterolemic


418

évolocumab immunoglobuline G2-lambda, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9)], Homo sapiens anticorps monoclonal; chaîne lourde gamma2 (1-441) [Homo sapiens VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), charnière (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfure avec la chaîne légère lambda (1'-215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimère (217-217'':218-218'':221-221'':224-224'')-tétrakisdisulfure hypocholestérolémiant

evolocumab inmunoglobulina G2-lambda, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma2 (1-441) [Homo sapiens VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), bisagra(214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfuro con la cadena ligera lambda (1'-215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dímero (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro hipocolesterolemiante


EVQLVQSGAE VKKPGASVKV SCKASGYTLT SYGISWVRQA PGQGLEWMGW 50VSFYNGNTNY AQKLQGRGTM TTDPSTSTAY MELRSLRSDD TAVYYCARGY 100GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV 200DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE 350EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL 400YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K 441

Light chain / Chaîne légère / Cadena ligeraESALTQPASV SGSPGQSITI SCTGTSSDVG GYNSVSWYQQ HPGKAPKLMI 50YEVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC NSYTSTSMVF 100GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200EGSTVEKTVA PTECS 215



fedratinibum fedratinib N-tert-butyl-3-[(5-methyl-2-{4-[2-(pyrrolidin-

1-yl)ethoxy]anilino}pyrimidin-4-yl)amino]benzenesulfonamide tyrosine kinase inhibitor, antineoplastic

fédratinib N-tert-butyl-3-[(5-méthyl-2-{4-[2-(pyrrolidin- 1-yl)éthoxy]anilino}pyrimidin-4-yl)amino]benzènesulfonamide inhibiteur de la tyrosine kinase, antinéoplasique


419

fedratinib N-terc-butil-3-[(5-metil-2-{4-[2-(pirrolidin-1-il)etoxi]anilino}pirimidin- 4-il)amino]bencenosulfonamida inhibidor de la tirosina kinasa, antineoplásico

C27H36N6O3S 936091-26-8

SNH

HN

O O

NN

NH

ON

CH3 CH3

CH3

CH3

filgotinibum filgotinib N-(5-{4-[(1,1-oxo-λ6-thiomorpholin-

4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin- 2-yl)cyclopropanecarboxamide tyrosine kinase inhibitor, antineoplastic

filgotinib N-(5-{4-[(1,1-oxo-λ6-thiomorpholin- 4-yl)méthyl]phényl}[1,2,4]triazolo[1,5-a]pyridin- 2-yl)cyclopropanecarboxamide inhibiteur de la tyrosine kinase, antinéoplasique

filgotinib N-(5-{4-[(1,1-oxo-λ6-tiomorfolin-4-il)metil]fenil}[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropanocarboxamida inhibidor de la tirosina kinasa, antineoplásico

C21H23N5O3S 1206161-97-8

N

S N

N

N

HN

O

O

O

filorexantum filorexant [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-

1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone orexin receptor antagonist

filorexant [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]méthyl}-2-méthylpipéridin- 1-yl][5-méthyl-2-(pyrimidin-2-yl)phényl]méthanone antagoniste du récepteur de l'orexine

filorexant [(2R,5R)-5-{[(5-fluoropiridin-2-il)oxi]metil}-2-metilpiperidin-1-il][5-metil-2-(pirimidin-2-il)fenil]metanona antagonista del receptor de la orexina

C24H25FN4O2 1088991-73-4

N

O

O

N

CH3

H

CH3

NNF

H


420

finerenonum finerenone (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-

1,4-dihydro-1,6-naphthyridine-3-carboxamide aldosterone receptor antagonist

finérénone (4S)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl- 1,4-dihydro-1,6-naphtyridine-3-carboxamide antagoniste des récepteurs de l'aldostérone

finerenona (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro- 1,6-naftiridina-3-carboxamida antagonista de los receptores de aldosterona

C21H22N4O3 1050477-31-0

HN

N

CH3

O

NH2

OH3COCH3

CN

H

CH3

firtecanum peglumerum firtecan peglumer α-{3-[(α-N-acetylpoly-L-glutamyl)amino]propyl}-

ω-methoxypoly(oxyethan-1,2-diyl) where the free γ-carboxyl groups are partially esterified by (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin- 9-yl, partially converted to an amide with (propan-2-yl)[(propan- 2-yl)carbamoyl]amino and partially unchanged topoisomerase inhibitor, antineoplastic

firtécan péglumère α-{3-[(α-N-acétylpoly-L-glutamyl)amino]propyl}- ω-méthoxypoly(oxyéthylène) dont certains acides γ-carboxyliques sont estérifiés par le (4S)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin- 9-yle et d'autres amidifiés par le (propan-2-yl)[(propan- 2-yl)carbamoyl]amino inhibiteur de la topoisomérase, antinéoplasique

firtecán peglúmero α-{3-[(α-N-acetilpoli-L-glutamil)amino]propil}-ω-metoxipoli(oxietileno) cuyos algunos ácidos γ-carboxílicos estan esterificados por el (4S)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro- 1H-pirano[3',4':6,7]indolizino[1,2-b]quinolein-9-ilo y otros amidificados por el (propan-2-il)[(propan-2-il)carbamoil]amino inhibidor de la topoisomerasa, antineoplásico

C6H13NO2 [C5H6NO2]a [C2H4O]n (C22H19N2O5)x (C7H15N2O)y (HO)z a = x + y + z

1204768-03-5


421

ON

N

O

O

O

CH3

HO CH3

=

orouo

N

CH3

H3C

O

NH

R

orouo

OH

H3C

CH3

H3CNH

O

HN

HO

R

O

a

n

OO

CH3

flortanidazolum (18F) flortanidazole (18F) (2RS)-3-[18F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-yl)methyl]-

1H-1,2,3-triazol-1-yl}propan-1-ol radiodiagnostic agent

flortanidazole (18F) (2RS)-3-[18F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-yl)méthyl]- 1H-1,2,3-triazol-1-yl}propan-1-ol produit pour diagnostic radiologique

flortanidazol (18F) (2RS)-3-[18F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-il)metil]- 1H-1,2,3-triazol-1-il}propan-1-ol agente de radiodiagnóstico

C9H1118FN6O3

70878-86-2

NN

O2N

NN

N

H[18F]

OHand enantiomeret énantiomèrey enantiómero

flotegatidum (18F) flotegatide (18F) cyclo{L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-[2,6-anhydro-

7-deoxy-7-({2-[4-(3-[18F]fluoropropyl)-1H-1,2,3-triazol- 1-yl]acetyl}amino)-L-glycero-L-galacto-heptonoyl]-L-lysyl} radiodiagnostic agent

flotégatide (18F) cyclo{L-arginylglycyl-L-α-aspartyl-D-phénylalanyl-N6-[2,6-anhydro- 7-déoxy-7-({2-[4-(3-[18F]fluoropropyl)-1H-1,2,3-triazol- 1-yl]acétyl}amino)-L-glycéro-L-galacto-heptonoyl]-L-lysyl} produit pour diagnostic radiologique


422

flotegatida (18F) ciclo{L-arginilglicil-L-α-aspartil-D-fenilalanil-N6-[2,6-anhidro-7-desoxi-

7-({2-[4-(3-[18F]fluoropropil)-1H-1,2,3-triazol-1-il]acetil}amino)- L-glicero-L-galacto-heptonoil]-L-lisil} agente de radiodiagnóstico

C41H6018FN13O13

1010702-75-6

HN

NH

HN

HN

HN

O

NH

O

H2N

NH

O

CO2H

O

O

H

H

H

H

NH

OO

H

OHHO

HO

NH

N

O

N

N

[18F]

fluorfenidinum (18F) fluorfenidine (18F) 3-{2-chloro-5-[(2-[18F]fluoroethyl)sulfanyl]phenyl}-1-methyl-

1-[3-(methylsulfanyl)phenyl]guanidine diagnostic aid

fluorfénidine (18F) 3-{2-chloro-5-[(2-[18F]fluoroéthyl)sulfanyl]phényl}-1-méthyl- 1-[3-(méthylsulfanyl)phényl]guanidine produit à usage diagnostique

fluorfenidina (18F) 3-{2-cloro-5-[(2-[18F]fluoroetil)sulfanil]fenil}-1-metil- 1-[3-(metilsulfanil)fenil]guanidina agente de diagnóstico

C17H19Cl18FN3S2 917894-12-3

HN N

CH3

NH

SCH3

Cl

S[18F]

flutriciclamidum (18F) flutriciclamide (18F) (4S)-N,N-diethyl-9-(2-[18F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-

1H-carbazole-4-carboxamide diagnostic aid

flutriciclamide (18F) (4S)-N,N-diéthyl-9-(2-[18F]fluoroéthyl)-5-méthoxy-2,3,4,9-tétrahydro-1H-carbazole-4-carboxamide produit à usage diagnostique

flutriciclamida (18F) (4S)-N,N-dietil-9-(2-[18F]fluoroetil)-5-metoxi-2,3,4,9-tetrahidro- 1H-carbazol-4-carboxamida agente de diagnóstico


423

C20H27

18FN2O2

1274863-98-7

N[18F]

N CH3

CH3

OO

CH3

H

gandotinibum gandotinib 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-

1H-pyrazol-3-yl)-8-[(morpholin-4-yl)methyl]imidazo[1,2-b]pyridazin- 6-amine tyrosine kinase inhibitor, antineoplastic

gandotinib 3-[(4-chloro-2-fluorophényl)méthyl]-2-méthyl-N-(5-méthyl- 1H-pyrazol-3-yl)-8-[(morpholin-4-yl)méthyl]imidazo[1,2-b]pyridazin- 6-amine inhibiteur de la tyrosine kinase, antinéoplasique

gandotinib 3-[(4-cloro-2-fluorofenil)metil]-2-metil-N-(5-metil-1H-pirazol-3-il)- 8-[(morfolin-4-il)metil]imidazo[1,2-b]piridazin-6-amina inhibidor de la tirosina kinasa, antineoplásico

C23H25ClFN7O 1229236-86-5

N

N

N

CH3

N

NH

O

NHN

H3C

F

Cl

hemoglobinum crosfumarilum (bovinum) # hemoglobin crosfumaril (bovine) S3.β92,S3.β'92-bis(2-amino-2-oxoethyl)-N6.α99,N6.α'99-(but-

2-enedioyl)bovine hemoglobulin (α2β2 tetramer) oxygen carrier

hémoglobine crosfumaril (bovine) S3.β92,S3.β'92-bis(2-amino-2-oxoéthyl)-N6.α99,N6.α'99-(but- 2-ènedioyl)hémoglobuline bovine (α2β2 tétramère) transporteur d'oxygène

hemoglobina crosfumarilo (bovina) S3.β92,S3.β'92-bis(2-amino-2-oxoetil)-N6.α99,N6.α'99-(but- 2-enodioil)hemoglobulina bovina (α2β2 tetrámero) transportador de oxígeno


424

C2826H4406N762O802S10

1360741-07-6

H2N CO2H

H

CO2HH2N

HNH

O

HN

O

H2N CO2H

H S

O

NH2

Alpha chain / Chaîne alpha / Cadena alfaVLSAADKGNV KAAWGKVGGH AAEYGAEALE RMFLSFPTTK TYFPHFDLSH 50GSAQVKGHGA KVAAALTKAV EHLDDLPGAL SELSDLHAHK LRVDPVNFKL 100LSHSLLVTLA SHLPSDFTPA VHASLDKFLA NVSTVLTSKY R 141

Beta chain / Chaîne bêta / Cadena betaMLTAEEKAAV TAFWGKVKVD EVGGEALGRL LVVYPWTQRF FESFGDLSTA 50DAVMNNPKVK AHGKKVLDSF SNGMKHLDDL KGTFAALSEL HCDKLHVDPE 100NFKLLGNVLV VVLARNFGKE FTPVLQADFQ KVVAGVANAL AHRYH 145

Modified residues / Résidus modifiés / Restos modificadosK

99-Lys-crosfumaril-'99-LysC

92 , '92

ilorasertibum ilorasertib N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-

c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea antineoplastic

ilorasertib N-(4-{4-amino-7-[1-(2-hydroxyéthyl)-1H-pyrazol-4-yl]thiéno[3,2-c]pyridin-3-yl}phényl)-N'-(3-fluorophényl)urée antinéoplasique

ilorasertib N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin- 3-il}fenil)-N'-(3-fluorofenil)urea antineoplásico

C25H21FN6O2S

1227939-82-3

NH

NH

O

S

NNH2

NN

HOF

ipatasertibum ipatasertib (2S)-2-(4-chlorophenyl)-1-{4-[(5R,7R)-7-hydroxy-5-methyl-

6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl}- 3-[(propan-2-yl)amino]propan-1-one antineoplastic

ipatasertib (2S)-2-(4-chlorophényl)-1-{4-[(5R,7R)-7-hydroxy-5-méthyl- 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]pipérazin-1-yl}- 3-[(propan-2-yl)amino]propan-1-one antinéoplasique

ipatasertib (2S)-2-(4-clorofenil)-1-{4-[(5R,7R)-7-hidroxi-5-metil-6,7-dihidro- 5H-ciclopenta[d]pirimidin-4-il]piperazin-1-il}-3-[(propan- 2-il)amino]propan-1-ona antineoplásico


425

C24H32ClN5O2

1001264-89-6

H3C NH

N

O

N

N N

CH3

H

Cl

H3CH

OH

H

lexaptepidum pegolum lexaptepid pegol β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-

β-L-cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-cytidine 6-{2-(N-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan- 1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5'-phosphate antianaemic

lexaptépid pégol β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')- β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')- β-L-guanylyl-(3'→5')-β-L-cytidine 5’-hydrogénophosphate de 6-{2-(N-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan- 1,2-diyl)]oxy}acétamido)acétamido}hexyle antianémique


426

lexaptepid pegol β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-citidilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')- β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-uridilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-uridilil-(3'→5')- β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')- β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')- β-L-guanilil-(3'→5')-β-L-citidina 5’-hidrógenofosfato de 6-{2-(N-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan- 1,2-diil)]oxi}acetamido)acetamido}hexilo antianémico

C441H548N188O309P44S0[C2H4O]2n 1390631-57-8

R- =

HN

O

NCH2

O

O

O

OH3C

OH3C

n

n

-L-ribo-[(3'-5')-R-pG-C-G-C-C-G-U-A-U-G-G-G- A-U-U-A-A-G-U-A-A-A-U-G-A-G-G-A-G-U-U-G- G-A-G-G-A-A-G-G-G-C-G-C]

lodelcizumabum # lodelcizumab immunoglobulin G1-kappa, anti-[Homo sapiens PCSK9 (proprotein

convertase subtilisin/kexin type 9)], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (Homo sapiens IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo sapiens IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (227-227":230-230")-bisdisulfide antihypercholesterolemic agent

lodelcizumab immunoglobuline G1-kappa, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - Homo sapiens IGHG1*03 (CH1 (119-216), charnière (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimère (227-227":230-230")-bisdisulfure antihypercholestérolémiant


427

lodelcizumab inmunoglobulina G1-kappa, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - Homo sapiens IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizada (Homo sapiens IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dímero (227-227":230-230")-bisdisulfuro antihipercolesterolémico


QVQLVQSGAE VKKPGASVKV SCKASGYTFS TMYMSWVRQA PGQGLEWMGR 50IDPANEHTNY AQKFQGRVTM TRDTSISTAY MELSRLTSDD TAVYYCARSY 100YYYNMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPEAAGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligeraQIVLTQSPAT LSVSPGERAT LSCRASQSVS YMHWYQQKPG QAPRLLIYGV 50FRRATGIPDR FSGSGSGTDF TLTIGRLEPE DFAVYYCLQW SSDPPTFGQG 100TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200SSPVTKSFNR GEC 213



luminespibum luminespib 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-{4-[(morpholin-

4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide antineoplastic

luminespib 5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-N-éthyl-4-{4-[(morpholin- 4-yl)méthyl]phényl}-1,2-oxazole-3-carboxamide antinéoplasique

luminespib 5-[2,4-dihidroxi-5-(propan-2-il)fenil]-N-etil-4-{4-[(morfolin- 4-il)metil]fenil}-1,2-oxazol-3-carboxamida antineoplásico

C26H31N3O5

747412-49-3

OHHO

H3C

CH3

ON

NO

NHO

CH3


428

molidustatum molidustat 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-

1,2-dihydro-3H-pyrazol-3-one antianaemic

molidustat 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)- 1,2-dihydro-3H-pyrazol-3-one antianémique

molidustat 2-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1,2-dihidro-3H-pirazol-3-ona antianémico

C13H14N8O2 1154028-82-6

N N

N

NHN

N NN

O

O

nesvacumabum # nesvacumab immunoglobulin G1-kappa, anti-[Homo sapiens ANGPT2

(angiopoietin 2, Ang2)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220), hinge 221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide immunomodulator, antineoplastic

nesvacumab immunoglobuline G1-kappa, anti-[Homo sapiens ANGPT2 (angiopoïétine 2, Ang2)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V- KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure immunomodulateur, antinéoplasique

nesvacumab inmunoglobulina G1-kappa, anti-[Homo sapiens ANGPT2 (angiopoyetina 2, Ang2)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220),bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V- KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro inmunomodulador, antineoplásico


429


EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYDIHWVRQA TGKGLEWVSA 50IGPAGDTYYP GSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARGLI 100TFGGLIAPFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450GK 452

Light chain / Chaîne légère / Cadena ligeraEIVLTQSPGT LSLSPGERAT LSCRASQSVS STYLAWYQQK PGQAPRLLIY 50GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ HYDNSQTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214



nonacogum gamma # nonacog gamma variant_011773 (148-T>A) of human coagulation factor IX (EC

3.4.21.22, Christmas factor, plasma thromboplastin component), glycosylated (γ-glycoform) blood coagulation factor

nonacog gamma variant_011773 (148-T>A) du facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophile B) glycosylé (glycoforme γ) facteur de coagulation sanguine

nonacog gamma variante_011773 (148-T>A) del factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofílico B) glicosilado (glicoforma γ) factor de coagulación sanguínea

C2053H3116N558O675P2S26 (peptide) 181054-95-5

HO2C CO2H

NH2HHO2C

CO2H

NH2HO

SHO

O O

HO2CCO2H

NH2H

OH

OCO2H

NH2H

PO

HO OH

E7-8-15-17-20-21-26

27-30-33-36-404-carboxyGlu

D64

3-hydroxyAsp

Y155

O-sulfoTyr

S158

O-phosphonoSer

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación (N, S*, T* )Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179** potential sites / sites potentiels / posiciones posibles

Sequence / Séquence / Secuencia YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAEAVF 150PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400VSRYVNWIKE KTKLT 415

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro18-23 51-62 56-71 73-82 88-99 95-109111-124 132-289 206-222 336-350 361-389



430

olaptesedum pegolum olaptesed pegol β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-

β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine 6-{2-(N-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan- 1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5-phosphate antineoplastic

olaptésed pégol β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)- β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)- β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine 5’-hydrogénophosphate de 6-{2-(N-[ω-méthylpoly(oxyéthan- 1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan- 1,2-diyl)]oxy}acétamido)acétamido}hexyle antinéoplasique

olaptesed pegol β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-uridilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)- β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)- β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidina 5’-hidrógenofosfato de 6-{2-(N-[ω-metilpoli(oxietan- 1,2-diil)]-2-{[ω-metilpoli(oxietan- 1,2-diil)]oxi}acetamido)acetamido}hexilo antineoplásico


431

C442H554N169O326P45[C2H4O]2n

1390628-22-4

R- =

HN

O

NCH2

O

O

O

OH3C

OH3C

n

n

-L-ribo-[(3'-5')-R-pG-C-A-C-G-U-C-C-C-U-C-A-C-C-G-G-U-G-C-A-A-G-U-G-A-A-G-C-C-G-U-G-G-C-U-C-U-G-C-G]

ompinamerum ompinamer poly{[(piperazine-1,4-diyl N-oxide)ethylene]-co-[(piperazine-

1,4-diyl)ethylene]} detoxifying agent

ompinamère poly{[(N-oxyde de pipérazine-1,4-diyl)éthylène]-co-[(pipérazine- 1,4-diyl)éthylène]} agent détoxifiant

ompinámero poli{[(N-óxido de piperazina-1,4-diil)etileno]-co-[(piperazina- 1,4-diil)etileno]} destoxificante

[[C6H12N2]x [C6H12N2O]y]n

1359979-10-4

N

NN

N

O

x

yn

x = 8-9 , y = 1-2 , n = 8-24

ozanezumabum # ozanezumab immunoglobulin G1-kappa, anti-[Homo sapiens RTN4 (reticulon 4,

neurite outgrowth inhibitor, NOGO), isoform A], humanized monoclonal antibody; gamma1 heavy chain (1-443) [humanized VH (Homo sapiens IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens IGHG1*01 (CH1 (114-211), hinge (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (222-222":225-225")-bisdisulfide immunomodulator


432

ozanezumab immunoglobuline G1-kappa, anti-[Homo sapiens RTN4 (réticulon 4, inhibiteur de la croissance des neurites, NOGO), isoforme A], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-443) [VH humanisé (Homo sapiens IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens IGHG1*01 (CH1 (114-211), charnière (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (222-222":225-225")-bisdisulfure immunomodulateur

ozanezumab inmunoglobulina G1-kappa, anti-[Homo sapiens RTN4 (reticulon 4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-443) [VH humanizada (Homo sapiens IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens IGHG1*01 (CH1 (114-211), bisagra (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (222-222":225-225")-bisdisulfuro inmunomodulador


QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMHWVRQA PGQGLEWIGN 50INPSNGGTNY NEKFKSKATM TRDTSTSTAY MELSSLRSED TAVYYCELMQ 100GYWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH 200KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL AGAPSVFLFP PKPKDTLMIS 250RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 443

Light chain / Chaîne légère / Cadena ligeraDIVMTQSPLS NPVTLGQPVS ISCRSSKSLL YKDGKTYLNW FLQRPGQSPQ 50LLIYLMSTRA SGVPDRFSGG GSGTDFTLKI SRVEAEDVGV YYCQQLVEYP 100LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219


N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:293, 293'

peginterferonum beta-1a # peginterferon beta-1a N2.1-{(2RS)-2-methyl-3-[ω-methoxypoly(oxyethylene)]propyl}human

interferon beta (fibroblast interferon, IFN-beta) glycosylated expressed in mamelian cells immunomodulator


433

péginterféron bêta-1a N2.1-{(2RS)-2-méthyl-3-[ω-

méthoxypoly(oxyéthylène)]propyl}interféron bêta humain (interféron fibroblastoïde, IFN-bêta) glycosylé produit par les cellules de mammifères immunomodulateur

peginterferón beta-1a N2.1-{(2RS)-2-metil-3-[ω-metoxipoli(oxietileno)]propil}interferón beta humano (interferón fibroblastoide, IFN-beta) glicosilado producido por las células de mamífero inmunomodulador

C913H1417N246O256PS7 [C2H4O]n 1211327-92-2

H3CO

O NH

CO2H

H

S

CH3

nH CH3

*

and epimer at C*et l'épimère en C*y el epímero al C*

H2N CO2H

H

O P

O

OHOH

Sequence / Séquence / SecuenciaMSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF 50QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT 100VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI 150LRNFYFINRL TGYLRN 166

Disulfide bridge location / Position du pont disulfure / Posicion del puente disulfuro31-141


M1

N-pegMet

S119

O-phosphonoSer

Glycosylation site (N) / Site de glycosylation (N) / Posicion de glicosilación (N)Asn-80

pexastimogenum devacirepvecum # pexastimogene devacirepvec recombinant vaccinia virus vector (Wyeth strain) with its thymidine

kinase gene de-activated by insertion of a GM-CSF (Granulocytes-macrophages colony stimulating factor) gene under the control of a synthetic early/late promoter and a beta-galactosidase gene under the control of the p7.5 early/late promoter gene therapy product (antineoplastic)

pexastimogène dévacirépvec vecteur viral recombinant répliquant de la vaccine avec son gène de la thymidine kinase désactivé par l'insertion du gène GM-CSF(facteur de stimulation des colonies de granulocytes et de macrophages) sous le contrôle d'un promoteur synthétique précoce tardif et d'un gène de bêta-galactosidase sous le contrôle du promoteur p7.5 précoce tardif produit de thérapie génique (antinéoplasique)

pexastimogén devacirepvec vector virus vaccinia recombinante replicante con el gen de la timidina kinasa desactivado por inserción del gen GM-CSF(factor de estimulación de colonias de granulocitos y macrófagos) bajo control de un promotor sintético precoz tardío y de un gen de beta-galactosidasa bajo control del promotor p7.5 precoz tardío producto para terapia génica (antineoplásico)

1058624-46-6


434

pidilizumabum # pidilizumab immunoglobulin G1-kappa, anti-[Homo sapiens PDCD1

(programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 (118-215), hinge 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (226-226":229-229")-bisdisulfide immunomodulator

pidilizumab immunoglobuline G1-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 (118-215), charnière 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimère (226-226":229-229")-bisdisulfure immunomodulateur

pidilizumab inmunoglobulina G1-kappa, anti-[Homo sapiens PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 (118-215),bisagra 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dímero (226-226":229-229")-bisdisulfuro inmunomodulador

1036730-42-3

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGSE LKKPGASVKI SCKASGYTFT NYGMNWVRQA PGQGLQWMGW 50INTDSGESTY AEEFKGRFVF SLDTSVNTAY LQITSLTAED TGMYFCVRVG 100YDALDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligeraEIVLTQSPSS LSASVGDRVT ITCSARSSVS YMHWFQQKPG KAPKLWIYRT 50SNLASGVPSR FSGSGSGTSY CLTINSLQPE DFATYYCQQR SSFPLTFGGG 100TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200SSPVTKSFNR GEC 213




435

pilaralisibum pilaralisib 2-amino-N-(3-{[3-(2-chloro-5-methoxyanilino)quinoxalin-

2-yl]sulfamoyl}phenyl)-2-methylpropanamide antineoplastic

pilaralisib 2-amino-N-(3-{[3-(2-chloro-5-méthoxyanilino)quinoxalin- 2-yl]sulfamoyl}phényl)-2-méthylpropanamide antinéoplasique

pilaralisib 2-amino-N-(3-{[3-(2-cloro-5-metoxianilino)quinoxalin- 2-il]sulfamoil}fenil)-2-metilpropanamida antineoplásico

C25H25ClN6O4S 934526-89-3

HN

H2NS

NH

O

CH3H3C OO

N

NHN

Cl

OCH3

pinatuzumabum vedotinum # pinatuzumab vedotin immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens

CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide (if not conjugated) with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-cit-PABC) linker For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunomodulator, antineoplastic

pinatuzumab védotine immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo sapiens CD22 (Ig-like lectine 2 liant l'acide sialique, SIGLEC2, SIGLEC-2, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM, Leu-14)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl- p-aminobenzylcarbamate (mc-val-cit-PABC) Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunomodulateur, antinéoplasique


436

pinatuzumab vedotina inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo sapiens CD22 (Ig-like lectine 2 que liga ácido siálico, SIGLEC2, SIGLEC-2, molécula d'adhesión celular del linfocito B, BL-CAM, Leu-14)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-450) [VH humanizado (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro (si no conjugado ) con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en 3 - 4 restos cistenil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidacaproil-valil-citrulinil-p-aminobencilcarbamato (mc-val-cit-PABC) Para la fracción vedotina, se pueden dirigir al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*. inmunomodulador, antineoplásico

1313706-14-7

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGYEFS RSWMNWVRQA PGKGLEWVGR 50IYPGDGDTNY SGKFKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARDG 100SSWDWYFDVW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRSSQSIV HSVGNTFLEW YQQKPGKAPK 50LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCFQGSQFP 100YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 147-203 264-324 370-428 22''-96'' 147''-203'' 264''-324'' 370''-428''Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L* 223-219' 223''-219''' Inter-H-H* 229-229'' 232-232'' *Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 4 drug linkers each via a thioether bond. * Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:300, 300'' but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

Other post-translational modificationsAutres modifications post-traductionnellesOtras modificaciones post-traduccionalesLacking H chain C-terminal lysine (CHS K2>del)

piromelatinum piromelatine N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxo-4H-pyran-2-carboxamide

melatonin analogue


437

piromélatine N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]-4-oxo-4H-pyran-2-carboxamide analogue de la mélatonine

piromelatina N-[2-(5-metoxi-1H-indol-3-il)etil]-4-oxo-4H-piran-2-carboxamida análogo de la melatonina

C17H16N2O4 946846-83-9

O

NH

OHN

H3CO

O

polatuzumabum vedotinum # polatuzumab vedotin immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo

sapiens CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-218')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-cit-PABC) linker For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunomodulator, antineoplastic

polatuzumab védotine immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo sapiens CD79B (CD79 bêta associé à l'immunoglobuline)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl- p-aminobenzylcarbamate (mc-val-cit-PABC) Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunomodulateur, antinéoplasique


438

polatuzumab vedotina inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo sapiens CD79B (CD79 beta asociado a la inmunoglobulina)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfuro (si no está conjugado ) con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjugado, en 3 - 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidacaproil-valil-citrulinil-p-aminobencilcarbamato (mc-val-cit-PABC) Para la fracción vedotina se pueden referir al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*. inmunomodulador, antineoplásico


EVQLVESGGG LVQPGGSLRL SCAASGYTFS SYWIEWVRQA PGKGLEWIGE 50ILPGGGDTNY NEIFKGRATF SADTSKNTAY LQMNSLRAED TAVYYCTRRV 100PIRLDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligeraDIQLTQSPSS LSASVGDRVT ITCKASQSVD YEGDSFLNWY QQKPGKAPKL 50LIYAASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPL 100TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 144-200 261-321 367-425 22''-96'' 147''-203'' 261''-321'' 367''-425''Intra-L 23'-92' 138'-198' 23'''-92''' 138'''-198''' Inter-H-L* 220-218' 220''-218''' Inter-H-H* 226-226'' 229-229'' *Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 4 drug linkers each via a thioether bond. * Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:297, 297'' but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

Other post-translational modificationsAutres modifications post-traductionnellesOtras modificaciones post-traduccionalesLacking H chain C-terminal lysine (CHS K2>del)

poziotinibum poziotinib 1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-

6-yl]oxy}piperidin-1-yl)prop-2-en-1-one tyrosine kinase inhibitor, antineoplastic

poziotinib 1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-méthoxyquinazolin- 6-yl]oxy}pipéridin-1-yl)prop-2-èn-1-one inhibiteur de la tyrosine kinase, antinéoplasique


439

poziotinib 1-(4-{[4-(3,4-dicloro-2-fluoroanilino)-7-metoxiquinazolin- 6-il]oxi}piperidin-1-il)prop-2-en-1-ona inhibidor de la tirosina kinasa, antineoplásico

C23H21Cl2FN4O3

1092364-38-9

N

N

HN

F

O

Cl

Cl

O

CH3

NH2C

O

pritoxaximabum # pritoxaximab immunoglobulin G1-kappa, anti-[shiga toxin-producing Escherichia

coli (STEC) shiga toxin type 1 (stx1), B subunit)], chimeric monoclonal antibody; gamma1 heavy chain (1-454) [Mus musculus VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -Homo sapiens IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (233-233'':236-236'')-bisdisulfide immunomodulator

pritoxaximab immunoglobuline G1-kappa, anti-[sous-unité B de la toxine type 1 shiga (stx1) d'Escherichia coli produisant des shiga-toxines (STEC)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-454) [Mus musculus VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -Homo sapiens IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (233-233'':236-236'')-bisdisulfure immunomodulateur

pritoxaximab inmunoglobulina G1-kappa, anti-[subunidad B de la toxina tipo 1 shiga (stx1) de Escherichia coli productor de toxinas shiga (STEC)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-454) [Mus musculus VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -vínculo (123-124) -Homo sapiens IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (233-233'':236-236'')-bisdisulfuro inmunomodulador


440


QVQLQESGAE LVRSGASVRM SCKASGYTFT SYNMHWVKQT PGQGLEWIGY 50IYPGNGGTNY IQKFKGKAIL TADTSSSTAY MQISSLTSED SAVYFCTRSP 100SHYSSDPYFD YWGQGTTLTV SSEFASTKGP SVFPLAPSSK STSGGTAALG 150CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450SPGK 454

Light chain / Chaîne légère / Cadena ligeraDIVMSQSHKF MSTSVGDRVS ITCKASQDVG TAVAWYQQNP GQSPKFLIYW 50ASTRHTGVPD RFTGSGSGTD FTLTITNVQS EDLADYFCQQ YSSYPLTFGA 100GTSLELKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214



ramaterceptum # ramatercept fusion protein for immune applications (FPIA) comprising Homo

sapiens ACVR2B (activin A receptor type IIB, ActR-IIB) fragment, fused with Homo sapiens immunoglobulin G1 Fc fragment; Homo sapiens ACVR2B precursor fragment 20-134 (1-115) -triglycyl (116-118) -Homo sapiens IGHG1*03 H-CH2-CH3 fragment (hinge 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343); dimer (122-122':125-125')-bisdisulfide immunosuppressant

ramatercept protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'Homo sapiens ACVR2B (récepteur de type IIB de l'activine A, ActR-IIB), fusionné au fragment Fc de l'Homo sapiens immunoglobuline G1; Homo sapiens ACVR2B fragment 20-134 du précurseur (1-115) -triglycyl (116-118) -Homo sapiens IGHG1*03 fragment H-CH2-CH3 (charnière 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343)]; dimère (122-122':125-125')-bisdisulfure immunosuppresseur

ramatercept proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de Homo sapiens ACVR2B (receptor de tipo IIB de la activina A, ActR-IIB), fusionado con el fragmento Fc de la Homo sapiens inmunoglobulina G1; Homo sapiens ACVR2B fragmento 20-134 del precursor (1-115) -triglicil (116-118) -Homo sapiens IGHG1*03 fragmento H-CH2-CH3 (bisagra 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343)]; dímero (122-122':125-125')-bisdisulfuro inmunosupresor


441

1169766-01-1 Fused chain / Chaîne fusionnée / Cadena fusionada

GRGEAETREC IYYNANWELE RTNQSGLERC EGEQDKRLHC YASWRNSSGT 50IELVKKGCWL DDFNCYDRQE CVATEENPQV YFCCCEGNFC NERFTHLPEA 100GGPEVTYEPP PTAPTGGGTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 150RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 200VLTVLHQDWL NGKEYKCKVS NKALPVPIEK TISKAKGQPR EPQVYTLPPS 250REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 300FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 343

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-chain 10-40 30-58 65-84 71-83 85-90 157-217 263-321 10'-40' 30'-58' 65'-84' 71'-83' 85'-90' 157'-217' 263'-321'Inter-chains 122-122' 125-125'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación23, 46, 193 (CH2 N84.4)23', 46', 193' (CH2 N84.4)

rebastinibum rebastinib 4-[4-({[3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-

5-yl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridin- 2-carboxamide tyrosine kinase inhibitor, antineoplastic

rébastinib 4-(4-{[3-tert-butyl-1-(quinoléin-6-yl)-1H-pyrazol- 5-yl]carbamoyl}amino)-3-fluorophénoxy)-N-méthylpyridin- 2-carboxamide inhibiteur de la tyrosine kinase, antinéoplasique

rebastinib 4-[4-({[3-terc-butil-1-(quinolin-6-il)-1H-pirazol-5-il]carbamoil}amino)- 3-fluorofenoxi]-N-metilpiridin-2-carboxamida inhibidor de la tirosina kinasa, antineoplásico

C30H28FN7O3 1020172-07-9

N

OHN

CH3

O

HN

HN

OF

NN

N

H3CCH3

CH3

recilisibum recilisib 4-[(1E)-2-{[(4-chlorophenyl)methyl]sulfonyl}ethenyl]benzoic acid

antineoplastic

récilisib acide 4-[(1E)-2-{[(4-chlorophényl)méthyl]sulfonyl}éthényl]benzoïque antinéoplasique

recilisib ácido 4-[(1E)-2-{[(4-clorofenil)metil]sulfonil}etenil]benzoico antineoplásico

C16H13ClO4S 334969-03-8

S

CO2H

O OCl


442

revexepridum revexepride 4-amino-5-chloro-N-{[(3S,4S)-3-hydroxy-

1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide serotonin receptor agonist, prokinetic agent

révexépride 4-amino-5-chloro-N-{[(3S,4S)-3-hydroxy- 1-(3-méthoxypropyl)pipéridin-4-yl]méthyl}-2,2-diméthyl-2,3-dihydro-1-benzofurane-7-carboxamide agoniste des récepteurs de la sérotonine, agent prokinétique

revexeprida 4-amino-5-cloro-N-{[(3S,4S)-3-hidroxi-1-(3-metoxipropil)piperidin- 4-il]metil}-2,2-dimetil-2,3-dihidro-1-benzofuran-7-carboxamida agonista de los receptores de serotonina, procinético

C21H32ClN3O4

219984-49-3

O

O

NH

H2N

Cl

CH3H3C

N

HOH O CH3

H

roxadustatum roxadustat N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine

antianaemic

roxadustat N-[(4-hydroxy-1-méthyl-7-phénoxyisoquinoléin-3-yl)carbonyl]glycine antianémique

roxadustat N-[(4-hidroxi-1-metil-7-fenoxiisoquinolin-3-il)carbonil]glicina antianémico

C19H16N2O5 808118-40-3

NO

CH3

OH

HN CO2H

O

saroglitazarum saroglitazar (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-

1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid peroxisome proliferator activating receptor (PPAR) agonist

saroglitazar acide (2S)-2-éthoxy-3-[4-(2-{2-méthyl-5-[4-(méthylsulfanyl)phényl]-1H-pyrrol-1-yl}éthoxy)phényl]propanoïque agoniste des récepteurs activés par les proliférateurs de peroxysomes


443

saroglitazar ácido (2S)-2-etoxi-3-[4-(2-{2-metil-5-[4-(metilsulfanil)fenil]-1H-pirrol-1-il}etoxi)fenil]propanoico agonista de los receptores activados por factores de proliferación de peroxisomas

C25H29NO4S

495399-09-2

CO2H

ON OH

CH3

CH3

H3CS

seribantumabum # seribantumab immunoglobulin G2-lambda7, anti-[Homo sapiens ERBB3 (receptor

tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal antibody; gamma2 heavy chain (1-445) [Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfide with lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dimer (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide immunomodulator, antineoplastic

séribantumab immunoglobuline G2-lambda7, anti-[Homo sapiens ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], Homo sapiens anticorps monoclonal; chaîne lourde gamma2 (1-445) [Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfure avec la chaîne légère lambda (1'-217') [Homo sapiens V- LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dimère (221-221'':222-222'':225-225'':228-228'')-tétrakisdisulfure immunomodulateur, antinéoplasique

seribantumab inmunoglobulina G2-lambda7, anti-[Homo sapiens ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma2 (1-445) [Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), bisagra(218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfuro con la cadena ligera lambda (1'-217') [Homo sapiens V- LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dímero (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfuro inmunomodulador, antineoplásico


444


EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYVMAWVRQA PGKGLEWVSS 50ISSSGGWTLY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRGL 100KMATIFDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 445

Light chain / Chaîne légère / Cadena ligeraQSALTQPASV SGSPGQSITI SCTGTSSDVG SYNVVSWYQQ HPGKAPKLII 50YEVSQRPSGV SNRFSGSKSG NTASLTISGL QTEDEADYYC CSYAGSSIFV 100IFGGGTKVTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL VSDFYPGAVT 150VAWKADGSPV KVGVETTKPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCRV 200THEGSTVEKT VAPAECS 217



setoxaximabum # setoxaximab immunoglobulin G1-kappa, anti-[shiga toxin-producing Escherichia

coli (STEC) shiga toxin type 2 (stx2), A subunit)], chimeric monoclonal antibody; gamma1 heavy chain (1-451) [Mus musculus VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -Homo sapiens IGHG1*01 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451) (122-451)], (224-220')-disulfide with kappa light chain (1'-220') [Mus musculus V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-220')]; dimer (230-230'':233-233'')-bisdisulfide immunomodulator

sétoxaximab immunoglobuline G1-kappa, anti-[sous-unité A de la toxine type 2 shiga (stx2) d'Escherichia coli produisant des shiga-toxines (STEC)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-451) [Mus musculus VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -Homo sapiens IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-220')-disulfure avec la chaîne légère kappa (1'-220') [Mus musculus V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-220')]; (230-230'':233-233'')-bisdisulfure immunomodulateur

setoxaximab inmunoglobulina G1-kappa, anti-[subunidad A de la toxina tipo 2 shiga (stx2) de Escherichia coli productor de toxinas shiga (STEC)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-451) [Mus musculus VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -vínculo(120-121) -Homo sapiens IGHG1*01 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-220')-disulfuro con la cadena ligera kappa (1'-220') [Mus musculus V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-220')]; (230-230'':233-233'')-bisdisulfura inmunomodulador


445

1351470-17-1

Heavy chain / Chaîne lourde / Cadena pesada

EVQLQQPGPE LEKPGASVKL SCKASGYSFT DYNMNWVKQN NGESLEWIGK 50IDPYYGGPSY NQKFKDKATL TVDKSSSTAY MQLKSLTSED SAVYYCTRGG 100NRDWYFDVWG AGTTLTVSAE FASTKGPSVF PLAPSSKSTS GGTAALGCLV 150KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450K 451

Light chain / Chaîne légère / Cadena ligeraDIVLSQSPSS LVVSVGEKVT MSCKSSQSLL YSRNQKNYLA WYQQKPGQSP 50KVLIYWASTR ESGVPDRLTG SGSGTDFTLT ISSVKAEDLA VYYCQQYYSY 100PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200EVTHQGLSSP VTKSFNRGEC 220



sofosbuvirum sofosbuvir propan-2-yl N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-

3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan- 2-yl]methoxy}phenoxyphosphoryl]-L-alaninate antiviral

sofosbuvir N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-méthyloxolan- 2-yl]méthoxy}phénoxyphosphoryl]-L-alaninate de propan-2-yle antiviral

sofosbuvir N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2H)-il)- 4-fluoro-3-hidroxi-4-metiloxolan-2-il]metoxi}fenoxifosforil]-L-alaninato de propan-2-ilo antiviral

C22H29FN3O9P

1190307-88-0

O N

HN

OP

NH

OH3C

O OOO

HO FCH3

OCH3

HH3C

tecemotidum tecemotide human mucin-1 (carcinoma-associated mucin, episialin, CD227)-

(107-131)-peptide (sequence 40 times repeated) fusion protein with 6-N-hexadecanoyl-L-lysylglycine immunological agent for active immunization


446

técémotide mucine-1 humaine (mucine associée au carcinome, épisialine, CD227)-(107-131)-peptide (fragment présent 40 fois) protéine de fusion avec la 6-N-hexadécanoyl-L-lysylglycine agent immunologique d'immunisation active

tecemotida mucina-1 humana (mucina asociada al carcinoma, episialina, CD227)-(107-131)-péptido (fragmento presente 40 veces) proteína de fusión con la 6-N-hexadecanoil-L-lisilglicina agente inmunológico para inmunización activa

C124H203N33O38

221214-84-2

CO2H

NH2H

NH

H3C

O

14

Sequence / Séquence / SecuenciaSTAPPAHGVT SAPDTRPAPG STAPPKG 27

Modified residue / Résidu modifié / Resto modificado

K26

palmityl-Lys

telmapitantum telmapitant (5R,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-

8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione neurokinin NK1 receptor antagonist

telmapitant (5R,8S)-8-({(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}méthyl)- 8-phényl-1,3,7-triazaspiro[4.5]décane-2,4-dione antagoniste du récepteur NK1 de la neurokinine

telmapitant (5R,8S)-8-({(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi}metil)-8-fenil-1,3,7-triazaspiro[4.5]decano-2,4-diona antagonista del receptor NK1 de neurokinina

C24H23F6N3O3

552292-58-7

O

H CH3

CF3

CF3

NH

NH

HN

O

O

tildrakizumabum # tildrakizumab immunoglobulin G1-kappa, anti-[Homo sapiens IL23A (interleukin 23

alpha subunit (p19), IL-23A)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (Homo sapiens IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo sapiens IGHG1*01 (CH1 (117-214, hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (225-225":228-228")-bisdisulfide immunomodulator


447

tildrakizumab immunoglobuline G1-kappa, anti-[Homo sapiens IL23A (sous-unité alpha (p19) de l'interleukine 23, IL-23A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo sapiens IGHG1*01 (CH1 (117-214, charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225-225":228-228")-bisdisulfure immunomodulateur

tildrakizumab inmunoglobulina G1-kappa, anti-[Homo sapiens IL23A (subunidad alfa (p19) de la interleukina 23, IL-23A)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (Homo sapiens IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo sapiens IGHG1*01 (CH1 (117-214, bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro inmunomodulador


QVQLVQSGAE VKKPGASVKV SCKASGYIFI TYWMTWVRQA PGQGLEWMGQ 50IFPASGSADY NEKFEGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARGG 100GGFAYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRTSENIY SYLAWYQQKP GKAPKLLIYN 50AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYGIPFTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214



tomicoratum tomicorat 4-{5-[(5-fluoro-2-methylphenoxy)methyl]-2,2,4-trimethyl-

1,2-dihydroquinolin-6-yl}-3-methoxyphenyl furan-2-carboxylate anti-inflammatory

tomicorat furane-2-carboxylate de 4-{5-[(5-fluoro-2-méthylphénoxy)méthyl]-2,2,4-triméthyl-1,2-dihydroquinoléin-6-yl}-3-méthoxyphényle anti-inflammatoire


448

tomicorat furan-2-carboxilato de 4-{5-[(5-fluoro-2-metilfenoxi)metil]-

2,2,4-trimetil-1,2-dihidroquinolin-6-il}-3-metoxifenilo antiinflamatorio

C32H30FNO5 1027099-03-1

HN

H3C

H3CCH3

O

O

O

O

H3C

F

H3CO

turoctocogum alfa pegolum # turoctocog alfa pegol human coagulation factor VIII-(1-750)-(1638-1648)-peptide

compound with human coagulation factor VIIIa light chain, glycosylated and pegylated; O3.750-[α-methylpoly(oxyethylene) 5-(acetylamino)-2,5-dideoxy- D-glycero-β-D-galacto-non-2-ulopyranosylonate-(2→4)- α-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- α-D-galactopyranosyl]-des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells) blood coagulation factor

turoctocog alfa pégol facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés et pégylés O3.750-[5-(acétylamino)-2,5-didéoxy-D-glycéro-β-D-galacto-non- 2-ulopyranosylonate de α-méthylpoly(oxyéthylène)-(2→4)- α-D-galactopyranosyl-(1→4)-2-(acétylamino)-2-déoxy- α-D-galactopyranosyl]-dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du factor VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO) facteur de coagulation sanguine

turoctocog alfa pegol factor VIII de coagulación humano-(1-750)-(1638-1648)-péptido asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados y pegilados O3.750-[5-(acetilamino)-2,5-didesoxi-D-glicero-β-D-galacto-non-2-ulopiranosilonato de α-metilpoli(oxietileno)-(2→4)- α-D-galactopiranosil-(1→4)-2-(acetlamino)-2-desoxi- α-D-galactopiranosil]-des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92 kDa del factor VIIIa asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicoforma alfa producido por células CHO) factor de coagulación sanguínea


449

1309086-46-1

O

OHNH

O

OHH2N CO2H

H

O

OHHO

O

OH

O

OH

H

OH

HO

NH

CH3

O

OH

O

OO

OCH3

n

H3C

O

Heavy chain / Chaîne lourde / Cadena pesadaATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750QNPPVLKRHQ R 761

Light chain / Chaîne légère / Cadena ligera EI 1650TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

Modified residue / Résidu modifié / Resto modificado

S750

O-(PEG-Glyc)Ser

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)Asn-41 Asn-239 Asn-1810 Asn-2118

ulodesinum ulodesine 7-{[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl}-

1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one antihyperuricemic

ulodésine 7-{[(3R,4R)-3-hydroxy-4-(hydroxyméthyl)pyrrolidin-1-yl]méthyl}- 1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one antihyperuricémique

ulodesina 7-{[(3R,4R)-3-hidroxi-4-(hidroximetil)pirrolidin-1-il]metil}-1,5-dihidro-4H-pirrolo[3,2-d]pirimidin-4-ona antihiperuricémico


450

C12H16N4O3 548486-59-5

N

NH

HN

O

N

OH

OH

vibegronum vibegron (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-

2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide β3-adrenoreceptor agonist

vibégron (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxyphénylméthyl]pyrrolidin- 2-yl}méthyl)phényl]-4-oxo-4,6,7,8-tétrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide agoniste β3-adrénergique

vibegrón (6S)-N-[4-({(2S,5R)-5-[(R)-hidroxi(fenil)metil]pirrolidin-2-il}metil)fenil]-4-oxo-4,6,7,8-tetrahidropirrolo[1,2-a]pirimidina-6-carboxamida agonista del adrenoreceptor β3

C26H28N4O3 1190389-15-1 H

N

HH

NH H N

N

OHH

O

O

voxtalisibum voxtalisib 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-

7(8H)-one antineoplastic

voxtalisib 2-amino-8-éthyl-4-méthyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one antinéoplasique

voxtalisib 2-amino-8-etil-4-metil-6-(1H-pirazol-3-il)pirido[2,3-d]pirimidin-

7(8H)-ona antineoplásico

C13H14N6O

934493-76-2

N

N

NH2N

CH3

O

H3C

NNH


451

zamicastatum zamicastat 5-(2-(benzylamino)ethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-

2H-1-benzopyran-3-yl)-1,3-dihydro-2H-imidazole-2-thione dopamine β-mono-oxygenase inhibitor

zamicastat 5-[2-(benzylamino)éthyl]-1-[(3R)-6,8-difluoro-3,4-dihydro- 2H-1-benzopyran-3-yl]-1,3-dihydro-2H-imidazole-2-thione inhibiteur de la dopamine β-mono-oxygénase

zamicastat 5-(2-(bencilamino)etil)-1-[(3R)-6,8-difluoro-3,4-dihidro- 2H-1-benzopiran-3-il)-1,3-dihidro-2H-imidazol-2-tiona inhibidor de la dopamina β-mono-oxigenasa

C21H21F2N3OS

1080028-80-3

O

NNH

SF

FH

NH

* http://www.who.int/medicines/services/inn/publication/en/index.html # Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/


452

AMENDMENTS TO PREVIOUS LISTS

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Nonproprietary Names (Prop. INN): List 97 Dénominations communes internationales proposées (DCI Prop.): Liste 97 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 97 (WHO Drug Information, Vol. 21, No. 2, 2007) p. 197 gantenerumabum gantenerumab replace the CAS registry number by the following one

ganténérumab remplacer le numéro de registre du CAS par le suivant

gantenerumab sustitúyase el número de registro del CAS por el siguiente

1043556-46-2

Proposed International Nonproprietary Names (Prop. INN): List 98 Dénominations communes internationales proposées (DCI Prop.): Liste 98 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 98(WHO Drug Information, Vol. 21, No. 4, 2007) p. 381 ridaforolimusum ridaforolimus

(previously deforolimus)

replace the chemical name by the following one

ridaforolimus (anteriormente deferolimus)

sustitúyase el nombre químico por el siguiente

(1R,2R,4S)-4-[(2R)-2-{(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxaazacyclohentriacontin- 3-yl}propyl]-2-methoxycyclohexyl dimethylphosphinate

dimetilfosfinato de (1R,2R,4S)-4-[(2R)-2-{(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahidro-3H-23,27-epoxipirido[2,1-c][1,4]oxaazaciclohentriacontin-3-il}propil]- 2-metoxiciclohexilo


453

Proposed International Nonproprietary Names (Prop. INN): List 99 Dénominations communes internationales proposées (DCI Prop.): Liste 99Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 99 (WHO Drug Information, Vol. 22, No. 2, 2008) p. 396 obinutuzumabum obinutuzumab

(previously afatuzumab)

replace the structure by the following one

obinutuzumab (auparavant afatuzumab)

remplacer la structure par la suivante

obinutuzumab (anteriormente afatuzumab)

sustitúyase la estructura por la siguiente

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR 50IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligeraDIVMTQTPLS LPVTPGEPAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ 50'LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLELP 100'YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150'VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200'VTHQGLSSPV TKSFNRGEC 219'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro22-96 22''-96'' 23'-93' 23'''-93''' 139'-199' 139'''-199''' 146-202 146''-202''219'-222 219'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilaciónH CH2 N84.4299, 299" (enriched in bisected non-fucosylated oligosaccharides)

p. 126 & 127

bevasiranibum

bevasiranib replace the description and the structure by the following ones

bévasiranib remplacer la description et la structure par les suivants

bevasiranib sustitúyase la descripción y la estructura por los siguientes

siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production; duplex of adenylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-uridylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-adenylyl-(3'5')-guanylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-cytidylyl-(3'5')-thymidylyl-(3'5')-thymidine and thymidylyl-(5'3')-thymidylyl-(5'3')-uridylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-adenylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-uridylyl-(5'3')-cytidylyl-(5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanosine


454

petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l’endothélium vasculaire (VEGF) ; duplex d’adénylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-uridylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-adénylyl-(3'5')-guanylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-cytidylyl-(3'5')-thymidylyl-(3'5')-thymidine et de thymidylyl-(5'3')-thymidylyl-(5'3')-uridylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-adénylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-uridylyl-(5'3')-cytidylyl-(5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanosine

ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor de crecimiento endotelial vascular (VEGF);dúplex de adenilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-uridilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-adenilil-(3'5')-guanilil-(3'5')-guanilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-guanilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-citidilil-(3'5')-timidill-(3'5')-timidina y timidill-(5'3')-timidill-(5'3')-uridilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-adenilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-uridilil-(5'3')-citidilil-(5'3')-citidilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-citidilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-guanosina

(5'-3')

(3'-5')

dT dT U G G A G U G G U U C C G G U C G U G

A C C U C A C C A A G G C C A G C A C dT dT.. . . . . . . . . . . . . . . . . .

p. 152 tasimelteonum tasimelteon replace the mechanism of action by the following one

tasimeltéon remplacer le mécanisme d’action par le suivant

tasimelteón sustitúyase el mecanismo de acción por el siguiente

melatonin receptor agonist

agoniste du récepteur de la mélatonine

agonista del receptor de melatonina

Proposed International Nonproprietary Names (Prop. INN): List 101 Dénominations communes internationales proposées (DCI Prop.): Liste 101 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 101 (WHO Drug Information, Vol. 23, No. 2, 2009) p. 171

teprotumumabum

teprotumumab replace the CAS registry number by the following one

téprotumumab remplacer le numéro de registre du CAS par le suivant

teprotumumab sustitúyase el número de registro del CAS por el siguiente

1036734-93-6


455

Proposed International Nonproprietary Names (Prop. INN): List 103Dénominations communes internationales proposées (DCI Prop.): Liste 103Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 103 (WHO Drug Information Vol. 24, No. 2, 2010) p. 161 & 162

peginesatidum

peginesatide replace the description, CAS RN and the structure by the following ones

péginésatide remplacer la description, le numéro de registre du CAS et la structure par les suivants

peginesatida sustitúyase la descripción, el número de registro del CAS y la estructura por los siguientes

pegylated erythropoietin receptor agonist; N6.21,N6.21'-{[(N2,N6-bis{[ω-methoxypoly(oxyethylene)]carbonyl}-DL-lysyl- β-alanyl)imino]bis(methylenecarbonyl)}bis[acetylglycylglycyl-L-leucyl-L-tyrosyl- L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl- 3-(naphtalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] (6→15:6'→15')-bisdisulfure cyclic

agoniste du récepteur de l'érythropoïétine, pégylé ; (6→15:6'→15')-bisdisulfure cyclique du N6.21,N6.21'-{[(N2,N6-bis{[ω-méthoxypoly(oxyéthylène)]carbonyl}-DL-lysyl- β-alanyl)imino]bis(méthylènecarbonyl)}bis[acétylglycylglycyl-L-leucyl-L-tyrosyl- L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl- 3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-méthylglycyl-L-lysinamide]

agonista del receptor de la eritropoyetina, pegilado; (6→15:6'→15')-bisdisulfuro cíclico del N6.21,N6.21'-{[(N2,N6-bis{[ω-metoxipoly(oxietileno)]carbonil}-DL-lisil- β-alanil)imino]bis(metilenocarbonil)}bis[acetilglicilglicil-L-leucil-L-tirosil-L-alanil- L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-L-glutaminil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisinamida]

1350810-60-4

H3CO

O NH

NH

O

O

H

NH

O

O

OH3C

O

N

O

Oa

b

n = a + b # 900

2010

Gly Gly Leu Tyr Ala Cys His Met Gly

O

H3C

Cys Gln Pro Leu Arg Sar Lys NH2ValNalThrIlePro

20'10'

Gly Gly Leu Tyr Ala Cys His Met Gly

O

H3C

Cys Gln Pro Leu Arg Sar Lys NH2ValNalThrIleProN6

N6

Sar

Nal

N

CH3 O

=

= NH

O

H

3-(naphthalen-1-yl)-L-alanyl

N-methylglycyl

** DL-lysine


456

Proposed International Nonproprietary Names (Prop. INN): List 104 Dénominations communes internationales proposées (DCI Prop.): Liste 104 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 104 (WHO Drug Information, Vol. 24, No. 4, 2010) p. 381 mericitabinum mericitabine replace the chemical name by the following one

mericitabina sustitúyase el nombre químico por el siguiente

(2’R)-2’-deoxy-2’-fluoro-2’-methyl-3’,5’-bis-O-(2-methylpropanoyl)cytidine

(2’R)-2’-desoxi-2’-fluoro-2’-metil-3’,5’-bis-O-(2-metilpropanoil)citidina

p. 396 turoctocogum alfa # turoctocog alfa replace the description, the molecular formula and the structure by the following

ones

turoctocog alfa remplacer la description, la formule moléculaire et la structure par les suivantes

turoctocog alfa sustitúyase la descripción, la fórmula molecular y la estructura por las siguientes

human coagulation factor VIII-(1-750)-(1638-1648)-peptide compound with human coagulation factor VIIIa light chain, glycosylated des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells)

facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du factor VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)

factor VIII de coagulación humano-(1-750)-(1648)-péptido asociado a la cadena ligera del factor VIIIa de coagulación humano, glicosilados des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92kDa del factor VIIIa asociada a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicoforma alfa producida por células CHO)

C7480H11381N1999O2195S68 (peptide)


457

Heavy chain / Chaîne lourde / Cadena pesadaATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750QNPPVLKRHQ R 761

Light chain / Chaîne légère / Cadena ligera EI 1650TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

Glycosylation sites (N, S) / Sites de glycosylation (N, S) / Posiciones de glicosilación (N, S)Asn-41 Asn-239 Ser-750 Asn-1810 Asn-2118

Proposed International Nonproprietary Names (Prop. INN): List 107 Dénominations communes internationales proposées (DCI Prop.): Liste 107 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 107 (WHO Drug Information, Vol. 26, No. 2, 2012) p. 190 supprimer insérer nécéprevir nécéprévir

p. 197 perakizumabum perakizumab replace the CAS registry number by the following one

pérakizumab remplacer le numéro de registre du CAS par le suivant

perakizumab sustitúyase el número de registro del CAS por el siguiente

1331830-76-2


458

ANNEX 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL

NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

The following procedure shall be followed by the World Health Organization (hereinafter also referred to as “WHO”) in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11 of the World Health Assembly, and in the substitution of such names. Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted. Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members hereinafter referred to as “the INN Expert Group”, for consideration in accordance with the “General principles for guidance in devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this procedure2. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary. Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed international nonproprietary name is being considered. a) Such notice shall be given by publication in WHO Drug Information3

and by letter to Member States and to national and regional pharmacopoeia commissions or other bodies designated by Member States.

i) Notice shall also be sent to the person who submitted the proposal (“the original applicant”) and other persons known to be concerned with a name under consideration.

b) Such notice shall:

i) set forth the name under consideration; ii) identify the person who submitted the proposal for naming the substance, if so requested by such person; iii) identify the substance for which a name is being considered; iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed; v) state the authority under which WHO is acting and refer to these rules of procedure.

c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO. Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of publication, under article 3, of the name in WHO Drug Information.

1 See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution EB15.R7 and amended in resolutions EB43.R9 and EB115.R4.

2 See Annex 2.

3 Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.


459

Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in WHO Drug Information.

Such objection shall:

i) identify the person objecting;

ii) state his or her interest in the name; iii) set forth the reasons for his or her objection to the name proposed. Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn. Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Secretariat shall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a recommended international nonproprietary name. Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat shall: a) request that it be recognized as the nonproprietary name for the substance; and b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name and to prohibit registration of the name as a trademark or trade name. Article 9 a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved through other interventions than a possible substitution of a previously recommended international nonproprietary name, or in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested person. Such proposals shall be submitted on the form provided therefore and shall: i) identify the person making the proposal;

ii) state his or her interest in the proposed substitution; and iii) set forth the reasons for the proposal; and

iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to resolve the situation, and the reasons why these other interventions were inadequate.

Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with the General principles, which takes into account the pharmaceutical substance for which the new substitute international nonproprietary name is being proposed. The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations). In addition, the Secretariat shall request comments on the proposal from:

i) Member States and national and regional pharmacopoeia commissions or other bodies designated by Member States (by including a notice to that effect in the letter referred to in article 3(a), and

ii) any other persons known to be concerned by the proposed substitution.


460

The request for comments shall:

i) state the recommended international nonproprietary name that is being proposed for substitution (and the proposed substitute name, if provided);

ii) identify the person who submitted the proposal for substitution (if so requested by such person);

iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution; iv) set forth the time within which comments will be received and the person and place to whom they should be directed; and v) state the authority under which WHO is acting and refer to these rules of procedure.

Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the request for comments. b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert Group for further processing. Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed for substitution.

In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3 and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously recommended international nonproprietary name and that Member States may wish to make transitional arrangements in order to accommodate existing products that use the previously recommended international nonproprietary name on their label in accordance with national legislation.

If, after consideration of the proposal for substitution and the comments received in accordance with the procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why the proposal for substitution was not considered sufficiently compelling).


461

ANNEX 2

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

These primary principles are to be implemented by using the following secondary principles:

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and “ibufenac sodium”.

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base. For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t” instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and “k” should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.2 Where a stem is shown without any hyphens it may be used anywhere in the name. Latin English -acum -ac anti-inflammatory agents, ibufenac derivatives -adolum -adol } analgesics -adol- -adol-} -astum -ast antiasthmatic, antiallergic substances not acting primarily as antihistaminics -astinum -astine antihistaminics -azepamum -azepam diazepam derivatives bol bol steroids, anabolic -cain- -cain- class I antiarrhythmics, procainamide and lidocaine derivatives -cainum -caine local anaesthetics 1

In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are fully discussed. The guiding principles were updated during the 13th Consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983).

2 A more extensive listing of stems is contained in the working document WHO/EMP/QSM/2011.3 which is regularly updated and can be requested from the INN Programme, WHO, Geneva.


462

cef- cef- antibiotics, cefalosporanic acid derivatives -cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives -conazolum -conazole systemic antifungal agents, miconazole derivatives cort cort corticosteroids, except prednisolone derivatives -coxibum -coxib selective cyclo-oxygenase inhibitors -entanum -entan endothelin receptor antagonists gab gab gabamimetic agents gado- gado- diagnostic agents, gadolinium derivatives -gatranum -gatran thrombin inhibitors, antithrombotic agents gest gest steroids, progestogens gli gli antihyperglycaemics io- io- iodine-containing contrast media -metacinum -metacin anti-inflammatory, indometacin derivatives -mycinum -mycin antibiotics, produced by Streptomyces strains -nidazolum -nidazole antiprotozoal substances, metronidazole derivatives -ololum -olol β-adrenoreceptor antagonists -oxacinum -oxacin antibacterial agents, nalidixic acid derivatives -platinum -platin antineoplastic agents, platinum derivatives -poetinum -poetin erythropoietin type blood factors -pril(at)um -pril(at) angiotensin-converting enzyme inhibitors -profenum -profen anti-inflammatory substances, ibuprofen derivatives prost prost prostaglandins -relinum -relin pituitary hormone release-stimulating peptides -sartanum -sartan angiotensin II receptor antagonists, antihypertensive (non-peptidic) -vaptanum -vaptan vasopressin receptor antagonists vin- vin- } vinca-type alkaloids -vin- -vin-}

ANNEXE 1

PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES

PHARMACEUTIQUES1

L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS ») observe la procédure exposée ci-dessous pour l’attribution de dénominations communes internationales recommandées pour les substances pharmaceutiques, conformément à la résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles dénominations. Article 1 - Les propositions de dénominations communes internationales recommandées et les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe administrative destinée uniquement à couvrir les coûts correspondants assumés par le Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le Secrétariat et peut être modifié de temps à autre. Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour la formation de dénominations communes internationales pour les substances pharmaceutiques » reproduites ci-après2.

La dénomination acceptée est la dénomination employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de cette règle.

1 Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4.

2 Voir annexe 2.


463

Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de dénomination commune internationale est à l’étude. a) Cette notification est faite par une insertion dans WHO Drug Information1 et par l’envoi d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée ou autres organismes désignés par les Etats Membres.

i) Notification est également faite à la personne qui a soumis la proposition (« le demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un intérêt notoire.

b) Cette notification contient les indications suivantes :

i) dénomination mise à l’étude;

ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la substance, si cette personne le demande ;

iii) définition de la substance dont la dénomination est mise à l’étude ;

iv) délai pendant lequel seront reçues les observations et les objections à l’égard de cette dénomination ; nom et adresse de la personne habilitée à recevoir ces observations et objections ;

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement.

c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par l’OMS. Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par toute personne, dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Article 5 - Toute personne intéressée peut formuler une objection formelle contre la dénomination proposée dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Cette objection doit s’accompagner des indications suivantes :

i) nom de l’auteur de l’objection ; ii) intérêt qu’il ou elle porte à la dénomination en cause ; iii) raisons motivant l’objection contre la dénomination proposée. Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination commune internationale recommandée tant qu’une objection formelle présentée conformément à l’article 5 n’est pas levée. Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les objections présentées ont été levées, le Secrétariat fait une notification conformément aux dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie par l’OMS en tant que dénomination commune internationale recommandée. Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une dénomination commune internationale recommandée, le Secrétariat : a) demande que cette dénomination soit reconnue comme dénomination commune de la substance considérée ; et b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette dénomination comme marque ou appellation commerciale. 1

Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la Santé.


464

Article 9 - a) Dans le cas exceptionnel où une dénomination commune internationale déjà recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou en comporte un risque démontrable, en raison d’une similitude avec une autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres interventions que le remplacement éventuel d’une dénomination commune internationale déjà recommandée, ou dans le cas où une dénomination commune internationale déjà recommandée diffère sensiblement de la dénomination commune approuvée dans un nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui justifient le remplacement d’une dénomination commune internationale recommandée, toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes :

i) nom de l’auteur de la proposition ;

ii) intérêt qu’il ou elle porte au remplacement proposé ;

iii) raisons motivant la proposition ; et

iv) description, faits à l’appui, des autres interventions entreprises pour tenter de régler le problème et exposé des raisons pour lesquelles ces interventions ont échoué.

Les propositions peuvent comprendre une proposition de nouvelle dénomination commune internationale de remplacement, établie conformément aux Directives générales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune internationale de remplacement est proposée. Le Secrétariat transmet une copie de la proposition pour examen, conformément à la procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles). De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des observations sur la proposition :

i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet dans la lettre mentionnée à l’article 3.a), et

ii) toutes autres personnes portant au remplacement proposé un intérêt notoire. La demande d’observations contient les indications suivantes : i) dénomination commune internationale recommandée pour laquelle un remplacement est proposé (et la dénomination de remplacement proposée, si elle est fournie) ; ii) nom de l’auteur de la proposition de remplacement (si cette personne le demande) ; iii) définition de la substance faisant l’objet du remplacement proposé et raisons avancées pour le remplacement ; iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la personne habilitée à recevoir ces commentaires ; et v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. Des observations sur la proposition de remplacement peuvent être communiquées par toute personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations. b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts des DCI pour qu’il y donne suite.


465

Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer.

Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des DCI pour qu’il y donne

suite, le Groupe choisit une nouvelle dénomination commune internationale conformément aux Directives générales mentionnées à l’article 2 et selon la procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son successeur (si ce n’est pas la même personne que celle qui a proposé le remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui utilisent la dénomination commune internationale déjà recommandée sur leur étiquette conformément à la législation nationale.

Si, après examen de la proposition de remplacement et des observations communiquées conformément à la

procédure exposée plus haut, le Groupe d’experts des DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination commune internationale déjà recommandée, cette dernière est conservée (étant entendu toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement, ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions nationales et régionales de pharmacopée, les autres organismes désignés par les Etats Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination commune internationale déjà recommandée (avec une brève description de la ou des raisons pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative).

ANNEXE 2

DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS

COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES1

1. Les dénominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur excessive, ni prêter à confusion avec des appellations déjà couramment employées. 2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les dénominations susceptibles d’évoquer pour les malades des considérations anatomiques, physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du possible. Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants : 1. Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique, on tiendra compte de

la possibilité de former ultérieurement d’autres DCI appropriées pour les substances apparentées du même groupe.

1

Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes (segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies. Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques (Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983).


466

4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple «oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique».

5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive). En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé.

6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au trait d’union.

7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ; l’usage des lettres « h » et « k » sera aussi évité.

8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les dénominations déjà officiellement adoptées par un pays.

9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des exemples de segments-clés pour des groupes de substances, surtout pour des groupes récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination. Latin Français -acum -ac substances anti-inflammatoires du groupe de l’ibufénac -adolum -adol } analgésiques -adol- -adol- }

-astum -ast antiasthmatiques, antiallergiques n’agissant pas principalement en tant qu’antihistaminiques -astinum -astine antihistaminiques -azepamum -azépam substances du groupe du diazépam bol bol stéroïdes anabolisants -cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et de la lidocaïne -cainum -caïne anesthésiques locaux cef- céf- antibiotiques, dérivés de l’acide céphalosporanique -cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique -conazolum -conazole agents antifongiques systémiques du groupe du miconazole cort cort corticostéroïdes, autres que les dérivés de la prednisolone -coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase -entanum -entan antagonistes du récepteur de l’endothéline gab gab gabamimétiques gado- gado- agents diagnostiques, dérivés du gadolinium -gatranum -gatran antithrombines, antithrombotiques gest gest stéroïdes progestogènes gli gli antihyperglycémiants io- io- produits de contraste iodés -metacinum -métacine substances anti-inflammatoires du groupe de l’indométacine -mycinum -mycine antibiotiques produits par des souches de Streptomyces -nidazolum -nidazole substances antiprotozoaires du groupe du métronidazole -ololum -olol antagonistes des récepteurs β-adrénergiques -oxacinum -oxacine substances antibactériennes du groupe de l’acide nalidixique -platinum -platine antinéoplasiques, dérivés du platine -poetinum -poétine facteurs sanguins de type érythropoïétine -pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine -profenum -profène substances anti-inflammatoires du groupe de l’ibuprofène prost prost prostaglandines

1

Une liste plus complète de segments-clés est contenue dans le document de travail WHO/EMP/QSM/2011.3 qui est régulièrement mis à jour et qui peut être demandé auprès du programme des DCI, OMS, Genève.


467

-relinum -réline peptides stimulant la libération d’hormones hypophysaires -sartanum -sartan antagonistes d’un récepteur de l’angiotensine II, antihypertenseurs (non peptidiques) -vaptanum -vaptan antagonistes du récepteur de la vasopressine vin- vin- } alcaloïdes du type vinca -vin- -vin- }

ANEXO 1

PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1

La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a continuación tanto para seleccionar denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11, como para sustituir esas denominaciones. Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla periódicamente. Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su estudio, en adelante designados como «el Grupo de Expertos en DCI», para que las examinen de conformidad con los «Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas», anexos a este procedimiento.2 A menos que haya poderosas razones en contra, la denominación aceptada será la empleada por la persona que haya descubierto o fabricado y comercializado por primera vez esa sustancia farmacéutica. Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en estudio un proyecto de denominación internacional. a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3

y el envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros.

i) La notificación será enviada también a la persona que haya presentado la propuesta («el solicitante inicial») y a otras personas que tengan un interés especial en una denominación objeto de estudio.

b) En esa notificación se incluirán los siguientes datos: i) la denominación sometida a estudio; ii) la identidad de la persona que ha presentado la propuesta de denominación de la sustancia, si lo pide esa persona; iii) la identidad de la sustancia cuya denominación está en estudio; iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

1 Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4..

2 Véase el anexo 2.

3 Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud.


468

c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación propuesta, durante el periodo en que la OMS la tenga en estudio. Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Artículo 5 - Toda persona interesada puede presentar una objeción formal a una denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Esa objeción deberá acompañarse de los siguientes datos:

i) la identidad de la persona que formula la objeción; ii) las causas que motivan su interés por la denominación; y iii) las causas que motivan su objeción a la denominación propuesta.

Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo 5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objeción. La OMS no seleccionará como denominación común internacional una denominación a la que se haya hecho una objeción formal, presentada según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organización examine otra denominación o denominaciones sustitutivas. Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo 5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará, conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido seleccionada por la OMS como denominación común internacional recomendada. Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional, conforme a lo previsto en el artículo 7, la Secretaría: a) solicitará que esta denominación sea reconocida como denominación común para la sustancia de que se trate; y b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada como marca de fábrica o como nombre comercial. Artículo 9 a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en las prácticas farmacéuticas y/o de prescripción, una denominación común internacional recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución de esa denominación común internacional recomendada anteriormente; en el caso de que una denominación común internacional recomendada anteriormente difiera considerablemente de la denominación común aprobada en un número importante de Estados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominación común internacional recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que se proporcionen a estos efectos e incluirán los siguientes datos:

i) la identidad de la persona que presenta la propuesta;

ii) las causas que motivan su interés en la sustitución propuesta;

iii) las causas que motivan la propuesta; y

iv) una descripción, acompañada de pruebas documentales, de las otras medidas que se hayan adoptado con el fin de resolver la situación y de los motivos por los cuales dichas medidas no han sido suficientes.

Entre esas propuestas podrá figurar una relativa a una nueva denominación común internacional sustitutiva,

formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común internacional sustitutiva.


469

La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el párrafo b) infra. Además, la Secretaría solicitará observaciones sobre la propuesta:

i) a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros (ello se hará incluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del artículo 3), y

ii) a cualquier persona que tenga un interés especial en la sustitución propuesta.

Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos: i) la denominación común internacional recomendada que se propone sustituir (y la denominación sustitutiva propuesta, si se ha facilitado);

ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo pide esa persona); iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las razones para presentar la propuesta de sustitución; iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y

v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones. b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de Expertos en DCI para que la tramite. No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone.

En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI para que la tramite, este grupo seleccionará una nueva denominación común internacional de conformidad con los Principios generales a los que se refiere el artículo 2 y al procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), se indicará que la nueva denominación sustituye a una denominación común internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional recomendada anteriormente que se haya sustituido.

En caso de que, después de haber estudiado la propuesta de sustitución y los comentarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas para sustituir una denominación común internacional recomendada anteriormente, esta denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones nacionales y regionales de las farmacopeas o


470

a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga interés en la sustitución propuesta, que, pese a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación común internacional recomendada anteriormente (con una descripción de la o las razones por las que se ha considerado que la propuesta de sustitución no estaba respaldada por razones suficientemente poderosas).

ANEXO 2

PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES

COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS1

1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con denominaciones de uso común.

2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o terapéuticas para el paciente.

Estos principios primarios se pondrán en práctica utilizando los siguientes principios secundarios:

3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo.

4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica», «ibufenaco» y «ibufenaco sódico».

5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos. En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse adecuadamente por separado, como componentes independientes de una sustancia cuaternaria y no como sales de una amina.

6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo de guiones.

7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá evitar el empleo de las letras «h» y «k».

8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios, recibirán una consideración preferente las denominaciones propuestas por la persona que haya descubierto las sustancias, o que fabrique y comercialice por primera vez una sustancia farmacéutica, así como las denominaciones ya adoptadas oficialmente en cualquier país.

9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen muchas otras partículas que se usan habitualmente.2 Cuando una partícula aparece sin guión alguno, puede utilizarse en cualquier lugar de la palabra.

1 En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este cambio. Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983). 2 En el documento de trabajo WHO/EMP/QSM/2011.3, que se actualiza periódicamente y puede solicitarse al Programa sobre Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas.


471

Latin Español -acum -aco antiinflamatorios derivados del ibufenaco -adolum -adol ) analgésicos -adol- -adol- ) -astum -ast antiasmáticos, sustancias antialérgicas cuya acción principal no es la antihistamínica -astinum -astina antihistamínicos -azepamum -azepam derivados del diazepam bol bol esteroides anabolizantes -cain- -caína- antiarrítmicos de clase I, derivados de procainamida y lidocaína -cainum -caína- anestésicos locales cef- cef- antibióticos, derivados del ácido cefalosporánico -cillinum - cilina antibióticos derivados del ácido 6-aminopenicilánico -conazolum -conazol antifúngicos sistémicos derivados del miconazol cort cort corticosteroides, excepto derivados de prednisolona -coxibum -coxib inhibidores selectivos de ciclooxigenasa -entanum -entán antagonistas del receptor de endotelina gab gab gabamiméticos gado- gado- agentes para diagnóstico derivados de gadolinio -gartranum -gatrán inhibidores de la trombina antitrombóticos gest gest esteroides progestágenos gli gli hipoglucemiantes, antihiperglucémicos io- io- medios de contraste iodados -metacinum -metacina antiinflamatorios derivados de indometacina -mycinum -micina antibióticos producidos por cepas de Streptomyces -nidazolum -nidazol antiprotozoarios derivados de metronidazol -ololum -olol antagonistas de receptores -adrenérgicos -oxacinum -oxacino antibacterianos derivados del ácido nalidíxico -platinum -platino antineoplásicos derivados del platino -poetinum -poetina factores sanguíneos similares a la eritropoyetina -pril(at)um -pril(at) inhibidores de la enzima conversora de la angiotensina -profenum -profeno antiinflamatorios derivados del ibuprofeno prost prost prostaglandinas -relinum -relina péptidos estimulantes de la liberación de hormonas hipofisarias -sartanum -sartán antihipertensivos (no peptídicos) antagonistas del receptorde angiotensina II -vaptanum -vaptán antagonistas del receptor de vasopresina vin- vin- ) alcaloides de la vinca -vin- -vin- )

Date post:	25-Mar-2020
Category:	Documents
Upload:	others
View:	11 times
Download:	0 times

WHO Drug Informationapps.who.int/medicinedocs/documents/s20019en/s20019en.pdf · WHO Drug...

Documents